[
    {
        "text": "Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycerophosphoserine, and [CHEMICAL]phosphoserine[\\CHEMICAL], which are not transported by the plasma membrane flippase, do not activate [GENE]Atp8a1[\\GENE].",
        "label": 10,
        "major": 3,
        "len": 28
    },
    {
        "text": "The purified [GENE]Atp8a1[\\GENE] is inactive in detergent micelles or in micelles containing [CHEMICAL]phosphatidylcholine[\\CHEMICAL], phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS.",
        "label": 10,
        "major": 3,
        "len": 31
    },
    {
        "text": "However, [CHEMICAL]N-methyl-phosphatidylserine[\\CHEMICAL], which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating [GENE]Atp8a1[\\GENE] activity.",
        "label": 10,
        "major": 3,
        "len": 22
    },
    {
        "text": "The purified [GENE]Atp8a1[\\GENE] is inactive in detergent micelles or in micelles containing phosphatidylcholine, [CHEMICAL]phosphatidic acid[\\CHEMICAL], or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS.",
        "label": 10,
        "major": 3,
        "len": 31
    },
    {
        "text": "The purified [GENE]Atp8a1[\\GENE] is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or [CHEMICAL]phosphatidylinositol[\\CHEMICAL], is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS.",
        "label": 10,
        "major": 3,
        "len": 31
    },
    {
        "text": "This aminophospholipid \"[GENE]flippase[\\GENE]\" selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to [CHEMICAL]vanadate[\\CHEMICAL], Ca(2+), and modification by sulfhydryl reagents.",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "This aminophospholipid \"[GENE]flippase[\\GENE]\" selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to vanadate, [CHEMICAL]Ca(2+)[\\CHEMICAL], and modification by sulfhydryl reagents.",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "This aminophospholipid \"[GENE]flippase[\\GENE]\" selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by [CHEMICAL]sulfhydryl[\\CHEMICAL] reagents.",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "Similar to the [GENE]plasma membrane PS transporter[\\GENE], Atp8a1 is activated only by the naturally occurring [CHEMICAL]sn-1,2-glycerol[\\CHEMICAL] isomer of PS and not the sn-2,3-glycerol stereoisomer.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Similar to the plasma membrane PS transporter, [GENE]Atp8a1[\\GENE] is activated only by the naturally occurring [CHEMICAL]sn-1,2-glycerol[\\CHEMICAL] isomer of PS and not the sn-2,3-glycerol stereoisomer.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Weakly translocated lipids ([CHEMICAL]PE[\\CHEMICAL], phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak [GENE]Atp8a1[\\GENE] activators.",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "Weakly translocated lipids (PE, [CHEMICAL]phosphatidylhydroxypropionate[\\CHEMICAL], and phosphatidylhomoserine) are also weak [GENE]Atp8a1[\\GENE] activators.",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "Weakly translocated lipids (PE, phosphatidylhydroxypropionate, and [CHEMICAL]phosphatidylhomoserine[\\CHEMICAL]) are also weak [GENE]Atp8a1[\\GENE] activators.",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "These results indicate that the [GENE]ATPase[\\GENE] activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties ([CHEMICAL]PS[\\CHEMICAL] selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.",
        "label": 3,
        "major": 10,
        "len": 53
    },
    {
        "text": "These results indicate that the ATPase activity of the secretory granule [GENE]Atp8a1[\\GENE] is activated by phospholipids binding to a specific site whose properties ([CHEMICAL]PS[\\CHEMICAL] selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.",
        "label": 3,
        "major": 9,
        "len": 53
    },
    {
        "text": "The purified [GENE]Atp8a1[\\GENE] is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by [CHEMICAL]phosphatidylglycerol[\\CHEMICAL] or phosphatidylethanolamine (PE), and is maximally activated by PS.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "The purified [GENE]Atp8a1[\\GENE] is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or [CHEMICAL]phosphatidylethanolamine[\\CHEMICAL] (PE), and is maximally activated by PS.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "The purified [GENE]Atp8a1[\\GENE] is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine ([CHEMICAL]PE[\\CHEMICAL]), and is maximally activated by PS.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "The purified [GENE]Atp8a1[\\GENE] is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by [CHEMICAL]PS[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Activation of [GENE]Atp8a1[\\GENE] is also reduced by these modifications; [CHEMICAL]phosphatidylserine-O-methyl ester[\\CHEMICAL], lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.",
        "label": 4,
        "major": 10,
        "len": 28
    },
    {
        "text": "Activation of [GENE]Atp8a1[\\GENE] is also reduced by these modifications; phosphatidylserine-O-methyl ester, [CHEMICAL]lysophosphatidylserine[\\CHEMICAL], glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.",
        "label": 4,
        "major": 9,
        "len": 28
    },
    {
        "text": "Activation of [GENE]Atp8a1[\\GENE] is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, [CHEMICAL]glycerophosphoserine[\\CHEMICAL], and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Activation of [GENE]Atp8a1[\\GENE] is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycerophosphoserine, and [CHEMICAL]phosphoserine[\\CHEMICAL], which are not transported by the plasma membrane flippase, do not activate Atp8a1.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "However, [CHEMICAL]N-methyl-phosphatidylserine[\\CHEMICAL], which is transported by the plasma membrane [GENE]flippase[\\GENE] at a rate equivalent to PS, is incapable of activating Atp8a1 activity.",
        "label": 9,
        "major": 3,
        "len": 22
    },
    {
        "text": "This aminophospholipid \"[GENE]flippase[\\GENE]\" selectively transports [CHEMICAL]PS[\\CHEMICAL] to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "This fundamental significance of [GENE]NMDA receptor[\\GENE]-related excitotoxicity is discussed in the context of the developing clinical success of [CHEMICAL]Memantine[\\CHEMICAL], but moreover set into relation to various proteomic and genetic markers of said diseases.",
        "label": 2,
        "major": -1,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of [GENE]tyrosine kinases[\\GENE] that are known to be involved in tumor cell proliferation and tumor angiogenesis.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Sorafenib ([CHEMICAL]BAY 43-9006[\\CHEMICAL]) is a small-molecule inhibitor that has been shown to target members of multiple classes of [GENE]tyrosine kinases[\\GENE] that are known to be involved in tumor cell proliferation and tumor angiogenesis.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Here, we show that at noncytotoxic concentrations, [CHEMICAL]H(2)S[\\CHEMICAL] was able to inhibit NO production and inducible NO synthase (iNOS) expression via [GENE]heme oxygenase[\\GENE] (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "Here, we show that at noncytotoxic concentrations, [CHEMICAL]H(2)S[\\CHEMICAL] was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase ([GENE]HO-1[\\GENE]) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Hydrogen sulfide[\\CHEMICAL] inhibits nitric oxide production and nuclear factor-kappaB via [GENE]heme oxygenase-1[\\GENE] expression in RAW264.7 macrophages stimulated with lipopolysaccharide.",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of [CHEMICAL]H(2)S[\\CHEMICAL] on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either [GENE]HO-1[\\GENE] gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.",
        "label": 2,
        "major": 3,
        "len": 97
    },
    {
        "text": "Collectively, our results suggest that [CHEMICAL]H(2)S[\\CHEMICAL] can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of [GENE]HO-1[\\GENE]/CO.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Both [CHEMICAL]H(2)S[\\CHEMICAL] solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the [GENE]extracellular signal-regulated kinase[\\GENE] (ERK).",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Both [CHEMICAL]H(2)S[\\CHEMICAL] solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase ([GENE]ERK[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Both [CHEMICAL]H(2)S[\\CHEMICAL] solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced [GENE]HO-1[\\GENE] expression through the activation of the extracellular signal-regulated kinase (ERK).",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]CO[\\CHEMICAL] treatment also inhibited LPS-induced NO production and [GENE]iNOS[\\GENE] expression via its inactivation of NF-kappaB.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Here, we show that at noncytotoxic concentrations, [CHEMICAL]H(2)S[\\CHEMICAL] was able to inhibit NO production and [GENE]inducible NO synthase[\\GENE] (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "Here, we show that at noncytotoxic concentrations, [CHEMICAL]H(2)S[\\CHEMICAL] was able to inhibit NO production and inducible NO synthase ([GENE]iNOS[\\GENE]) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "Pretreatment with [CHEMICAL]H(2)S[\\CHEMICAL] or NaHS significantly inhibited LPS-induced [GENE]iNOS[\\GENE] expression and NO production.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Pretreatment with H(2)S or [CHEMICAL]NaHS[\\CHEMICAL] significantly inhibited LPS-induced [GENE]iNOS[\\GENE] expression and NO production.",
        "label": 4,
        "major": 9,
        "len": 13
    },
    {
        "text": "While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of [CHEMICAL]H(2)S[\\CHEMICAL] on [GENE]iNOS[\\GENE] expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.",
        "label": 4,
        "major": 4,
        "len": 97
    },
    {
        "text": "[CHEMICAL]CO[\\CHEMICAL] treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of [GENE]NF-kappaB[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Collectively, our results suggest that [CHEMICAL]H(2)S[\\CHEMICAL] can inhibit NO production and [GENE]NF-kappaB[\\GENE] activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective [GENE]CSE[\\GENE] inhibitor [CHEMICAL]beta-cyano-L-alanine[\\CHEMICAL] but not by the CBS inhibitor aminooxyacetic acid.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Hydrogen sulfide[\\CHEMICAL] inhibits nitric oxide production and [GENE]nuclear factor-kappaB[\\GENE] via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the [GENE]CBS[\\GENE] inhibitor [CHEMICAL]aminooxyacetic acid[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 39
    },
    {
        "text": "While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor [GENE](NF)-kappaB[\\GENE] activation was diminished in RAW264.7 macrophages preincubated with [CHEMICAL]H(2)S[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 60
    },
    {
        "text": "While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of [CHEMICAL]H(2)S[\\CHEMICAL] on [GENE]NF-kappaB[\\GENE] activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.",
        "label": 4,
        "major": 4,
        "len": 97
    },
    {
        "text": "While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with [CHEMICAL]carbon monoxide[\\CHEMICAL] (CO), an end product of [GENE]HO-1[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 97
    },
    {
        "text": "While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide ([CHEMICAL]CO[\\CHEMICAL]), an end product of [GENE]HO-1[\\GENE].",
        "label": 9,
        "major": 3,
        "len": 97
    },
    {
        "text": "CO treatment also inhibited LPS-induced [CHEMICAL]NO[\\CHEMICAL] production and [GENE]iNOS[\\GENE] expression via its inactivation of NF-kappaB.",
        "label": 9,
        "major": 3,
        "len": 15
    },
    {
        "text": "Hydrogen sulfide ([CHEMICAL]H(2)S[\\CHEMICAL]), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ([GENE]CSE[\\GENE]) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "Hydrogen sulfide ([CHEMICAL]H(2)S[\\CHEMICAL]), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or [GENE]cystathionine beta-synthase[\\GENE] (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "Hydrogen sulfide ([CHEMICAL]H(2)S[\\CHEMICAL]), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ([GENE]CBS[\\GENE]) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "Hydrogen sulfide ([CHEMICAL]H(2)S[\\CHEMICAL]), a regulatory gaseous molecule that is endogenously synthesized by [GENE]cystathionine gamma-lyase[\\GENE] (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of [GENE]HO-1[\\GENE]/[CHEMICAL]CO[\\CHEMICAL].",
        "label": 9,
        "major": 3,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Hydrogen sulfide[\\CHEMICAL] (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ([GENE]CSE[\\GENE]) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "[CHEMICAL]Hydrogen sulfide[\\CHEMICAL] (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or [GENE]cystathionine beta-synthase[\\GENE] (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "[CHEMICAL]Hydrogen sulfide[\\CHEMICAL] (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ([GENE]CBS[\\GENE]) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "[CHEMICAL]Hydrogen sulfide[\\CHEMICAL] (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by [GENE]cystathionine gamma-lyase[\\GENE] (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit [CHEMICAL]NO[\\CHEMICAL] production and [GENE]inducible NO synthase[\\GENE] (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).",
        "label": 9,
        "major": 3,
        "len": 32
    },
    {
        "text": "Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit [CHEMICAL]NO[\\CHEMICAL] production and inducible NO synthase ([GENE]iNOS[\\GENE]) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).",
        "label": 9,
        "major": 3,
        "len": 32
    },
    {
        "text": "Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced [GENE]iNOS[\\GENE] expression and [CHEMICAL]NO[\\CHEMICAL] production.",
        "label": 9,
        "major": 9,
        "len": 13
    },
    {
        "text": "While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on [GENE]iNOS[\\GENE] expression and [CHEMICAL]NO[\\CHEMICAL] production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.",
        "label": 9,
        "major": 4,
        "len": 97
    },
    {
        "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ([GENE]CSE[\\GENE]) and/or cystathionine beta-synthase (CBS) from [CHEMICAL]L-cysteine[\\CHEMICAL] (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or [GENE]cystathionine beta-synthase[\\GENE] (CBS) from [CHEMICAL]L-cysteine[\\CHEMICAL] (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ([GENE]CBS[\\GENE]) from [CHEMICAL]L-cysteine[\\CHEMICAL] (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by [GENE]cystathionine gamma-lyase[\\GENE] (CSE) and/or cystathionine beta-synthase (CBS) from [CHEMICAL]L-cysteine[\\CHEMICAL] (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ([GENE]CSE[\\GENE]) and/or cystathionine beta-synthase (CBS) from L-cysteine ([CHEMICAL]L-Cys[\\CHEMICAL]) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or [GENE]cystathionine beta-synthase[\\GENE] (CBS) from L-cysteine ([CHEMICAL]L-Cys[\\CHEMICAL]) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ([GENE]CBS[\\GENE]) from L-cysteine ([CHEMICAL]L-Cys[\\CHEMICAL]) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by [GENE]cystathionine gamma-lyase[\\GENE] (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine ([CHEMICAL]L-Cys[\\CHEMICAL]) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "Moreover, NO production in LPS-stimulated macrophages that are expressing [GENE]CSE[\\GENE] mRNA was significantly reduced by the addition of [CHEMICAL]L-Cys[\\CHEMICAL], a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid.",
        "label": 9,
        "major": 9,
        "len": 39
    },
    {
        "text": "However, in vitro experiments simulating a uremic milieu revealed a marked concentration-dependent inhibition of [GENE]arginase[\\GENE] activity by [CHEMICAL]urea[\\CHEMICAL] in the tissue lysates.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "CONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of [GENE]arginase[\\GENE], the inherent rise in [CHEMICAL]urea[\\CHEMICAL] concentration inhibits its enzymatic activity.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "L-arg is converted to [CHEMICAL]urea[\\CHEMICAL] by [GENE]arginase I[\\GENE] in the liver and arginase II in the kidney.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "L-arg is converted to [CHEMICAL]urea[\\CHEMICAL] by arginase I in the liver and [GENE]arginase II[\\GENE] in the kidney.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "Sources of [CHEMICAL]L-arg[\\CHEMICAL] include dietary proteins and endogenous synthesis by [GENE]argininosuccinate synthetase[\\GENE] and argininosuccinate lyase.",
        "label": 9,
        "major": -1,
        "len": 15
    },
    {
        "text": "Sources of [CHEMICAL]L-arg[\\CHEMICAL] include dietary proteins and endogenous synthesis by argininosuccinate synthetase and [GENE]argininosuccinate lyase[\\GENE].",
        "label": 9,
        "major": -1,
        "len": 15
    },
    {
        "text": "[CHEMICAL]L-arg[\\CHEMICAL] is converted to urea by [GENE]arginase I[\\GENE] in the liver and arginase II in the kidney.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[CHEMICAL]L-arg[\\CHEMICAL] is converted to urea by arginase I in the liver and [GENE]arginase II[\\GENE] in the kidney.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "We hypothesized that preservation of plasma [CHEMICAL]L-arg[\\CHEMICAL] in CRF may be, partly, due to downregulation/inhibition of [GENE]arginase[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 17
    },
    {
        "text": "However, several promising nonpeptide, [GENE]vasopressin receptor[\\GENE] antagonists have been described; these agents are [CHEMICAL]VPA-985[\\CHEMICAL] (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "However, several promising nonpeptide, [GENE]vasopressin receptor[\\GENE] antagonists have been described; these agents are VPA-985 ([CHEMICAL]lixivaptan[\\CHEMICAL]), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "However, several promising nonpeptide, [GENE]vasopressin receptor[\\GENE] antagonists have been described; these agents are VPA-985 (lixivaptan), [CHEMICAL]YM-087[\\CHEMICAL] (conivaptan), OPC-41061 (tolvaptan), and SR-121463.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "However, several promising nonpeptide, [GENE]vasopressin receptor[\\GENE] antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 ([CHEMICAL]conivaptan[\\CHEMICAL]), OPC-41061 (tolvaptan), and SR-121463.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "However, several promising nonpeptide, [GENE]vasopressin receptor[\\GENE] antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), [CHEMICAL]OPC-41061[\\CHEMICAL] (tolvaptan), and SR-121463.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "However, several promising nonpeptide, [GENE]vasopressin receptor[\\GENE] antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 ([CHEMICAL]tolvaptan[\\CHEMICAL]), and SR-121463.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "However, several promising nonpeptide, [GENE]vasopressin receptor[\\GENE] antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and [CHEMICAL]SR-121463[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "BG also showed a protective effect in the presence of a [GENE]DNA polymerase beta[\\GENE] inhibitor ([CHEMICAL]cytosine arabinoside-3-phosphate[\\CHEMICAL], Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "BG also showed a protective effect in the presence of a [GENE]DNA polymerase beta[\\GENE] inhibitor (cytosine arabinoside-3-phosphate, [CHEMICAL]Ara-C[\\CHEMICAL]), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "METHODS: We identified seven SNP(single [CHEMICAL]nucleotide[\\CHEMICAL] polymorphism) (-141Cins>del, TaqIB, TaqID, [GENE]Ser311Cys[\\GENE], rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.",
        "label": 1,
        "major": -1,
        "len": 41
    },
    {
        "text": "METHODS: We identified seven SNP(single [CHEMICAL]nucleotide[\\CHEMICAL] polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the [GENE]DRD2[\\GENE] gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.",
        "label": 1,
        "major": -1,
        "len": 41
    },
    {
        "text": "CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the [GENE]DRD2[\\GENE] gene plays a major role in the individually variable adverse effect induced by [CHEMICAL]chlorpromazine[\\CHEMICAL], at least in Chinese patients with schizophrenia.",
        "label": 2,
        "major": 3,
        "len": 39
    },
    {
        "text": "Calcium-chelating reagents such as [CHEMICAL]EDTA[\\CHEMICAL] and 1,2-bis-(o-aminphenoxy)-ethane-N,N,N',N'-tetra-acetic acid tetra-acetoxy-methyl ester prevented the cleavage of [GENE]GAD65[\\GENE].",
        "label": 10,
        "major": -1,
        "len": 15
    },
    {
        "text": "Calcium-chelating reagents such as EDTA and [CHEMICAL]1,2-bis-(o-aminphenoxy)-ethane-N,N,N',N'-tetra-acetic acid tetra-acetoxy-methyl ester[\\CHEMICAL] prevented the cleavage of [GENE]GAD65[\\GENE].",
        "label": 10,
        "major": -1,
        "len": 15
    },
    {
        "text": "Previously, we reported that l-glutamic acid decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the [CHEMICAL]N[\\CHEMICAL]-terminus, [GENE]GAD65(Delta1-69)[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 30
    },
    {
        "text": "Agents that specifically target [GENE]BRAF[\\GENE], such as [CHEMICAL]sorafenib[\\CHEMICAL], as well as new molecules that function both upstream and downstream of BRAF, are being actively investigated.",
        "label": 2,
        "major": -1,
        "len": 25
    },
    {
        "text": "Our purpose was to test the impact of single and/or combined treatment with the [GENE]AT(1)[\\GENE]-receptor blocker [CHEMICAL]candesartan[\\CHEMICAL] and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the [GENE]HMG-CoA reductase[\\GENE] inhibitor [CHEMICAL]rosuvastatin[\\CHEMICAL] and their combination.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Reduction of cerebral infarct size by the [GENE]AT1[\\GENE]-receptor blocker [CHEMICAL]candesartan[\\CHEMICAL], the HMG-CoA reductase inhibitor rosuvastatin and their combination.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Our purpose was to test the impact of single and/or combined treatment with the AT(1)-receptor blocker candesartan and the [GENE]HMG-CoA reductase[\\GENE] inhibitor [CHEMICAL]rosuvastatin[\\CHEMICAL] on infarct size and neuroscore in transient cerebral ischemia in rats.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "The phosphorylation by gammaPKC resulted in activation of DGKgamma because a [GENE]DGKgamma[\\GENE] mutant in which Ser-776 and Ser-779 were substituted with [CHEMICAL]glutamic acid[\\CHEMICAL] to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.",
        "label": 1,
        "major": 1,
        "len": 40
    },
    {
        "text": "Mass spectrometric analysis and mutation studies revealed that [GENE]gammaPKC[\\GENE] [CHEMICAL]phosphorylated Ser[\\CHEMICAL]-776 and Ser-779 in the AD of DGKgamma.",
        "label": 1,
        "major": 1,
        "len": 18
    },
    {
        "text": "Mass spectrometric analysis and mutation studies revealed that gammaPKC phosphorylated Ser-776 and [CHEMICAL]Ser[\\CHEMICAL]-779 in the AD of [GENE]DGKgamma[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 18
    },
    {
        "text": "The phosphorylation by gammaPKC resulted in activation of DGKgamma because a [GENE]DGKgamma[\\GENE] mutant in which [CHEMICAL]Ser[\\CHEMICAL]-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.",
        "label": 1,
        "major": 1,
        "len": 40
    },
    {
        "text": "The phosphorylation by gammaPKC resulted in activation of DGKgamma because a [GENE]DGKgamma[\\GENE] mutant in which Ser-776 and [CHEMICAL]Ser[\\CHEMICAL]-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.",
        "label": 1,
        "major": 3,
        "len": 40
    },
    {
        "text": "[GENE]gammaPKC[\\GENE] directly associated with DGKgamma through its accessory domain (AD), depending on [CHEMICAL]Ca2+[\\CHEMICAL] as well as phosphatidylserine/diolein in vitro.",
        "label": 2,
        "major": -1,
        "len": 19
    },
    {
        "text": "gammaPKC directly associated with [GENE]DGKgamma[\\GENE] through its accessory domain (AD), depending on [CHEMICAL]Ca2+[\\CHEMICAL] as well as phosphatidylserine/diolein in vitro.",
        "label": 2,
        "major": -1,
        "len": 19
    },
    {
        "text": "[GENE]gammaPKC[\\GENE] directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as [CHEMICAL]phosphatidylserine[\\CHEMICAL]/diolein in vitro.",
        "label": 2,
        "major": -1,
        "len": 19
    },
    {
        "text": "gammaPKC directly associated with [GENE]DGKgamma[\\GENE] through its accessory domain (AD), depending on Ca2+ as well as [CHEMICAL]phosphatidylserine[\\CHEMICAL]/diolein in vitro.",
        "label": 2,
        "major": -1,
        "len": 19
    },
    {
        "text": "[GENE]gammaPKC[\\GENE] directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/[CHEMICAL]diolein[\\CHEMICAL] in vitro.",
        "label": 2,
        "major": -1,
        "len": 19
    },
    {
        "text": "gammaPKC directly associated with [GENE]DGKgamma[\\GENE] through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/[CHEMICAL]diolein[\\CHEMICAL] in vitro.",
        "label": 2,
        "major": -1,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Diacylglycerol[\\CHEMICAL] (DAG) acts as an allosteric activator of [GENE]protein kinase C[\\GENE] (PKC) and is converted to phosphatidic acid by DAG kinase (DGK).",
        "label": 7,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Diacylglycerol[\\CHEMICAL] (DAG) acts as an allosteric activator of protein kinase C ([GENE]PKC[\\GENE]) and is converted to phosphatidic acid by DAG kinase (DGK).",
        "label": 7,
        "major": 7,
        "len": 22
    },
    {
        "text": "Diacylglycerol ([CHEMICAL]DAG[\\CHEMICAL]) acts as an allosteric activator of [GENE]protein kinase C[\\GENE] (PKC) and is converted to phosphatidic acid by DAG kinase (DGK).",
        "label": 7,
        "major": 3,
        "len": 22
    },
    {
        "text": "Diacylglycerol ([CHEMICAL]DAG[\\CHEMICAL]) acts as an allosteric activator of protein kinase C ([GENE]PKC[\\GENE]) and is converted to phosphatidic acid by DAG kinase (DGK).",
        "label": 7,
        "major": 9,
        "len": 22
    },
    {
        "text": "Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to [CHEMICAL]phosphatidic acid[\\CHEMICAL] by [GENE]DAG kinase[\\GENE] (DGK).",
        "label": 9,
        "major": 7,
        "len": 22
    },
    {
        "text": "Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to [CHEMICAL]phosphatidic acid[\\CHEMICAL] by DAG kinase ([GENE]DGK[\\GENE]).",
        "label": 9,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Diacylglycerol[\\CHEMICAL] (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by [GENE]DAG kinase[\\GENE] (DGK).",
        "label": 9,
        "major": 7,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Diacylglycerol[\\CHEMICAL] (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase ([GENE]DGK[\\GENE]).",
        "label": 9,
        "major": 3,
        "len": 22
    },
    {
        "text": "Diacylglycerol ([CHEMICAL]DAG[\\CHEMICAL]) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by [GENE]DAG kinase[\\GENE] (DGK).",
        "label": 9,
        "major": 3,
        "len": 22
    },
    {
        "text": "Diacylglycerol ([CHEMICAL]DAG[\\CHEMICAL]) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase ([GENE]DGK[\\GENE]).",
        "label": 9,
        "major": 3,
        "len": 22
    },
    {
        "text": "The effect of [CHEMICAL]folic acid[\\CHEMICAL] level on this end-point was modulated by the [GENE]MTHFR[\\GENE] genotype (P for interaction = 0.02), with TT cells grown at low folic acid concentration apparently resistant to the induction of radiation-induced bridges.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "The [GENE]C677T[\\GENE] polymorphism of the methylene-tetrahydrofolate reductase (MTHFR) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on [CHEMICAL]folate[\\CHEMICAL] status.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "The C677T polymorphism of the [GENE]methylene-tetrahydrofolate reductase[\\GENE] (MTHFR) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on [CHEMICAL]folate[\\CHEMICAL] status.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "The C677T polymorphism of the methylene-tetrahydrofolate reductase ([GENE]MTHFR[\\GENE]) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on [CHEMICAL]folate[\\CHEMICAL] status.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "The main molecular target of [CHEMICAL]azole[\\CHEMICAL] antifungals is the [GENE]cytochrome P-450[\\GENE] protein Erg11p/Cyp51p.",
        "label": 2,
        "major": -1,
        "len": 13
    },
    {
        "text": "The main molecular target of [CHEMICAL]azole[\\CHEMICAL] antifungals is the cytochrome P-450 protein [GENE]Erg11p[\\GENE]/Cyp51p.",
        "label": 2,
        "major": -1,
        "len": 13
    },
    {
        "text": "The main molecular target of [CHEMICAL]azole[\\CHEMICAL] antifungals is the cytochrome P-450 protein Erg11p/[GENE]Cyp51p[\\GENE].",
        "label": 2,
        "major": -1,
        "len": 13
    },
    {
        "text": "The [CHEMICAL]phenylmorpholines[\\CHEMICAL], of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: [GENE]Erg24p[\\GENE] (delta 14 reductase) and Erg2p (delta 8-delta 7 isomerase).",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "The [CHEMICAL]phenylmorpholines[\\CHEMICAL], of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p ([GENE]delta 14 reductase[\\GENE]) and Erg2p (delta 8-delta 7 isomerase).",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "The [CHEMICAL]phenylmorpholines[\\CHEMICAL], of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and [GENE]Erg2p[\\GENE] (delta 8-delta 7 isomerase).",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "The [CHEMICAL]phenylmorpholines[\\CHEMICAL], of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and Erg2p ([GENE]delta 8-delta 7 isomerase[\\GENE]).",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "The phenylmorpholines, of which [CHEMICAL]amorolfine[\\CHEMICAL] is the sole representative in human therapy, affect two targets in the ergosterol pathway: [GENE]Erg24p[\\GENE] (delta 14 reductase) and Erg2p (delta 8-delta 7 isomerase).",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "The phenylmorpholines, of which [CHEMICAL]amorolfine[\\CHEMICAL] is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p ([GENE]delta 14 reductase[\\GENE]) and Erg2p (delta 8-delta 7 isomerase).",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "The phenylmorpholines, of which [CHEMICAL]amorolfine[\\CHEMICAL] is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and [GENE]Erg2p[\\GENE] (delta 8-delta 7 isomerase).",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "The phenylmorpholines, of which [CHEMICAL]amorolfine[\\CHEMICAL] is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and Erg2p ([GENE]delta 8-delta 7 isomerase[\\GENE]).",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "The [CHEMICAL]sordarins[\\CHEMICAL] group are protein synthesis inhibitors that work by blocking the function of [GENE]fungal translation elongation factor 2[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "The short lifetime of [CHEMICAL]IP3[\\CHEMICAL] makes this detection very challenging in measuring [GENE]GPCR[\\GENE] responses.",
        "label": 2,
        "major": -1,
        "len": 14
    },
    {
        "text": "We show here that [CHEMICAL]IP1[\\CHEMICAL] can be used as a surrogate of IP3 to monitor [GENE]GPCR[\\GENE] activation.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "We show here that IP1 can be used as a surrogate of [CHEMICAL]IP3[\\CHEMICAL] to monitor [GENE]GPCR[\\GENE] activation.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]D-myo-inositol 1-phosphate[\\CHEMICAL] as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor [GENE]G protein-coupled receptor[\\GENE] activation.",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "D-myo-inositol 1-phosphate as a surrogate of [CHEMICAL]D-myo-inositol 1,4,5-tris phosphate[\\CHEMICAL] to monitor [GENE]G protein-coupled receptor[\\GENE] activation.",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "[GENE]Phospholipase C beta[\\GENE] (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by [CHEMICAL]D-myo-inositol 1,4,5-trisphosphate[\\CHEMICAL] (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.",
        "label": 2,
        "major": 9,
        "len": 36
    },
    {
        "text": "Phospholipase C beta ([GENE]PLC-beta[\\GENE])-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by [CHEMICAL]D-myo-inositol 1,4,5-trisphosphate[\\CHEMICAL] (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.",
        "label": 2,
        "major": 9,
        "len": 36
    },
    {
        "text": "Phospholipase C beta (PLC-beta)-coupled [GENE]G protein-coupled receptor[\\GENE] (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by [CHEMICAL]D-myo-inositol 1,4,5-trisphosphate[\\CHEMICAL] (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.",
        "label": 2,
        "major": 9,
        "len": 36
    },
    {
        "text": "Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor ([GENE]GPCR[\\GENE]) activities traditionally are assessed by measuring Ca2+ triggered by [CHEMICAL]D-myo-inositol 1,4,5-trisphosphate[\\CHEMICAL] (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.",
        "label": 2,
        "major": 9,
        "len": 36
    },
    {
        "text": "It has been known for decades that [CHEMICAL]lithium chloride[\\CHEMICAL] (LiCl) leads to D-myo-inositol 1-phosphate accumulation on [GENE]GPCR[\\GENE] activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "It has been known for decades that lithium chloride ([CHEMICAL]LiCl[\\CHEMICAL]) leads to D-myo-inositol 1-phosphate accumulation on [GENE]GPCR[\\GENE] activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade.",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "It has been known for decades that [CHEMICAL]lithium chloride[\\CHEMICAL] (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting [GENE]inositol monophosphatase[\\GENE], the final enzyme of the IP3 metabolic cascade.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "It has been known for decades that lithium chloride ([CHEMICAL]LiCl[\\CHEMICAL]) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting [GENE]inositol monophosphatase[\\GENE], the final enzyme of the IP3 metabolic cascade.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "It has the advantage over the traditional [CHEMICAL]Ca2+[\\CHEMICAL] assay of allowing the measurement of inverse agonist activity as well as the analysis of [GENE]PLC-beta[\\GENE] activity in any nontransfected primary cultures.",
        "label": 8,
        "major": 5,
        "len": 30
    },
    {
        "text": "[GENE]Phospholipase C beta[\\GENE] (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring [CHEMICAL]Ca2+[\\CHEMICAL] triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.",
        "label": 8,
        "major": 9,
        "len": 36
    },
    {
        "text": "Phospholipase C beta ([GENE]PLC-beta[\\GENE])-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring [CHEMICAL]Ca2+[\\CHEMICAL] triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.",
        "label": 8,
        "major": 9,
        "len": 36
    },
    {
        "text": "Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by [CHEMICAL]D-myo-inositol 1,4,5-trisphosphate[\\CHEMICAL] (IP3), a [GENE]PLC-beta[\\GENE] hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate ([CHEMICAL]IP3[\\CHEMICAL]), a [GENE]PLC-beta[\\GENE] hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a [GENE]PLC-beta[\\GENE] hydrolysis product, or by measuring the production of [CHEMICAL]inositol phosphate[\\CHEMICAL] using cumbersome radioactive assays.",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "It has been known for decades that lithium chloride (LiCl) leads to [CHEMICAL]D-myo-inositol 1-phosphate[\\CHEMICAL] accumulation on GPCR activation by inhibiting [GENE]inositol monophosphatase[\\GENE], the final enzyme of the IP3 metabolic cascade.",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting [GENE]inositol monophosphatase[\\GENE], the final enzyme of the [CHEMICAL]IP3[\\CHEMICAL] metabolic cascade.",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "Once formed, the molecule can be converted to [CHEMICAL]glycine[\\CHEMICAL] by [GENE]alanine-glyoxylate aminotransferase[\\GENE] (AGAT).",
        "label": 9,
        "major": 10,
        "len": 13
    },
    {
        "text": "Once formed, the molecule can be converted to [CHEMICAL]glycine[\\CHEMICAL] by alanine-glyoxylate aminotransferase ([GENE]AGAT[\\GENE]).",
        "label": 9,
        "major": 10,
        "len": 13
    },
    {
        "text": "11Beta-HSD1 activates [CHEMICAL]cortisone[\\CHEMICAL] to cortisol to facilitate [GENE]glucocorticoid receptor[\\GENE] (GR)-mediated action.",
        "label": 2,
        "major": 3,
        "len": 11
    },
    {
        "text": "11Beta-HSD1 activates [CHEMICAL]cortisone[\\CHEMICAL] to cortisol to facilitate glucocorticoid receptor ([GENE]GR[\\GENE])-mediated action.",
        "label": 2,
        "major": 3,
        "len": 11
    },
    {
        "text": "11Beta-HSD1 activates cortisone to [CHEMICAL]cortisol[\\CHEMICAL] to facilitate [GENE]glucocorticoid receptor[\\GENE] (GR)-mediated action.",
        "label": 2,
        "major": 3,
        "len": 11
    },
    {
        "text": "11Beta-HSD1 activates cortisone to [CHEMICAL]cortisol[\\CHEMICAL] to facilitate glucocorticoid receptor ([GENE]GR[\\GENE])-mediated action.",
        "label": 2,
        "major": 3,
        "len": 11
    },
    {
        "text": "By contrast, [GENE]11beta-HSD2[\\GENE] plays a pivotal role in [CHEMICAL]aldosterone[\\CHEMICAL] target tissues where it catalyses the opposite reaction (i.e.",
        "label": 2,
        "major": 9,
        "len": 18
    },
    {
        "text": "inactivation of cortisol to cortisone) to prevent activation of the [GENE]mineralocorticoid receptor[\\GENE] (MR) by [CHEMICAL]cortisol[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor ([GENE]MR[\\GENE]) by [CHEMICAL]cortisol[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which [CHEMICAL]cortisol[\\CHEMICAL] activates the [GENE]MR[\\GENE] resulting in severe hypertension and hypokalemia.",
        "label": 3,
        "major": 1,
        "len": 31
    },
    {
        "text": "Ingestion of competitive inhibitors of [GENE]11beta-HSD2[\\GENE] such as liquorice and [CHEMICAL]carbenoxolone[\\CHEMICAL] result in a similar but milder clinical phenotype.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[GENE]11Beta-HSD1[\\GENE] activates cortisone to [CHEMICAL]cortisol[\\CHEMICAL] to facilitate glucocorticoid receptor (GR)-mediated action.",
        "label": 9,
        "major": 3,
        "len": 11
    },
    {
        "text": "By contrast, [GENE]11beta-HSD2[\\GENE] plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to [CHEMICAL]cortisone[\\CHEMICAL]) to prevent activation of the mineralocorticoid receptor (MR) by cortisol.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "[GENE]11Beta-HSD1[\\GENE] activates [CHEMICAL]cortisone[\\CHEMICAL] to cortisol to facilitate glucocorticoid receptor (GR)-mediated action.",
        "label": 9,
        "major": 3,
        "len": 11
    },
    {
        "text": "By contrast, [GENE]11beta-HSD2[\\GENE] plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of [CHEMICAL]cortisol[\\CHEMICAL] to cortisone) to prevent activation of the mineralocorticoid receptor (MR) by cortisol.",
        "label": 9,
        "major": 3,
        "len": 33
    },
    {
        "text": "[CHEMICAL]ATRA[\\CHEMICAL] regulates gene expression via the activation of the [GENE]retinoic acid receptor (RAR)alpha[\\GENE] in human DCs, and RARalpha acutely regulates CD1d expression.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]ATRA[\\CHEMICAL] regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and [GENE]RARalpha[\\GENE] acutely regulates CD1d expression.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]ATRA[\\CHEMICAL] regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and RARalpha acutely regulates [GENE]CD1d[\\GENE] expression.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "The [CHEMICAL]retinoic acid[\\CHEMICAL]-induced elevated expression of [GENE]CD1d[\\GENE] is coupled to enhanced iNKT cell activation.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit [CHEMICAL]retinoid[\\CHEMICAL] signaling leading to [GENE]CD1d[\\GENE] up-regulation.",
        "label": 3,
        "major": -1,
        "len": 19
    },
    {
        "text": "Here we demonstrate that PPARgamma, turns on [CHEMICAL]retinoic acid[\\CHEMICAL] synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as [GENE]retinol dehydrogenase 10[\\GENE] and retinaldehyde dehydrogenase type 2 (RALDH2).",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "Here we demonstrate that PPARgamma, turns on [CHEMICAL]retinoic acid[\\CHEMICAL] synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and [GENE]retinaldehyde dehydrogenase type 2[\\GENE] (RALDH2).",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "Here we demonstrate that PPARgamma, turns on [CHEMICAL]retinoic acid[\\CHEMICAL] synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 ([GENE]RALDH2[\\GENE]).",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of [CHEMICAL]retinol[\\CHEMICAL] and retinal metabolizing enzymes such as [GENE]retinol dehydrogenase 10[\\GENE] and retinaldehyde dehydrogenase type 2 (RALDH2).",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of [CHEMICAL]retinol[\\CHEMICAL] and retinal metabolizing enzymes such as retinol dehydrogenase 10 and [GENE]retinaldehyde dehydrogenase type 2[\\GENE] (RALDH2).",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of [CHEMICAL]retinol[\\CHEMICAL] and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 ([GENE]RALDH2[\\GENE]).",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and [CHEMICAL]retinal[\\CHEMICAL] metabolizing enzymes such as [GENE]retinol dehydrogenase 10[\\GENE] and retinaldehyde dehydrogenase type 2 (RALDH2).",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and [CHEMICAL]retinal[\\CHEMICAL] metabolizing enzymes such as retinol dehydrogenase 10 and [GENE]retinaldehyde dehydrogenase type 2[\\GENE] (RALDH2).",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and [CHEMICAL]retinal[\\CHEMICAL] metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 ([GENE]RALDH2[\\GENE]).",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "CONTEXT: [CHEMICAL]Ramelteon[\\CHEMICAL] is a novel [GENE]MT1[\\GENE] and MT2 melatonin receptor selective agonist recently approved for insomnia treatment.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "CONTEXT: [CHEMICAL]Ramelteon[\\CHEMICAL] is a novel MT1 and [GENE]MT2 melatonin receptor[\\GENE] selective agonist recently approved for insomnia treatment.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "Late INa induced by the [GENE]VGSC[\\GENE] long QT mutant R1623Q was reduced by [CHEMICAL]resveratrol[\\CHEMICAL] and quercetin.",
        "label": 4,
        "major": 1,
        "len": 16
    },
    {
        "text": "Late INa induced by the VGSC long QT mutant [GENE]R1623Q[\\GENE] was reduced by [CHEMICAL]resveratrol[\\CHEMICAL] and quercetin.",
        "label": 4,
        "major": 1,
        "len": 16
    },
    {
        "text": "Late INa induced by the [GENE]VGSC[\\GENE] long QT mutant R1623Q was reduced by resveratrol and [CHEMICAL]quercetin[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Late INa induced by the VGSC long QT mutant [GENE]R1623Q[\\GENE] was reduced by resveratrol and [CHEMICAL]quercetin[\\CHEMICAL].",
        "label": 4,
        "major": 1,
        "len": 16
    },
    {
        "text": "Enhancement of radiosensitivity by [GENE]topoisomerase II[\\GENE] inhibitor, [CHEMICAL]amrubicin[\\CHEMICAL] and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Enhancement of radiosensitivity by [GENE]topoisomerase II[\\GENE] inhibitor, amrubicin and [CHEMICAL]amrubicinol[\\CHEMICAL], in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Similar to [CHEMICAL]AMR[\\CHEMICAL] and AMROH, adriamycin and etoposide (VP-16) are [GENE]DNA topoisomerase II[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Similar to AMR and [CHEMICAL]AMROH[\\CHEMICAL], adriamycin and etoposide (VP-16) are [GENE]DNA topoisomerase II[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Similar to AMR and AMROH, [CHEMICAL]adriamycin[\\CHEMICAL] and etoposide (VP-16) are [GENE]DNA topoisomerase II[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Similar to AMR and AMROH, adriamycin and [CHEMICAL]etoposide[\\CHEMICAL] (VP-16) are [GENE]DNA topoisomerase II[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Similar to AMR and AMROH, adriamycin and etoposide ([CHEMICAL]VP-16[\\CHEMICAL]) are [GENE]DNA topoisomerase II[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Accumulated evidence in humans and animals shows that both [CHEMICAL]aspirin[\\CHEMICAL] and H. pylori upregulate the expression of cyclooxygenase (COX)-2 both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of [GENE]COX-1[\\GENE].",
        "label": 10,
        "major": 3,
        "len": 37
    },
    {
        "text": "It was, therefore, proposed that H. pylori may in fact, antagonize, [CHEMICAL]aspirin[\\CHEMICAL]-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from [GENE]COX-2[\\GENE] expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "Accumulated evidence in humans and animals shows that both [CHEMICAL]aspirin[\\CHEMICAL] and H. pylori upregulate the expression of [GENE]cyclooxygenase (COX)-2[\\GENE] both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of COX-1.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "It was, therefore, proposed that H. pylori may in fact, antagonize, [CHEMICAL]aspirin[\\CHEMICAL]-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as [GENE]TGF alpha[\\GENE] and VEGF.",
        "label": 3,
        "major": 6,
        "len": 47
    },
    {
        "text": "It was, therefore, proposed that H. pylori may in fact, antagonize, [CHEMICAL]aspirin[\\CHEMICAL]-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and [GENE]VEGF[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "It was, therefore, proposed that H. pylori may in fact, antagonize, [CHEMICAL]aspirin[\\CHEMICAL]-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from [GENE]COX-2[\\GENE] expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.",
        "label": 3,
        "major": 6,
        "len": 47
    },
    {
        "text": "It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in [CHEMICAL]PGE(2)[\\CHEMICAL] possibly derived from [GENE]COX-2[\\GENE] expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.",
        "label": 9,
        "major": 3,
        "len": 47
    },
    {
        "text": "Based on selective nucleoside protection, [GENE]TS[\\GENE] was found to be the primary [CHEMICAL]pemetrexed[\\CHEMICAL] target in both cell lines with GARFT inhibition requiring 20- to 30-fold higher pemetrexed concentrations.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "These data indicate that suppression of constitutive MTAP has no effect on [CHEMICAL]pemetrexed[\\CHEMICAL] activity when the primary target is [GENE]TS[\\GENE].",
        "label": 2,
        "major": -1,
        "len": 20
    },
    {
        "text": "There is a modest salutary effect when the [CHEMICAL]pemetrexed[\\CHEMICAL] target is [GENE]GARFT[\\GENE] alone.",
        "label": 2,
        "major": -1,
        "len": 13
    },
    {
        "text": "Based on selective nucleoside protection, TS was found to be the primary pemetrexed target in both cell lines with [GENE]GARFT[\\GENE] inhibition requiring 20- to 30-fold higher [CHEMICAL]pemetrexed[\\CHEMICAL] concentrations.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[GENE]Methylthioadenosine phosphorylase[\\GENE] (MTAP) salvages purines by releasing [CHEMICAL]adenine[\\CHEMICAL] from methylthioadenosine and is often deleted in mesothelioma.",
        "label": 9,
        "major": -1,
        "len": 16
    },
    {
        "text": "Methylthioadenosine phosphorylase ([GENE]MTAP[\\GENE]) salvages purines by releasing [CHEMICAL]adenine[\\CHEMICAL] from methylthioadenosine and is often deleted in mesothelioma.",
        "label": 9,
        "major": -1,
        "len": 16
    },
    {
        "text": "[GENE]Methylthioadenosine phosphorylase[\\GENE] (MTAP) salvages purines by releasing adenine from [CHEMICAL]methylthioadenosine[\\CHEMICAL] and is often deleted in mesothelioma.",
        "label": 9,
        "major": -1,
        "len": 16
    },
    {
        "text": "Methylthioadenosine phosphorylase ([GENE]MTAP[\\GENE]) salvages purines by releasing adenine from [CHEMICAL]methylthioadenosine[\\CHEMICAL] and is often deleted in mesothelioma.",
        "label": 9,
        "major": -1,
        "len": 16
    },
    {
        "text": "Our work shows that [CHEMICAL]sulfonylureas[\\CHEMICAL] and glinides additionally bind to [GENE]PPARgamma[\\GENE] and exhibit PPARgamma agonistic activity.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Our work shows that sulfonylureas and [CHEMICAL]glinides[\\CHEMICAL] additionally bind to [GENE]PPARgamma[\\GENE] and exhibit PPARgamma agonistic activity.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "This dual mode of action of [CHEMICAL]sulfonylureas[\\CHEMICAL] and glinides may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the [GENE]sulfonylurea receptor[\\GENE] and PPARgamma.",
        "label": 2,
        "major": -1,
        "len": 37
    },
    {
        "text": "This dual mode of action of [CHEMICAL]sulfonylureas[\\CHEMICAL] and glinides may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the sulfonylurea receptor and [GENE]PPARgamma[\\GENE].",
        "label": 2,
        "major": -1,
        "len": 37
    },
    {
        "text": "This dual mode of action of sulfonylureas and [CHEMICAL]glinides[\\CHEMICAL] may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the [GENE]sulfonylurea receptor[\\GENE] and PPARgamma.",
        "label": 2,
        "major": -1,
        "len": 37
    },
    {
        "text": "This dual mode of action of sulfonylureas and [CHEMICAL]glinides[\\CHEMICAL] may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the sulfonylurea receptor and [GENE]PPARgamma[\\GENE].",
        "label": 2,
        "major": -1,
        "len": 37
    },
    {
        "text": "[CHEMICAL]Sulfonylureas[\\CHEMICAL] and glinides exhibit [GENE]peroxisome proliferator-activated receptor gamma[\\GENE] activity: a combined virtual screening and biological assay approach.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Sulfonylureas and [CHEMICAL]glinides[\\CHEMICAL] exhibit [GENE]peroxisome proliferator-activated receptor gamma[\\GENE] activity: a combined virtual screening and biological assay approach.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Most drugs currently employed in the treatment of type 2 diabetes either target the [GENE]sulfonylurea receptor[\\GENE] stimulating insulin release ([CHEMICAL]sulfonylureas[\\CHEMICAL], glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "Most drugs currently employed in the treatment of type 2 diabetes either target the [GENE]sulfonylurea receptor[\\GENE] stimulating insulin release (sulfonylureas, [CHEMICAL]glinides[\\CHEMICAL]), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the [GENE]peroxisome proliferator-activated receptor[\\GENE] (PPARgamma) improving insulin resistance ([CHEMICAL]thiazolidinediones[\\CHEMICAL]).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor ([GENE]PPARgamma[\\GENE]) improving insulin resistance ([CHEMICAL]thiazolidinediones[\\CHEMICAL]).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "The most active of these compounds, [CHEMICAL]gliquidone[\\CHEMICAL], is shown to be as potent as pioglitazone at inducing [GENE]PPARgamma[\\GENE] target gene expression.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "The most active of these compounds, gliquidone, is shown to be as potent as [CHEMICAL]pioglitazone[\\CHEMICAL] at inducing [GENE]PPARgamma[\\GENE] target gene expression.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating [GENE]insulin[\\GENE] release ([CHEMICAL]sulfonylureas[\\CHEMICAL], glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating [GENE]insulin[\\GENE] release (sulfonylureas, [CHEMICAL]glinides[\\CHEMICAL]), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "Among the measured compounds, [CHEMICAL]gliquidone[\\CHEMICAL] and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit [GENE]PPARgamma[\\GENE] agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
        "label": 5,
        "major": 5,
        "len": 28
    },
    {
        "text": "Among the measured compounds, gliquidone and [CHEMICAL]glipizide[\\CHEMICAL] (two sulfonylureas), as well as nateglinide (a glinide), exhibit [GENE]PPARgamma[\\GENE] agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
        "label": 5,
        "major": 5,
        "len": 28
    },
    {
        "text": "Among the measured compounds, gliquidone and glipizide (two [CHEMICAL]sulfonylureas[\\CHEMICAL]), as well as nateglinide (a glinide), exhibit [GENE]PPARgamma[\\GENE] agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
        "label": 5,
        "major": 5,
        "len": 28
    },
    {
        "text": "Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as [CHEMICAL]nateglinide[\\CHEMICAL] (a glinide), exhibit [GENE]PPARgamma[\\GENE] agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
        "label": 5,
        "major": 5,
        "len": 28
    },
    {
        "text": "Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nateglinide (a [CHEMICAL]glinide[\\CHEMICAL]), exhibit [GENE]PPARgamma[\\GENE] agonistic activity at concentrations comparable with those reached under pharmacological treatment.",
        "label": 5,
        "major": 5,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Glinides[\\CHEMICAL], sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new [GENE]PPARgamma[\\GENE] agonists.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "Glinides, [CHEMICAL]sulfonylureas[\\CHEMICAL], and other acidified sulfonamides may be promising leads in the development of new [GENE]PPARgamma[\\GENE] agonists.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "Glinides, sulfonylureas, and other [CHEMICAL]acidified sulfonamides[\\CHEMICAL] may be promising leads in the development of new [GENE]PPARgamma[\\GENE] agonists.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "Our work shows that [CHEMICAL]sulfonylureas[\\CHEMICAL] and glinides additionally bind to PPARgamma and exhibit [GENE]PPARgamma[\\GENE] agonistic activity.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "Our work shows that sulfonylureas and [CHEMICAL]glinides[\\CHEMICAL] additionally bind to PPARgamma and exhibit [GENE]PPARgamma[\\GENE] agonistic activity.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "There is a growing appreciation that the [CHEMICAL]cyclic adenosine monophosphate[\\CHEMICAL] (cAMP)-[GENE]protein kinase A[\\GENE] (PKA) signaling pathway is organized to form transduction units that function to deliver specific messages.",
        "label": 2,
        "major": -1,
        "len": 28
    },
    {
        "text": "There is a growing appreciation that the [CHEMICAL]cyclic adenosine monophosphate[\\CHEMICAL] (cAMP)-protein kinase A ([GENE]PKA[\\GENE]) signaling pathway is organized to form transduction units that function to deliver specific messages.",
        "label": 2,
        "major": -1,
        "len": 28
    },
    {
        "text": "There is a growing appreciation that the cyclic adenosine monophosphate ([CHEMICAL]cAMP[\\CHEMICAL])-[GENE]protein kinase A[\\GENE] (PKA) signaling pathway is organized to form transduction units that function to deliver specific messages.",
        "label": 2,
        "major": -1,
        "len": 28
    },
    {
        "text": "There is a growing appreciation that the cyclic adenosine monophosphate ([CHEMICAL]cAMP[\\CHEMICAL])-protein kinase A ([GENE]PKA[\\GENE]) signaling pathway is organized to form transduction units that function to deliver specific messages.",
        "label": 2,
        "major": -1,
        "len": 28
    },
    {
        "text": "Such organization results in the local activation of [GENE]PKA[\\GENE] subsets through the generation of confined intracellular gradients of [CHEMICAL]cAMP[\\CHEMICAL], but the mechanisms responsible for limiting the diffusion of cAMP largely remain to be clarified.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized [GENE]PDE4B[\\GENE] and PDE4D are responsible for selectively modulating the concentration of [CHEMICAL]cAMP[\\CHEMICAL] in individual subcellular compartments.",
        "label": 9,
        "major": 7,
        "len": 29
    },
    {
        "text": "By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and [GENE]PDE4D[\\GENE] are responsible for selectively modulating the concentration of [CHEMICAL]cAMP[\\CHEMICAL] in individual subcellular compartments.",
        "label": 9,
        "major": 7,
        "len": 29
    },
    {
        "text": "We propose a model whereby compartmentalized [GENE]PDEs[\\GENE], rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different [CHEMICAL]cAMP[\\CHEMICAL] concentrations irrespective of their distance from the site of cAMP synthesis.",
        "label": 9,
        "major": -1,
        "len": 48
    },
    {
        "text": "We propose a model whereby compartmentalized [GENE]PDEs[\\GENE], rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different cAMP concentrations irrespective of their distance from the site of [CHEMICAL]cAMP[\\CHEMICAL] synthesis.",
        "label": 9,
        "major": -1,
        "len": 48
    },
    {
        "text": "We failed to observe any significant activation of [GENE]FAS promoter[\\GENE] following exposure to the anti-metabolite [CHEMICAL]5-fluorouracil[\\CHEMICAL], the alkylating drug cisplatin, or the microtubule interfering-agents paclitaxel and vincristine.",
        "label": 10,
        "major": 3,
        "len": 27
    },
    {
        "text": "We failed to observe any significant activation of [GENE]FAS promoter[\\GENE] following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug [CHEMICAL]cisplatin[\\CHEMICAL], or the microtubule interfering-agents paclitaxel and vincristine.",
        "label": 10,
        "major": 3,
        "len": 27
    },
    {
        "text": "We failed to observe any significant activation of [GENE]FAS promoter[\\GENE] following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug cisplatin, or the microtubule interfering-agents [CHEMICAL]paclitaxel[\\CHEMICAL] and vincristine.",
        "label": 10,
        "major": 3,
        "len": 27
    },
    {
        "text": "We failed to observe any significant activation of [GENE]FAS promoter[\\GENE] following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug cisplatin, or the microtubule interfering-agents paclitaxel and [CHEMICAL]vincristine[\\CHEMICAL].",
        "label": 10,
        "major": 3,
        "len": 27
    },
    {
        "text": "SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors [CHEMICAL]doxorubicin[\\CHEMICAL] and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in [GENE]FAS promoter[\\GENE] activity when compared with control cells growing in drug-free culture conditions.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and [CHEMICAL]etopoxide[\\CHEMICAL] (VP-16) demonstrated a 2- to 3-fold increase in [GENE]FAS promoter[\\GENE] activity when compared with control cells growing in drug-free culture conditions.",
        "label": 3,
        "major": 4,
        "len": 35
    },
    {
        "text": "SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide ([CHEMICAL]VP-16[\\CHEMICAL]) demonstrated a 2- to 3-fold increase in [GENE]FAS promoter[\\GENE] activity when compared with control cells growing in drug-free culture conditions.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "SK-Br3 cells cultured in the presence of [GENE]topoisomerase IIalpha[\\GENE] (TOP2A) inhibitors [CHEMICAL]doxorubicin[\\CHEMICAL] and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "SK-Br3 cells cultured in the presence of topoisomerase IIalpha ([GENE]TOP2A[\\GENE]) inhibitors [CHEMICAL]doxorubicin[\\CHEMICAL] and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "SK-Br3 cells cultured in the presence of [GENE]topoisomerase IIalpha[\\GENE] (TOP2A) inhibitors doxorubicin and [CHEMICAL]etopoxide[\\CHEMICAL] (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "SK-Br3 cells cultured in the presence of topoisomerase IIalpha ([GENE]TOP2A[\\GENE]) inhibitors doxorubicin and [CHEMICAL]etopoxide[\\CHEMICAL] (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "SK-Br3 cells cultured in the presence of [GENE]topoisomerase IIalpha[\\GENE] (TOP2A) inhibitors doxorubicin and etopoxide ([CHEMICAL]VP-16[\\CHEMICAL]) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "SK-Br3 cells cultured in the presence of topoisomerase IIalpha ([GENE]TOP2A[\\GENE]) inhibitors doxorubicin and etopoxide ([CHEMICAL]VP-16[\\CHEMICAL]) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Mifepristone[\\CHEMICAL] alters expression of endometrial [GENE]steroid receptors[\\GENE] and their cofactors in new users of medroxyprogesterone acetate.",
        "label": 2,
        "major": 8,
        "len": 16
    },
    {
        "text": "RESULT(S): The expression of endometrial [GENE]ERalpha[\\GENE], PRAB, PRB, and SRC-1 was increased significantly after 1 week of [CHEMICAL]mifepristone[\\CHEMICAL], but the increase was no longer seen after 10 weeks.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "RESULT(S): The expression of endometrial ERalpha, [GENE]PRAB[\\GENE], PRB, and SRC-1 was increased significantly after 1 week of [CHEMICAL]mifepristone[\\CHEMICAL], but the increase was no longer seen after 10 weeks.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "RESULT(S): The expression of endometrial ERalpha, PRAB, [GENE]PRB[\\GENE], and SRC-1 was increased significantly after 1 week of [CHEMICAL]mifepristone[\\CHEMICAL], but the increase was no longer seen after 10 weeks.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "RESULT(S): The expression of endometrial ERalpha, PRAB, PRB, and [GENE]SRC-1[\\GENE] was increased significantly after 1 week of [CHEMICAL]mifepristone[\\CHEMICAL], but the increase was no longer seen after 10 weeks.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "CONCLUSION(S): Short-term exposure of [CHEMICAL]mifepristone[\\CHEMICAL] in new starters of DMPA increases the expression of endometrial [GENE]ERalpha[\\GENE], PRAB, PRB, and SRC-1 and promotes cell proliferation.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "CONCLUSION(S): Short-term exposure of [CHEMICAL]mifepristone[\\CHEMICAL] in new starters of DMPA increases the expression of endometrial ERalpha, [GENE]PRAB[\\GENE], PRB, and SRC-1 and promotes cell proliferation.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "CONCLUSION(S): Short-term exposure of [CHEMICAL]mifepristone[\\CHEMICAL] in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, [GENE]PRB[\\GENE], and SRC-1 and promotes cell proliferation.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "CONCLUSION(S): Short-term exposure of [CHEMICAL]mifepristone[\\CHEMICAL] in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, PRB, and [GENE]SRC-1[\\GENE] and promotes cell proliferation.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "The cytosolic fraction obtained from pancreatic islets obtained from [CHEMICAL]GalN[\\CHEMICAL]-treated rats had an increased [GENE]PTB[\\GENE] level compared to the levels obtained from the pancreatic islets of control rats.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "In the present study, [CHEMICAL]glucose[\\CHEMICAL]-stimulated [GENE]insulin[\\GENE] secretion was significantly increased in GalN-treated rats compared to controls.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "In the present study, glucose-stimulated [GENE]insulin[\\GENE] secretion was significantly increased in [CHEMICAL]GalN[\\CHEMICAL]-treated rats compared to controls.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Levels of mRNA encoding [GENE]insulin 1[\\GENE], ICA512, and PC1/3 were increased in the pancreatic islets of [CHEMICAL]GalN[\\CHEMICAL]-treated rats.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Levels of mRNA encoding insulin 1, [GENE]ICA512[\\GENE], and PC1/3 were increased in the pancreatic islets of [CHEMICAL]GalN[\\CHEMICAL]-treated rats.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "This mRNA level elevation was not prevented by pretreatment with actinomycin D. When the [GENE]PTB-binding site[\\GENE] in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from [CHEMICAL]GalN[\\CHEMICAL]-treated rats compared to the level in control rats.",
        "label": 3,
        "major": 3,
        "len": 48
    },
    {
        "text": "This mRNA level elevation was not prevented by pretreatment with actinomycin D. When the PTB-binding site in [GENE]insulin 1[\\GENE] mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from [CHEMICAL]GalN[\\CHEMICAL]-treated rats compared to the level in control rats.",
        "label": 3,
        "major": 3,
        "len": 48
    },
    {
        "text": "The changes in [GENE]CysLT1 receptor[\\GENE] expression 24 h after [CHEMICAL]NMDA[\\CHEMICAL] injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.",
        "label": 2,
        "major": 6,
        "len": 39
    },
    {
        "text": "[GENE]Cysteinyl leukotriene receptor 1[\\GENE] is involved in [CHEMICAL]N-methyl-D-aspartate[\\CHEMICAL]-mediated neuronal injury in mice.",
        "label": 2,
        "major": -1,
        "len": 12
    },
    {
        "text": "RESULTS: In the [CHEMICAL]NMDA[\\CHEMICAL]-injured brain, the [GENE]CysLT1 receptor[\\GENE] mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "CONCLUSION: [GENE]CysLT1 receptor[\\GENE] expression in neurons is upregulated after [CHEMICAL]NMDA[\\CHEMICAL] injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased [GENE]CysLT1 receptor[\\GENE] is involved in [CHEMICAL]NMDA[\\CHEMICAL] excitotoxicity.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Pranlukast, ketamine and edaravone decreased NMDA-induced injury; [CHEMICAL]pranlukast[\\CHEMICAL] (0.1 mg/kg) and ketamine inhibited the upregulated expression of the [GENE]CysLT1 receptor[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and [CHEMICAL]ketamine[\\CHEMICAL] inhibited the upregulated expression of the [GENE]CysLT1 receptor[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a [GENE]CysLT1 receptor[\\GENE] antagonist, [CHEMICAL]pranlukast[\\CHEMICAL] (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an [GENE]NMDA receptor[\\GENE] antagonist, [CHEMICAL]ketamine[\\CHEMICAL] (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "We have previously demonstrated that phosphorylation of [GENE]Fas-associated death domain-containing protein[\\GENE] (FADD) at 194 [CHEMICAL]serine[\\CHEMICAL] through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.",
        "label": 1,
        "major": 3,
        "len": 51
    },
    {
        "text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein ([GENE]FADD[\\GENE]) at 194 [CHEMICAL]serine[\\CHEMICAL] through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.",
        "label": 1,
        "major": 3,
        "len": 51
    },
    {
        "text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that [GENE]Bcl-2[\\GENE] phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 51
    },
    {
        "text": "We have previously demonstrated that phosphorylation of [GENE]Fas-associated death domain-containing protein[\\GENE] (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 51
    },
    {
        "text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein ([GENE]FADD[\\GENE]) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 51
    },
    {
        "text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through [GENE]c-jun NH2-terminal kinase[\\GENE] (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 51
    },
    {
        "text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase ([GENE]JNK[\\GENE]) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 51
    },
    {
        "text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of [GENE]JNK[\\GENE]/FADD plays an important role in cell growth suppression by [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 51
    },
    {
        "text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/[GENE]FADD[\\GENE] plays an important role in cell growth suppression by [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 51
    },
    {
        "text": "[GENE]5-HT3 receptor[\\GENE] antagonism with alosetron reduced responses to [CHEMICAL]5-HT[\\CHEMICAL] in controls but not during inflammation.",
        "label": 2,
        "major": 6,
        "len": 15
    },
    {
        "text": "[GENE]5-HT3 receptor[\\GENE] antagonism with [CHEMICAL]alosetron[\\CHEMICAL] reduced responses to 5-HT in controls but not during inflammation.",
        "label": 6,
        "major": 10,
        "len": 15
    },
    {
        "text": "Progestin induction of cell cycle progression was also abrogated in cells expressing PR-BDeltaSH3, and no effect of [CHEMICAL]progestin[\\CHEMICAL] on [GENE]cyclin D1[\\GENE] expression and cell cycle was observed in the presence of PR-A.",
        "label": 10,
        "major": 3,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Progestin[\\CHEMICAL] activation of Src/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with [GENE]PR-A[\\GENE] that was predominantly nuclear.",
        "label": 10,
        "major": 3,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Progestin[\\CHEMICAL] induction of the [GENE]cyclin D1[\\GENE] gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.",
        "label": 2,
        "major": 3,
        "len": 51
    },
    {
        "text": "[CHEMICAL]Progestin[\\CHEMICAL] induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the [GENE]Sgk[\\GENE] (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.",
        "label": 2,
        "major": 3,
        "len": 51
    },
    {
        "text": "[CHEMICAL]Progestin[\\CHEMICAL] induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk ([GENE]serum and glucocorticoid regulated kinase[\\GENE]) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.",
        "label": 2,
        "major": 3,
        "len": 51
    },
    {
        "text": "The role of extranuclear signaling actions of [GENE]progesterone receptor[\\GENE] in mediating [CHEMICAL]progesterone[\\CHEMICAL] regulation of gene expression and the cell cycle.",
        "label": 2,
        "major": -1,
        "len": 20
    },
    {
        "text": "Progestin induction of cell cycle progression was also abrogated in cells expressing PR-BDeltaSH3, and no effect of [CHEMICAL]progestin[\\CHEMICAL] on cyclin D1 expression and cell cycle was observed in the presence of [GENE]PR-A[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Progestin[\\CHEMICAL] activation of Src/MAPK occurred outside the nucleus with the [GENE]B isoform of PR[\\GENE] that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "These results highlight the importance of [GENE]PR[\\GENE] activation of the Src/MAPK signaling pathway for [CHEMICAL]progesterone[\\CHEMICAL]-induced transcription of select target genes and cell cycle progression.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "These results highlight the importance of PR activation of the [GENE]Src[\\GENE]/MAPK signaling pathway for [CHEMICAL]progesterone[\\CHEMICAL]-induced transcription of select target genes and cell cycle progression.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "These results highlight the importance of PR activation of the Src/[GENE]MAPK[\\GENE] signaling pathway for [CHEMICAL]progesterone[\\CHEMICAL]-induced transcription of select target genes and cell cycle progression.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Progestin[\\CHEMICAL] activation of [GENE]Src[\\GENE]/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.",
        "label": 3,
        "major": 10,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Progestin[\\CHEMICAL] activation of Src/[GENE]MAPK[\\GENE] occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.",
        "label": 3,
        "major": 10,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Progestin[\\CHEMICAL] induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on [GENE]PR[\\GENE] activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.",
        "label": 3,
        "major": 3,
        "len": 51
    },
    {
        "text": "[CHEMICAL]Progestin[\\CHEMICAL] induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the [GENE]Src[\\GENE]/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.",
        "label": 3,
        "major": 3,
        "len": 51
    },
    {
        "text": "[CHEMICAL]Progestin[\\CHEMICAL] induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/[GENE]MAPK[\\GENE] pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.",
        "label": 3,
        "major": 3,
        "len": 51
    },
    {
        "text": "injection of a subthreshold dose of [CHEMICAL]picrotoxin[\\CHEMICAL], a use-dependent [GENE]gamma-aminobutyric acid receptor[\\GENE] antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice.",
        "label": 6,
        "major": 4,
        "len": 28
    },
    {
        "text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and [CHEMICAL]2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane[\\CHEMICAL] (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ([GENE]SERT[\\GENE], DAT, and NET, respectively) using transfected cells.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and [CHEMICAL]2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane[\\CHEMICAL] (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, [GENE]DAT[\\GENE], and NET, respectively) using transfected cells.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and [CHEMICAL]2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane[\\CHEMICAL] (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and [GENE]NET[\\GENE], respectively) using transfected cells.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "Chase studies with [CHEMICAL]citalopram[\\CHEMICAL] and methylphenidate demonstrated that this uptake is the result of preferential binding to the [GENE]SERT[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Chase studies with citalopram and [CHEMICAL]methylphenidate[\\CHEMICAL] demonstrated that this uptake is the result of preferential binding to the [GENE]SERT[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Synthesis, radiosynthesis, and biological evaluation of [CHEMICAL]carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes[\\CHEMICAL]: candidate radioligands for in vivo imaging of the [GENE]serotonin transporter[\\GENE] with positron emission tomography.",
        "label": 2,
        "major": 9,
        "len": 23
    },
    {
        "text": "[CHEMICAL]2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane[\\CHEMICAL] (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ([GENE]SERT[\\GENE], DAT, and NET, respectively) using transfected cells.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "[CHEMICAL]2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane[\\CHEMICAL] (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, [GENE]DAT[\\GENE], and NET, respectively) using transfected cells.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "[CHEMICAL]2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane[\\CHEMICAL] (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and [GENE]NET[\\GENE], respectively) using transfected cells.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane ([CHEMICAL]mZBrENT[\\CHEMICAL], 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ([GENE]SERT[\\GENE], DAT, and NET, respectively) using transfected cells.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane ([CHEMICAL]mZBrENT[\\CHEMICAL], 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, [GENE]DAT[\\GENE], and NET, respectively) using transfected cells.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane ([CHEMICAL]mZBrENT[\\CHEMICAL], 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and [GENE]NET[\\GENE], respectively) using transfected cells.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane ([CHEMICAL]mZIENT[\\CHEMICAL], 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ([GENE]SERT[\\GENE], DAT, and NET, respectively) using transfected cells.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane ([CHEMICAL]mZIENT[\\CHEMICAL], 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, [GENE]DAT[\\GENE], and NET, respectively) using transfected cells.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane ([CHEMICAL]mZIENT[\\CHEMICAL], 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and [GENE]NET[\\GENE], respectively) using transfected cells.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "MicroPET imaging in nonhuman primates with [[CHEMICAL]11C[\\CHEMICAL]]1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the [GENE]SERT[\\GENE]-rich brain regions and peak uptake being achieved in about 55 min postinjection.",
        "label": 9,
        "major": -1,
        "len": 37
    },
    {
        "text": "MicroPET imaging in nonhuman primates with [11C]1 and [[CHEMICAL]11C[\\CHEMICAL]]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the [GENE]SERT[\\GENE]-rich brain regions and peak uptake being achieved in about 55 min postinjection.",
        "label": 9,
        "major": -1,
        "len": 37
    },
    {
        "text": "This trial investigated the possibility of pharmacokinetic interactions between the [GENE]AT1 receptor[\\GENE] antagonist [CHEMICAL]olmesartan medoxomil[\\CHEMICAL] and the thiazide diuretic hydrochlorothiazide in healthy subjects.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "In vivo, cromolyn inhibited tumor growth in mice bearing tumor with endogenous [GENE]S100P[\\GENE] (BxPC-3: control, mean = 1.6 x 10(9) photons/s, versus cromolyn, mean = 4.4 x 10(8) photons/s, difference = 1.2 x 10(9) photons/s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons/s; P<.001, n = 5; MPanc-96: control, mean = 1.1 x 10(10) photons/s, versus cromolyn, mean = 4.8 x 10(9) photons/s, difference = 6.2 x 10(9) photons/s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons/s; P = .009, n = 5) and increased the effectiveness of [CHEMICAL]gemcitabine[\\CHEMICAL] (BxPC-3: gemcitabine, mean = 9.2 x 10(8) photons/s, versus combination, mean = 1.8 x 10(8) photons/s, difference = 7.4 x 10(8) photons/s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons/s; P<.001; MPanc-96: gemcitabine, mean = 4.1 x 10(9) photons/s, versus combination, mean = 2.0 x 10(9) photons/s, difference = 2.1 x 10(9) photons/s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons/s; P<.001).",
        "label": 2,
        "major": 3,
        "len": 163
    },
    {
        "text": "In vivo, cromolyn inhibited tumor growth in mice bearing tumor with endogenous [GENE]S100P[\\GENE] (BxPC-3: control, mean = 1.6 x 10(9) photons/s, versus cromolyn, mean = 4.4 x 10(8) photons/s, difference = 1.2 x 10(9) photons/s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons/s; P<.001, n = 5; MPanc-96: control, mean = 1.1 x 10(10) photons/s, versus cromolyn, mean = 4.8 x 10(9) photons/s, difference = 6.2 x 10(9) photons/s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons/s; P = .009, n = 5) and increased the effectiveness of gemcitabine (BxPC-3: [CHEMICAL]gemcitabine[\\CHEMICAL], mean = 9.2 x 10(8) photons/s, versus combination, mean = 1.8 x 10(8) photons/s, difference = 7.4 x 10(8) photons/s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons/s; P<.001; MPanc-96: gemcitabine, mean = 4.1 x 10(9) photons/s, versus combination, mean = 2.0 x 10(9) photons/s, difference = 2.1 x 10(9) photons/s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons/s; P<.001).",
        "label": 2,
        "major": 4,
        "len": 163
    },
    {
        "text": "CONCLUSION: Cromolyn binds [GENE]S100P[\\GENE], prevents activation of RAGE, inhibits tumor growth, and increases the effectiveness of [CHEMICAL]gemcitabine[\\CHEMICAL] in experimental models.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "In addition, we found that selenophosphate synthetase 2 could synthesize [CHEMICAL]monoselenophosphate[\\CHEMICAL] in vitro but [GENE]selenophosphate synthetase 1[\\GENE] could not.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Herein, comparative genomics and experimental analyses revealed that the [GENE]mammalian Sec synthase[\\GENE] (SecS) is the previously identified [CHEMICAL]pyridoxal phosphate[\\CHEMICAL]-containing protein known as the soluble liver antigen.",
        "label": 8,
        "major": -1,
        "len": 26
    },
    {
        "text": "Herein, comparative genomics and experimental analyses revealed that the mammalian Sec synthase ([GENE]SecS[\\GENE]) is the previously identified [CHEMICAL]pyridoxal phosphate[\\CHEMICAL]-containing protein known as the soluble liver antigen.",
        "label": 8,
        "major": -1,
        "len": 26
    },
    {
        "text": "Herein, comparative genomics and experimental analyses revealed that the mammalian Sec synthase (SecS) is the previously identified [CHEMICAL]pyridoxal phosphate[\\CHEMICAL]-containing protein known as the [GENE]soluble liver antigen[\\GENE].",
        "label": 8,
        "major": -1,
        "len": 26
    },
    {
        "text": "[GENE]SecS[\\GENE] required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate [CHEMICAL]selenocysteyl[\\CHEMICAL]-tRNA([Ser]Sec).",
        "label": 9,
        "major": 9,
        "len": 10
    },
    {
        "text": "In addition, we found that [GENE]selenophosphate synthetase 2[\\GENE] could synthesize [CHEMICAL]monoselenophosphate[\\CHEMICAL] in vitro but selenophosphate synthetase 1 could not.",
        "label": 9,
        "major": 10,
        "len": 19
    },
    {
        "text": "[GENE]SecS[\\GENE] required selenophosphate and [CHEMICAL]O-phosphoseryl[\\CHEMICAL]-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec).",
        "label": 9,
        "major": 9,
        "len": 10
    },
    {
        "text": "[GENE]SecS[\\GENE] required [CHEMICAL]selenophosphate[\\CHEMICAL] and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec).",
        "label": 9,
        "major": 9,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Triflusal[\\CHEMICAL] (30 mg/kg) or aspirin treatment (30 mg/kg) did not reduce the levels of [GENE]GFAP[\\GENE] or Hsp27 immunostaining.",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Triflusal[\\CHEMICAL] (30 mg/kg) or aspirin treatment (30 mg/kg) did not reduce the levels of GFAP or [GENE]Hsp27[\\GENE] immunostaining.",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "Triflusal (30 mg/kg) or [CHEMICAL]aspirin[\\CHEMICAL] treatment (30 mg/kg) did not reduce the levels of [GENE]GFAP[\\GENE] or Hsp27 immunostaining.",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "Triflusal (30 mg/kg) or [CHEMICAL]aspirin[\\CHEMICAL] treatment (30 mg/kg) did not reduce the levels of GFAP or [GENE]Hsp27[\\GENE] immunostaining.",
        "label": 10,
        "major": 10,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Triflusal[\\CHEMICAL] (30 mg/kg) also significantly decreased the protein levels of IL-Ibeta but not [GENE]nuclear factor kappa B[\\GENE] or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion.",
        "label": 10,
        "major": 10,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Triflusal[\\CHEMICAL] (30 mg/kg) also significantly decreased the protein levels of IL-Ibeta but not nuclear factor kappa B or [GENE]tumor necrosis factor-alpha[\\GENE] in the cortex ipsilateral to the middle cerebral artery occlusion.",
        "label": 10,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Triflusal[\\CHEMICAL], a selective [GENE]cyclooxygenase-2[\\GENE], and its active metabolite 3-hydroxy-4-trifluoromethylbenzoic acid may inhibit apoptosis and inflammation after cerebral ischemia.",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "Triflusal, a selective [GENE]cyclooxygenase-2[\\GENE], and its active metabolite [CHEMICAL]3-hydroxy-4-trifluoromethylbenzoic acid[\\CHEMICAL] may inhibit apoptosis and inflammation after cerebral ischemia.",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Triflusal[\\CHEMICAL] (30 mg/kg) also significantly decreased the protein levels of [GENE]IL-Ibeta[\\GENE] but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The [GENE]GRIP1[\\GENE] reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by [CHEMICAL]6-cyano-7-nitroquinoxaline-2,3-dione[\\CHEMICAL] (CNQX), an AMPA receptor antagonist.",
        "label": 10,
        "major": 4,
        "len": 21
    },
    {
        "text": "The [GENE]GRIP1[\\GENE] reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione ([CHEMICAL]CNQX[\\CHEMICAL]), an AMPA receptor antagonist.",
        "label": 10,
        "major": 4,
        "len": 21
    },
    {
        "text": "EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not [CHEMICAL]nifedipine[\\CHEMICAL], an L-type Ca2+ channel blocker, prevented [GENE]GRIP1[\\GENE] degradation.",
        "label": 10,
        "major": 10,
        "len": 21
    },
    {
        "text": "Here we report that [CHEMICAL]glutamate[\\CHEMICAL] stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor [GENE](GluR) 1[\\GENE], GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures.",
        "label": 10,
        "major": 2,
        "len": 38
    },
    {
        "text": "Here we report that [CHEMICAL]glutamate[\\CHEMICAL] stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor (GluR) 1, [GENE]GluR2[\\GENE] and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures.",
        "label": 10,
        "major": 2,
        "len": 38
    },
    {
        "text": "Here we report that [CHEMICAL]glutamate[\\CHEMICAL] stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor (GluR) 1, GluR2 and [GENE]protein interacting with C kinase 1[\\GENE] (PICK1) in rat primary cortical neuron cultures.",
        "label": 10,
        "major": 10,
        "len": 38
    },
    {
        "text": "Here we report that [CHEMICAL]glutamate[\\CHEMICAL] stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 ([GENE]PICK1[\\GENE]) in rat primary cortical neuron cultures.",
        "label": 10,
        "major": 3,
        "len": 38
    },
    {
        "text": "Our results suggest that [CHEMICAL]glutamate[\\CHEMICAL] induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating [GENE]GluR2[\\GENE] surface expression.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "Furthermore, [CHEMICAL]MG132[\\CHEMICAL] prevented glutamate-stimulated reduction in surface amount of [GENE]GluR2[\\GENE], and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Glutamate[\\CHEMICAL] stimulates glutamate receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of [GENE]GluR2[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Down-regulation of [GENE]GRIP1[\\GENE] by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal ([CHEMICAL]MG132[\\CHEMICAL]), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.",
        "label": 2,
        "major": 4,
        "len": 24
    },
    {
        "text": "Our results suggest that [CHEMICAL]glutamate[\\CHEMICAL] induces GRIP1 degradation by [GENE]proteasome[\\GENE] through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "Our results suggest that [CHEMICAL]glutamate[\\CHEMICAL] induces GRIP1 degradation by proteasome through an [GENE]NMDA receptor[\\GENE]-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Glutamate[\\CHEMICAL] stimulates glutamate receptor interacting protein 1 degradation by [GENE]ubiquitin[\\GENE]-proteasome system to regulate surface expression of GluR2.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Glutamate[\\CHEMICAL] stimulates glutamate receptor interacting protein 1 degradation by ubiquitin-[GENE]proteasome[\\GENE] system to regulate surface expression of GluR2.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "Down-regulation of [GENE]GRIP1[\\GENE] by glutamate was blocked by [CHEMICAL]carbobenzoxyl-leucinyl-leucinyl-leucinal[\\CHEMICAL] (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.",
        "label": 2,
        "major": 4,
        "len": 24
    },
    {
        "text": "The [GENE]GRIP1[\\GENE] reduction was inhibited by [CHEMICAL]MK-801[\\CHEMICAL], an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]EGTA[\\CHEMICAL] and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented [GENE]GRIP1[\\GENE] degradation.",
        "label": 3,
        "major": 10,
        "len": 21
    },
    {
        "text": "EGTA and [CHEMICAL]1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis[\\CHEMICAL] (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented [GENE]GRIP1[\\GENE] degradation.",
        "label": 3,
        "major": 10,
        "len": 21
    },
    {
        "text": "EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis ([CHEMICAL]BAPTA[\\CHEMICAL]), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented [GENE]GRIP1[\\GENE] degradation.",
        "label": 3,
        "major": 10,
        "len": 21
    },
    {
        "text": "Our results suggest that [CHEMICAL]glutamate[\\CHEMICAL] induces [GENE]GRIP1[\\GENE] degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Our results suggest that [CHEMICAL]glutamate[\\CHEMICAL] induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that [GENE]GRIP1[\\GENE] degradation may play an important role in regulating GluR2 surface expression.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Glutamate[\\CHEMICAL] stimulates [GENE]glutamate receptor interacting protein 1[\\GENE] degradation by ubiquitin-proteasome system to regulate surface expression of GluR2.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "Down-regulation of [GENE]GRIP1[\\GENE] by [CHEMICAL]glutamate[\\CHEMICAL] was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Furthermore, MG132 prevented [CHEMICAL]glutamate[\\CHEMICAL]-stimulated reduction in surface amount of [GENE]GluR2[\\GENE], and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Here we report that [CHEMICAL]glutamate[\\CHEMICAL] stimulation caused a rapid reduction in protein levels of [GENE]GRIP1[\\GENE], but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures.",
        "label": 4,
        "major": 2,
        "len": 38
    },
    {
        "text": "Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal ([CHEMICAL]MG132[\\CHEMICAL]), a [GENE]proteasome[\\GENE] inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not [CHEMICAL]nifedipine[\\CHEMICAL], an [GENE]L-type Ca2+ channel[\\GENE] blocker, prevented GRIP1 degradation.",
        "label": 4,
        "major": 10,
        "len": 21
    },
    {
        "text": "Down-regulation of GRIP1 by glutamate was blocked by [CHEMICAL]carbobenzoxyl-leucinyl-leucinyl-leucinal[\\CHEMICAL] (MG132), a [GENE]proteasome[\\GENE] inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The GRIP1 reduction was inhibited by [CHEMICAL]MK-801[\\CHEMICAL], an [GENE]N-methyl-d-aspartate (NMDA) receptor[\\GENE] antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.",
        "label": 6,
        "major": 4,
        "len": 21
    },
    {
        "text": "The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by [CHEMICAL]6-cyano-7-nitroquinoxaline-2,3-dione[\\CHEMICAL] (CNQX), an [GENE]AMPA receptor[\\GENE] antagonist.",
        "label": 6,
        "major": 4,
        "len": 21
    },
    {
        "text": "The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione ([CHEMICAL]CNQX[\\CHEMICAL]), an [GENE]AMPA receptor[\\GENE] antagonist.",
        "label": 6,
        "major": 4,
        "len": 21
    },
    {
        "text": "Cytokines, lipopolysaccharides and other inflammatory mediators such as [CHEMICAL]prostaglandin[\\CHEMICAL] and leukotriene are related to the secretion and production of [GENE]mucin[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 20
    },
    {
        "text": "Cytokines, lipopolysaccharides and other inflammatory mediators such as prostaglandin and [CHEMICAL]leukotriene[\\CHEMICAL] are related to the secretion and production of [GENE]mucin[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 20
    },
    {
        "text": "However, the relationship of [CHEMICAL]leukotrienes[\\CHEMICAL] with [GENE]mucin[\\GENE] genes expression is not clear.",
        "label": 2,
        "major": 10,
        "len": 12
    },
    {
        "text": "RESULTS: [CHEMICAL]Leukotriene D(4)[\\CHEMICAL] upregulated [GENE]MUC2/5AC[\\GENE] gene expression and mucin secretion in a dose dependent pattern.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "RESULTS: [CHEMICAL]Leukotriene D(4)[\\CHEMICAL] upregulated MUC2/5AC gene expression and [GENE]mucin[\\GENE] secretion in a dose dependent pattern.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "The inhibitory effect of the leukotriene receptor antagonist on [CHEMICAL]leukotriene D4[\\CHEMICAL]-induced MUC2/5AC gene expression and [GENE]mucin[\\GENE] secretion in human airway epithelial cells.",
        "label": 3,
        "major": 4,
        "len": 22
    },
    {
        "text": "The inhibitory effect of the leukotriene receptor antagonist on [CHEMICAL]leukotriene D4[\\CHEMICAL]-induced [GENE]MUC2/5AC[\\GENE] gene expression and mucin secretion in human airway epithelial cells.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Pranlukast hydrate (ONO-1078, 100 microM) downregulated the [CHEMICAL]leukotriene D(4)[\\CHEMICAL]-induced [GENE]MUC2/5AC[\\GENE] gene expression and mucin secretion.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Pranlukast hydrate (ONO-1078, 100 microM) downregulated the [CHEMICAL]leukotriene D(4)[\\CHEMICAL]-induced MUC2/5AC gene expression and [GENE]mucin[\\GENE] secretion.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Pranlukast hydrate[\\CHEMICAL] (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced [GENE]MUC2/5AC[\\GENE] gene expression and mucin secretion.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Pranlukast hydrate[\\CHEMICAL] (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and [GENE]mucin[\\GENE] secretion.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Pranlukast hydrate ([CHEMICAL]ONO-1078[\\CHEMICAL], 100 microM) downregulated the leukotriene D(4)-induced [GENE]MUC2/5AC[\\GENE] gene expression and mucin secretion.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Pranlukast hydrate ([CHEMICAL]ONO-1078[\\CHEMICAL], 100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and [GENE]mucin[\\GENE] secretion.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "METHODS: The effect of leukotriene D(4) and the [GENE]leukotriene receptor[\\GENE] antagonist, [CHEMICAL]pranlukast hydrate[\\CHEMICAL] (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "METHODS: The effect of leukotriene D(4) and the [GENE]leukotriene receptor[\\GENE] antagonist, pranlukast hydrate ([CHEMICAL]ONO-1078[\\CHEMICAL]) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "CONCLUSION: In postmenopausal women, isolated [CHEMICAL]isoflavone[\\CHEMICAL] treatment does not affect [GENE]ABCA1[\\GENE]-dependent cholesterol efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.",
        "label": 10,
        "major": 3,
        "len": 29
    },
    {
        "text": "Thus, [CHEMICAL]isoflavone[\\CHEMICAL] supplementation did not affect [GENE]ABCA1[\\GENE]-dependent cholesterol efflux to serum.",
        "label": 10,
        "major": 10,
        "len": 11
    },
    {
        "text": "We studied in a clinical trial whether isolated [CHEMICAL]isoflavone[\\CHEMICAL] treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by [GENE]adenosine triphosphate-binding cassette A1[\\GENE]- (ABCA1), dependent cholesterol efflux from macrophages.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "We studied in a clinical trial whether isolated [CHEMICAL]isoflavone[\\CHEMICAL] treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- ([GENE]ABCA1[\\GENE]), dependent cholesterol efflux from macrophages.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "CONCLUSION: In postmenopausal women, isolated [CHEMICAL]isoflavone[\\CHEMICAL] treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating [GENE]pre-beta high-density lipoprotein[\\GENE] level, which could provide beneficial vascular effects.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "However, as a novel finding, [CHEMICAL]isoflavone[\\CHEMICAL] treatment increased a subclass of [GENE]high-density lipoprotein[\\GENE], the pre-beta high-density lipoprotein levels by 18% without affecting any other serum lipid concentrations.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "However, as a novel finding, [CHEMICAL]isoflavone[\\CHEMICAL] treatment increased a subclass of high-density lipoprotein, the [GENE]pre-beta high-density lipoprotein[\\GENE] levels by 18% without affecting any other serum lipid concentrations.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect [GENE]ABCA1[\\GENE]-dependent [CHEMICAL]cholesterol[\\CHEMICAL] efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.",
        "label": 9,
        "major": 10,
        "len": 29
    },
    {
        "text": "We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by [GENE]adenosine triphosphate-binding cassette A1[\\GENE]- (ABCA1), dependent [CHEMICAL]cholesterol[\\CHEMICAL] efflux from macrophages.",
        "label": 9,
        "major": 2,
        "len": 31
    },
    {
        "text": "We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- ([GENE]ABCA1[\\GENE]), dependent [CHEMICAL]cholesterol[\\CHEMICAL] efflux from macrophages.",
        "label": 9,
        "major": 2,
        "len": 31
    },
    {
        "text": "[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and [GENE]ABCA1[\\GENE]-dependent [CHEMICAL]cholesterol[\\CHEMICAL] efflux and serum lipid and lipoprotein levels were assessed.",
        "label": 9,
        "major": -1,
        "len": 26
    },
    {
        "text": "Thus, isoflavone supplementation did not affect [GENE]ABCA1[\\GENE]-dependent [CHEMICAL]cholesterol[\\CHEMICAL] efflux to serum.",
        "label": 9,
        "major": 10,
        "len": 11
    },
    {
        "text": "[GENE]ABCA1[\\GENE]-facilitated [CHEMICAL]cholesterol[\\CHEMICAL] efflux and lipid parameters did not differ between equol-producing and non-equol-producing women.",
        "label": 9,
        "major": 9,
        "len": 14
    },
    {
        "text": "The [CHEMICAL]imatinib[\\CHEMICAL]-resistant [GENE]KIT[\\GENE](D816V) mutant, associated with systemic mastocytosis, was found to be resistant to sorafenib.",
        "label": 10,
        "major": 1,
        "len": 15
    },
    {
        "text": "The [CHEMICAL]imatinib[\\CHEMICAL]-resistant KIT([GENE]D816V[\\GENE]) mutant, associated with systemic mastocytosis, was found to be resistant to sorafenib.",
        "label": 10,
        "major": 1,
        "len": 15
    },
    {
        "text": "The imatinib-resistant [GENE]KIT[\\GENE](D816V) mutant, associated with systemic mastocytosis, was found to be resistant to [CHEMICAL]sorafenib[\\CHEMICAL].",
        "label": 10,
        "major": 1,
        "len": 15
    },
    {
        "text": "The imatinib-resistant KIT([GENE]D816V[\\GENE]) mutant, associated with systemic mastocytosis, was found to be resistant to [CHEMICAL]sorafenib[\\CHEMICAL].",
        "label": 10,
        "major": 1,
        "len": 15
    },
    {
        "text": "The direct effect of [CHEMICAL]sorafenib[\\CHEMICAL] on the activity of these [GENE]kinases[\\GENE] and their downstream signaling was tested using phospho-specific antibodies.",
        "label": 2,
        "major": -1,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against [GENE]receptor tyrosine kinases[\\GENE] from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the [GENE]platelet-derived growth factor receptor[\\GENE] (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor ([GENE]PDGFR[\\GENE]) and vascular endothelial growth factor receptor (VEGFR) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and [GENE]vascular endothelial growth factor receptor[\\GENE] (VEGFR) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor ([GENE]VEGFR[\\GENE]) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Sorafenib ([CHEMICAL]BAY43-9006[\\CHEMICAL], Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against [GENE]receptor tyrosine kinases[\\GENE] from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Sorafenib ([CHEMICAL]BAY43-9006[\\CHEMICAL], Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the [GENE]platelet-derived growth factor receptor[\\GENE] (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Sorafenib ([CHEMICAL]BAY43-9006[\\CHEMICAL], Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor ([GENE]PDGFR[\\GENE]) and vascular endothelial growth factor receptor (VEGFR) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Sorafenib ([CHEMICAL]BAY43-9006[\\CHEMICAL], Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and [GENE]vascular endothelial growth factor receptor[\\GENE] (VEGFR) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Sorafenib ([CHEMICAL]BAY43-9006[\\CHEMICAL], Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor ([GENE]VEGFR[\\GENE]) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Sorafenib (BAY43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against [GENE]receptor tyrosine kinases[\\GENE] from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Sorafenib (BAY43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the [GENE]platelet-derived growth factor receptor[\\GENE] (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Sorafenib (BAY43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor ([GENE]PDGFR[\\GENE]) and vascular endothelial growth factor receptor (VEGFR) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Sorafenib (BAY43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and [GENE]vascular endothelial growth factor receptor[\\GENE] (VEGFR) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Sorafenib (BAY43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor ([GENE]VEGFR[\\GENE]) families.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "We investigated the efficacy of [CHEMICAL]sorafenib[\\CHEMICAL] at inhibiting mutants of the [GENE]receptor tyrosine kinases[\\GENE] PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "We investigated the efficacy of [CHEMICAL]sorafenib[\\CHEMICAL] at inhibiting mutants of the receptor tyrosine kinases [GENE]PDGFRbeta[\\GENE], KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "We investigated the efficacy of [CHEMICAL]sorafenib[\\CHEMICAL] at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, [GENE]KIT[\\GENE], and FLT3, which are implicated in the pathogenesis of myeloid malignancies.",
        "label": 4,
        "major": 1,
        "len": 27
    },
    {
        "text": "We investigated the efficacy of [CHEMICAL]sorafenib[\\CHEMICAL] at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, KIT, and [GENE]FLT3[\\GENE], which are implicated in the pathogenesis of myeloid malignancies.",
        "label": 4,
        "major": 1,
        "len": 27
    },
    {
        "text": "The ability of [CHEMICAL]sorafenib[\\CHEMICAL] to inhibit oncogenic [GENE]PDGFRbeta[\\GENE] and FLT3 mutants and overcome resistance to other small molecule inhibitors.",
        "label": 4,
        "major": 1,
        "len": 19
    },
    {
        "text": "The ability of [CHEMICAL]sorafenib[\\CHEMICAL] to inhibit oncogenic PDGFRbeta and [GENE]FLT3[\\GENE] mutants and overcome resistance to other small molecule inhibitors.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "RESULTS: We show that [CHEMICAL]sorafenib[\\CHEMICAL] is a potent inhibitor of [GENE]ETV6[\\GENE]-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors.",
        "label": 4,
        "major": 1,
        "len": 28
    },
    {
        "text": "RESULTS: We show that [CHEMICAL]sorafenib[\\CHEMICAL] is a potent inhibitor of ETV6-[GENE]PDGFRbeta[\\GENE] and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors.",
        "label": 4,
        "major": 1,
        "len": 28
    },
    {
        "text": "RESULTS: We show that [CHEMICAL]sorafenib[\\CHEMICAL] is a potent inhibitor of ETV6-PDGFRbeta and [GENE]FLT3[\\GENE] mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "RESULTS: We show that [CHEMICAL]sorafenib[\\CHEMICAL] is a potent inhibitor of ETV6-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other [GENE]FLT3[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing [GENE]FLT3[\\GENE] with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] (BAY43-9006, Nexavar) is a small molecule [GENE]B-RAF[\\GENE] inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of [CHEMICAL]sorafenib[\\CHEMICAL] for the treatment of myeloid malignancies expressing activated forms of [GENE]PDGFRbeta[\\GENE] and FLT3.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of [CHEMICAL]sorafenib[\\CHEMICAL] for the treatment of myeloid malignancies expressing activated forms of PDGFRbeta and [GENE]FLT3[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Sorafenib ([CHEMICAL]BAY43-9006[\\CHEMICAL], Nexavar) is a small molecule [GENE]B-RAF[\\GENE] inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "Sorafenib (BAY43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]) is a small molecule [GENE]B-RAF[\\GENE] inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "[GENE]ENaC[\\GENE] expression and activity could account for the low [CHEMICAL]Na(+)[\\CHEMICAL] concentration that is typical of milk.",
        "label": 2,
        "major": -1,
        "len": 16
    },
    {
        "text": "We conclude that [CHEMICAL]Na(+)[\\CHEMICAL] movement across mammary epithelia is modulated by corticosteroids via a [GENE]glucocorticoid receptor[\\GENE]-mediated mechanism that regulates the expression of the beta- and gamma-subunits of ENaC.",
        "label": 2,
        "major": 7,
        "len": 28
    },
    {
        "text": "[GENE]ENaC[\\GENE] expression and activity could account for the low [CHEMICAL]Na(+)[\\CHEMICAL] concentration that is typical of milk.",
        "label": 2,
        "major": -1,
        "len": 16
    },
    {
        "text": "Exposure to [CHEMICAL]mifepristone[\\CHEMICAL] (a [GENE]glucocorticoid receptor[\\GENE] antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.",
        "label": 6,
        "major": 6,
        "len": 31
    },
    {
        "text": "Exposure to mifepristone (a glucocorticoid receptor antagonist), but not [CHEMICAL]spironolactone[\\CHEMICAL] (a [GENE]mineralocorticoid receptor[\\GENE] antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.",
        "label": 6,
        "major": 3,
        "len": 31
    },
    {
        "text": "All three [CHEMICAL]salicylates[\\CHEMICAL] inhibited the diabetes-induced translocation of [GENE]p50[\\GENE] (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "All three [CHEMICAL]salicylates[\\CHEMICAL] inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of [GENE]p50[\\GENE] and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.",
        "label": 4,
        "major": 3,
        "len": 48
    },
    {
        "text": "All three [CHEMICAL]salicylates[\\CHEMICAL] inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and [GENE]p65[\\GENE] into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "Oral [CHEMICAL]aspirin[\\CHEMICAL] (as a representative of the salicylate family) inhibited diabetes-induced increase in [GENE]NF-kappaB[\\GENE] DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina.",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "Oral aspirin (as a representative of the [CHEMICAL]salicylate[\\CHEMICAL] family) inhibited diabetes-induced increase in [GENE]NF-kappaB[\\GENE] DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina.",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "All three [CHEMICAL]salicylates[\\CHEMICAL] inhibited the diabetes-induced translocation of p50 (a subunit of [GENE]NF-kappaB[\\GENE]) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Sulfasalazine[\\CHEMICAL] (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by [GENE]NF-kappaB[\\GENE], including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Sulfasalazine[\\CHEMICAL] (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, [GENE]intracellular adhesion molecule-1[\\GENE], inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Sulfasalazine[\\CHEMICAL] (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, [GENE]inducible nitric oxide synthase[\\GENE], and cyclooxygenase-2 in whole-retinal lysate.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Sulfasalazine[\\CHEMICAL] (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and [GENE]cyclooxygenase-2[\\GENE] in whole-retinal lysate.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Sulfasalazine (also as a representative of the [CHEMICAL]salicylates[\\CHEMICAL]) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by [GENE]NF-kappaB[\\GENE], including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Salicylates[\\CHEMICAL], in doses administrated in our experiments, inhibited [GENE]NF-kappa[\\GENE]B and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Fluoxetine[\\CHEMICAL] affected mainly the hSERT transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total [GENE]hSERT[\\GENE] protein content or the hSERT mRNA level.",
        "label": 10,
        "major": 9,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Fluoxetine[\\CHEMICAL] affected mainly the hSERT transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total hSERT protein content or the [GENE]hSERT[\\GENE] mRNA level.",
        "label": 10,
        "major": 9,
        "len": 33
    },
    {
        "text": "These results suggest that the effect of [CHEMICAL]fluoxetine[\\CHEMICAL] on the expression of hSERT is post-translational and has shown itself to be independent of [GENE]PKC[\\GENE] and PKA activity.",
        "label": 10,
        "major": -1,
        "len": 27
    },
    {
        "text": "These results suggest that the effect of [CHEMICAL]fluoxetine[\\CHEMICAL] on the expression of hSERT is post-translational and has shown itself to be independent of PKC and [GENE]PKA[\\GENE] activity.",
        "label": 10,
        "major": -1,
        "len": 27
    },
    {
        "text": "These results suggest that the effect of [CHEMICAL]fluoxetine[\\CHEMICAL] on the expression of [GENE]hSERT[\\GENE] is post-translational and has shown itself to be independent of PKC and PKA activity.",
        "label": 2,
        "major": -1,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Fluoxetine[\\CHEMICAL] affected mainly the [GENE]hSERT[\\GENE] transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total hSERT protein content or the hSERT mRNA level.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "Collectively then, these results indicate that [GENE]LFA-1[\\GENE] contributes to the regulation of lymphocytic cholinergic activity via CD11a-mediated pathways and suggest that [CHEMICAL]simvastatin[\\CHEMICAL] exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.",
        "label": 2,
        "major": -1,
        "len": 34
    },
    {
        "text": "Collectively then, these results indicate that LFA-1 contributes to the regulation of lymphocytic cholinergic activity via [GENE]CD11a[\\GENE]-mediated pathways and suggest that [CHEMICAL]simvastatin[\\CHEMICAL] exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.",
        "label": 2,
        "major": -1,
        "len": 34
    },
    {
        "text": "In addition, activation of protein kinase C and increases in intracellular [CHEMICAL]cAMP[\\CHEMICAL] also enhance cholinergic activity in T cells, and [GENE]lymphocyte function associated antigen-1[\\GENE] (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "In addition, activation of protein kinase C and increases in intracellular [CHEMICAL]cAMP[\\CHEMICAL] also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 ([GENE]LFA-1[\\GENE]; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "In addition, activation of protein kinase C and increases in intracellular [CHEMICAL]cAMP[\\CHEMICAL] also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; [GENE]CD11a[\\GENE]/CD18) is an important mediator of leukocyte migration and T cell activation.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "In addition, activation of protein kinase C and increases in intracellular [CHEMICAL]cAMP[\\CHEMICAL] also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a/[GENE]CD18[\\GENE]) is an important mediator of leukocyte migration and T cell activation.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "We found that [CHEMICAL]simvastatin[\\CHEMICAL] abolishes anti-[GENE]CD11a[\\GENE] mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Lymphocytes possess the essential components of a cholinergic system, including acetylcholine ([CHEMICAL]ACh[\\CHEMICAL]); [GENE]choline acetyltransferase[\\GENE] (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).",
        "label": 9,
        "major": -1,
        "len": 29
    },
    {
        "text": "Lymphocytes possess the essential components of a cholinergic system, including acetylcholine ([CHEMICAL]ACh[\\CHEMICAL]); choline acetyltransferase ([GENE]ChAT[\\GENE]), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).",
        "label": 9,
        "major": -1,
        "len": 29
    },
    {
        "text": "Lymphocytes possess the essential components of a cholinergic system, including [CHEMICAL]acetylcholine[\\CHEMICAL] (ACh); [GENE]choline acetyltransferase[\\GENE] (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).",
        "label": 9,
        "major": -1,
        "len": 29
    },
    {
        "text": "Lymphocytes possess the essential components of a cholinergic system, including [CHEMICAL]acetylcholine[\\CHEMICAL] (ACh); choline acetyltransferase ([GENE]ChAT[\\GENE]), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).",
        "label": 9,
        "major": -1,
        "len": 29
    },
    {
        "text": "In addition, BALB/c and C57BL/6 females were treated with [CHEMICAL]progesterone[\\CHEMICAL] or MPA for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of [GENE]ER[\\GENE] and PR.",
        "label": 2,
        "major": -1,
        "len": 36
    },
    {
        "text": "In addition, BALB/c and C57BL/6 females were treated with [CHEMICAL]progesterone[\\CHEMICAL] or MPA for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of ER and [GENE]PR[\\GENE].",
        "label": 2,
        "major": -1,
        "len": 36
    },
    {
        "text": "In addition, BALB/c and C57BL/6 females were treated with progesterone or [CHEMICAL]MPA[\\CHEMICAL] for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of [GENE]ER[\\GENE] and PR.",
        "label": 2,
        "major": -1,
        "len": 36
    },
    {
        "text": "In addition, BALB/c and C57BL/6 females were treated with progesterone or [CHEMICAL]MPA[\\CHEMICAL] for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of ER and [GENE]PR[\\GENE].",
        "label": 2,
        "major": -1,
        "len": 36
    },
    {
        "text": "INTRODUCTION: Medroxyprogesterone acetate ([CHEMICAL]MPA[\\CHEMICAL]) induces estrogen receptor (ER)-positive and [GENE]progesterone receptor[\\GENE] (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "[GENE]PR isoform B[\\GENE] levels were low in virgin control mice and increased after [CHEMICAL]progestin[\\CHEMICAL] treatment in both strains.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "INTRODUCTION: Medroxyprogesterone acetate ([CHEMICAL]MPA[\\CHEMICAL]) induces estrogen receptor (ER)-positive and progesterone receptor ([GENE]PR[\\GENE])-positive ductal invasive mammary carcinomas in BALB/c mice.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "INTRODUCTION: Medroxyprogesterone acetate ([CHEMICAL]MPA[\\CHEMICAL]) induces [GENE]estrogen receptor[\\GENE] (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "INTRODUCTION: Medroxyprogesterone acetate ([CHEMICAL]MPA[\\CHEMICAL]) induces estrogen receptor ([GENE]ER[\\GENE])-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "INTRODUCTION: [CHEMICAL]Medroxyprogesterone acetate[\\CHEMICAL] (MPA) induces estrogen receptor (ER)-positive and progesterone receptor ([GENE]PR[\\GENE])-positive ductal invasive mammary carcinomas in BALB/c mice.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "INTRODUCTION: [CHEMICAL]Medroxyprogesterone acetate[\\CHEMICAL] (MPA) induces [GENE]estrogen receptor[\\GENE] (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "INTRODUCTION: [CHEMICAL]Medroxyprogesterone acetate[\\CHEMICAL] (MPA) induces estrogen receptor ([GENE]ER[\\GENE])-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "INTRODUCTION: [CHEMICAL]Medroxyprogesterone acetate[\\CHEMICAL] (MPA) induces estrogen receptor (ER)-positive and [GENE]progesterone receptor[\\GENE] (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "The expression of [GENE]ER-alpha[\\GENE] and PR isoform A in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in [CHEMICAL]progestin[\\CHEMICAL]-treated BALB/c mice (P < 0.05).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "The expression of ER-alpha and [GENE]PR isoform A[\\GENE] in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in [CHEMICAL]progestin[\\CHEMICAL]-treated BALB/c mice (P < 0.05).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Several genes involved with [CHEMICAL]steroid[\\CHEMICAL] metabolism also showed remarkable expression changes, including increased expression of [GENE]17beta-hydroxysteroid dehydrogenase-7[\\GENE] (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production).",
        "label": 2,
        "major": 9,
        "len": 31
    },
    {
        "text": "Several genes involved with [CHEMICAL]steroid[\\CHEMICAL] metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of [GENE]HSD17beta5[\\GENE] (involved in testosterone production).",
        "label": 2,
        "major": 9,
        "len": 31
    },
    {
        "text": "Various genes controlled by [CHEMICAL]estrogen[\\CHEMICAL], including [GENE]X-inactive-specific transcript[\\GENE], anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.",
        "label": 3,
        "major": -1,
        "len": 21
    },
    {
        "text": "Various genes controlled by [CHEMICAL]estrogen[\\CHEMICAL], including X-inactive-specific transcript, [GENE]anterior gradient-2[\\GENE], trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.",
        "label": 3,
        "major": -1,
        "len": 21
    },
    {
        "text": "Various genes controlled by [CHEMICAL]estrogen[\\CHEMICAL], including X-inactive-specific transcript, anterior gradient-2, [GENE]trefoil factor-1[\\GENE], CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.",
        "label": 3,
        "major": -1,
        "len": 21
    },
    {
        "text": "Various genes controlled by [CHEMICAL]estrogen[\\CHEMICAL], including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, [GENE]CRP-ductin[\\GENE], ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.",
        "label": 3,
        "major": -1,
        "len": 21
    },
    {
        "text": "Various genes controlled by [CHEMICAL]estrogen[\\CHEMICAL], including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, [GENE]ghrelin[\\GENE], and small proline-rich protein-2A, were dramatically over-expressed.",
        "label": 3,
        "major": -1,
        "len": 21
    },
    {
        "text": "Various genes controlled by [CHEMICAL]estrogen[\\CHEMICAL], including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and [GENE]small proline-rich protein-2A[\\GENE], were dramatically over-expressed.",
        "label": 3,
        "major": -1,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Estrogen[\\CHEMICAL]-regulated genes including cytokeratin 1-19 and [GENE]Cyp2a4[\\GENE] were over-expressed, although Cyp3a25 was suppressed.",
        "label": 3,
        "major": -1,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Estrogen[\\CHEMICAL]-regulated genes including [GENE]cytokeratin 1-19[\\GENE] and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed.",
        "label": 3,
        "major": -1,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Estrogen[\\CHEMICAL]-regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although [GENE]Cyp3a25[\\GENE] was suppressed.",
        "label": 4,
        "major": -1,
        "len": 13
    },
    {
        "text": "Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of [GENE]17beta-hydroxysteroid dehydrogenase-7[\\GENE] (HSD17beta7; involved in [CHEMICAL]estradiol[\\CHEMICAL] production) and decreased expression of HSD17beta5 (involved in testosterone production).",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 ([GENE]HSD17beta7[\\GENE]; involved in [CHEMICAL]estradiol[\\CHEMICAL] production) and decreased expression of HSD17beta5 (involved in testosterone production).",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of [GENE]HSD17beta5[\\GENE] (involved in [CHEMICAL]testosterone[\\CHEMICAL] production).",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "The expression of key genes important in [CHEMICAL]methionine[\\CHEMICAL] metabolism, such as [GENE]methionine adenosyltransferase-1a[\\GENE], betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed.",
        "label": 9,
        "major": -1,
        "len": 20
    },
    {
        "text": "The expression of key genes important in [CHEMICAL]methionine[\\CHEMICAL] metabolism, such as methionine adenosyltransferase-1a, [GENE]betaine-homocysteine methyltransferase[\\GENE] and thioether S-methyltransferase, were suppressed.",
        "label": 9,
        "major": -1,
        "len": 20
    },
    {
        "text": "The expression of key genes important in [CHEMICAL]methionine[\\CHEMICAL] metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and [GENE]thioether S-methyltransferase[\\GENE], were suppressed.",
        "label": 9,
        "major": -1,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Monosodium urate[\\CHEMICAL] crystals stimulate monocytes and macrophages to release IL-1beta through the [GENE]NALP3[\\GENE] component of the inflammasome.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Monosodium urate[\\CHEMICAL] crystals stimulate monocytes and macrophages to release [GENE]IL-1beta[\\GENE] through the NALP3 component of the inflammasome.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Our structural studies provide a view of a synthetic inhibitory compound in a [GENE]sirtuin[\\GENE] active site revealing that suramin binds into the [CHEMICAL]NAD(+)[\\CHEMICAL], the product, and the substrate-binding site.",
        "label": 1,
        "major": 9,
        "len": 29
    },
    {
        "text": "We identified [CHEMICAL]suramin[\\CHEMICAL] as a compound that binds to [GENE]human SIRT5[\\GENE] and showed that it inhibits SIRT5 NAD(+)-dependent deacetylase activity with an IC(50) value of 22 microM.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of [GENE]SIRT5[\\GENE], one in complex with [CHEMICAL]ADP[\\CHEMICAL]-ribose, the other bound to suramin.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of [GENE]SIRT5[\\GENE], one in complex with ADP-ribose, the other bound to [CHEMICAL]suramin[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "Our structural studies provide a view of a synthetic inhibitory compound in a [GENE]sirtuin[\\GENE] active site revealing that [CHEMICAL]suramin[\\CHEMICAL] binds into the NAD(+), the product, and the substrate-binding site.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "We identified [CHEMICAL]suramin[\\CHEMICAL] as a compound that binds to human SIRT5 and showed that it inhibits [GENE]SIRT5 NAD(+)-dependent deacetylase[\\GENE] activity with an IC(50) value of 22 microM.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Structural basis of inhibition of the [GENE]human NAD+-dependent deacetylase SIRT5[\\GENE] by [CHEMICAL]suramin[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "In humans, [GENE]methionine synthase[\\GENE] deficiency results in the accumulation of [CHEMICAL]methyltetrahydrofolate[\\CHEMICAL] at the expense of folate derivatives required for purine and thymidylate biosynthesis.",
        "label": 9,
        "major": -1,
        "len": 23
    },
    {
        "text": "In summary, [CHEMICAL]phenformin[\\CHEMICAL] and metformin increase [GENE]AMPK[\\GENE] activity and phosphorylation in the isolated heart.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "In summary, phenformin and [CHEMICAL]metformin[\\CHEMICAL] increase [GENE]AMPK[\\GENE] activity and phosphorylation in the isolated heart.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "Cytosolic [AMP] reported metabolically active [CHEMICAL]AMP[\\CHEMICAL], which triggered increased [GENE]AMPK[\\GENE] activity, but measures of total AMP did not.",
        "label": 3,
        "major": 10,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL] and phenformin, which are biguanides, have been reported to increase [GENE]AMPK[\\GENE] activity without increasing AMP/ATP.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Metformin and [CHEMICAL]phenformin[\\CHEMICAL], which are biguanides, have been reported to increase [GENE]AMPK[\\GENE] activity without increasing AMP/ATP.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Metformin and phenformin, which are [CHEMICAL]biguanides[\\CHEMICAL], have been reported to increase [GENE]AMPK[\\GENE] activity without increasing AMP/ATP.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "In hearts treated with [CHEMICAL]phenformin[\\CHEMICAL] for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and [GENE]AMPK[\\GENE] activity was elevated at 36 min.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "In hearts treated with [CHEMICAL]metformin[\\CHEMICAL], [AMP] was increased at 50 min and [GENE]AMPK[\\GENE] activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "In hearts treated with [CHEMICAL]metformin[\\CHEMICAL], [AMP] was increased at 50 min and AMPK activity, phosphorylated [GENE]AMPK[\\GENE], and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "In hearts treated with [CHEMICAL]metformin[\\CHEMICAL], [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and [GENE]phosphorylated acetyl-CoA carboxylase[\\GENE] were elevated at 61 min.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL] and phenformin activate [GENE]AMP-activated protein kinase[\\GENE] in the heart by increasing cytosolic AMP concentration.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Metformin and [CHEMICAL]phenformin[\\CHEMICAL] activate [GENE]AMP-activated protein kinase[\\GENE] in the heart by increasing cytosolic AMP concentration.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "It is currently not known how much this [GENE]H(1)[\\GENE] antagonism of clozapine contributes to the therapeutic or adverse side effects of [CHEMICAL]clozapine[\\CHEMICAL].",
        "label": 2,
        "major": 6,
        "len": 22
    },
    {
        "text": "[GENE]Histamine H1 receptor[\\GENE] involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of [CHEMICAL]clozapine[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "In the current project, we found that the selective [GENE]H(1)[\\GENE] antagonist pyrilamine also reversed the [CHEMICAL]dizocilpine[\\CHEMICAL]-induced impairment in PPI of tactile startle with an auditory prepulse.",
        "label": 3,
        "major": 6,
        "len": 26
    },
    {
        "text": "In summary, the therapeutic effect of [CHEMICAL]clozapine[\\CHEMICAL] in reversing PPI impairment was mimicked by the [GENE]H(1)[\\GENE] antagonist pyrilamine, while pyrilamine had a mixed effect on cognition.",
        "label": 4,
        "major": 6,
        "len": 26
    },
    {
        "text": "[GENE]Histamine H(1)[\\GENE] blockade is one of the more prominent actions of the multi-receptor acting antipsychotic [CHEMICAL]clozapine[\\CHEMICAL].",
        "label": 4,
        "major": -1,
        "len": 16
    },
    {
        "text": "Thus, [GENE]H(1)[\\GENE] antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as [CHEMICAL]clozapine[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 19
    },
    {
        "text": "It is currently not known how much this [GENE]H(1)[\\GENE] antagonism of [CHEMICAL]clozapine[\\CHEMICAL] contributes to the therapeutic or adverse side effects of clozapine.",
        "label": 6,
        "major": 6,
        "len": 22
    },
    {
        "text": "In the current project, we found that the selective [GENE]H(1)[\\GENE] antagonist [CHEMICAL]pyrilamine[\\CHEMICAL] also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse.",
        "label": 6,
        "major": 3,
        "len": 26
    },
    {
        "text": "In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the [GENE]H(1)[\\GENE] antagonist [CHEMICAL]pyrilamine[\\CHEMICAL], while pyrilamine had a mixed effect on cognition.",
        "label": 6,
        "major": 6,
        "len": 26
    },
    {
        "text": "In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the [GENE]H(1)[\\GENE] antagonist pyrilamine, while [CHEMICAL]pyrilamine[\\CHEMICAL] had a mixed effect on cognition.",
        "label": 6,
        "major": 6,
        "len": 26
    },
    {
        "text": "The mRNA expression of [GENE]PtdSer synthase 1[\\GENE] (PSS1) and PtdSer synthase 2 (PSS2) was not reduced by [CHEMICAL]ethanol[\\CHEMICAL].",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "The mRNA expression of PtdSer synthase 1 ([GENE]PSS1[\\GENE]) and PtdSer synthase 2 (PSS2) was not reduced by [CHEMICAL]ethanol[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 18
    },
    {
        "text": "The mRNA expression of PtdSer synthase 1 (PSS1) and [GENE]PtdSer synthase 2[\\GENE] (PSS2) was not reduced by [CHEMICAL]ethanol[\\CHEMICAL].",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "The mRNA expression of PtdSer synthase 1 (PSS1) and PtdSer synthase 2 ([GENE]PSS2[\\GENE]) was not reduced by [CHEMICAL]ethanol[\\CHEMICAL].",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "Similarly, the [GENE]PSS1[\\GENE] enzyme level did not change after [CHEMICAL]ethanol[\\CHEMICAL] exposure but PSS2 could not be probed with the antibody available currently.",
        "label": 10,
        "major": 10,
        "len": 22
    },
    {
        "text": "Furthermore, the enzymatic activity of [GENE]alanine aminotransferase[\\GENE] (ALT), which converts the critical gluconeogenic amino acid alanine into [CHEMICAL]pyruvate[\\CHEMICAL], is decreased (approximately 50%) in KLF15-/- hepatocytes.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "Furthermore, the enzymatic activity of alanine aminotransferase ([GENE]ALT[\\GENE]), which converts the critical gluconeogenic amino acid alanine into [CHEMICAL]pyruvate[\\CHEMICAL], is decreased (approximately 50%) in KLF15-/- hepatocytes.",
        "label": 9,
        "major": 1,
        "len": 25
    },
    {
        "text": "Furthermore, the enzymatic activity of [GENE]alanine aminotransferase[\\GENE] (ALT), which converts the critical gluconeogenic [CHEMICAL]amino acid[\\CHEMICAL] alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "Furthermore, the enzymatic activity of alanine aminotransferase ([GENE]ALT[\\GENE]), which converts the critical gluconeogenic [CHEMICAL]amino acid[\\CHEMICAL] alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.",
        "label": 9,
        "major": 4,
        "len": 25
    },
    {
        "text": "Furthermore, the enzymatic activity of [GENE]alanine aminotransferase[\\GENE] (ALT), which converts the critical gluconeogenic amino acid [CHEMICAL]alanine[\\CHEMICAL] into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.",
        "label": 9,
        "major": 4,
        "len": 25
    },
    {
        "text": "Furthermore, the enzymatic activity of alanine aminotransferase ([GENE]ALT[\\GENE]), which converts the critical gluconeogenic amino acid [CHEMICAL]alanine[\\CHEMICAL] into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.",
        "label": 9,
        "major": 4,
        "len": 25
    },
    {
        "text": "TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), [CHEMICAL]L-[(3)H]citrulline[\\CHEMICAL] formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter [GENE]eNOS[\\GENE] phosphorylation.",
        "label": 10,
        "major": 9,
        "len": 37
    },
    {
        "text": "TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from [CHEMICAL]L-[(3)H]arginine[\\CHEMICAL] (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter [GENE]eNOS[\\GENE] phosphorylation.",
        "label": 10,
        "major": 3,
        "len": 37
    },
    {
        "text": "[CHEMICAL]D-glucose[\\CHEMICAL] stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional [GENE]type II TGF-beta receptors[\\GENE] in human umbilical vein endothelium.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "High [CHEMICAL]D-glucose[\\CHEMICAL] increases L-arginine transport and eNOS expression following TbetaRII activation by [GENE]TGF-beta1[\\GENE] involving p42/44(mapk) and Smad2 in HUVEC.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "We studied whether [CHEMICAL]D-glucose[\\CHEMICAL]-stimulation of L-arginine transport and nitric oxide synthesis involves [GENE]TGF-beta1[\\GENE] in primary cultures of HUVEC.",
        "label": 2,
        "major": 9,
        "len": 18
    },
    {
        "text": "TGF-beta1 and high [CHEMICAL]D-glucose[\\CHEMICAL] increased p42/44(mapk) and [GENE]Smad2[\\GENE] phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor).",
        "label": 3,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]D-glucose[\\CHEMICAL] stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and [GENE]Smad2[\\GENE] requiring functional type II TGF-beta receptors in human umbilical vein endothelium.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "High [CHEMICAL]D-glucose[\\CHEMICAL] increases L-arginine transport and eNOS expression following [GENE]TbetaRII[\\GENE] activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "High [CHEMICAL]D-glucose[\\CHEMICAL] increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and [GENE]Smad2[\\GENE] in HUVEC.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "[GENE]TGF-beta1[\\GENE] release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal) [CHEMICAL]D-glucose[\\CHEMICAL].",
        "label": 3,
        "major": -1,
        "len": 17
    },
    {
        "text": "TGF-beta1 and high [CHEMICAL]D-glucose[\\CHEMICAL] increased [GENE]hCAT-1[\\GENE] mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.",
        "label": 3,
        "major": 10,
        "len": 37
    },
    {
        "text": "High [CHEMICAL]D-glucose[\\CHEMICAL] increases L-arginine transport and [GENE]eNOS[\\GENE] expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Elevated extracellular [CHEMICAL]D-glucose[\\CHEMICAL] increases [GENE]transforming growth factor beta1[\\GENE] (TGF-beta1) release from human umbilical vein endothelium (HUVEC).",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Elevated extracellular [CHEMICAL]D-glucose[\\CHEMICAL] increases transforming growth factor beta1 ([GENE]TGF-beta1[\\GENE]) release from human umbilical vein endothelium (HUVEC).",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "TGF-beta1 and high D-glucose increased p42/44(mapk) and [GENE]Smad2[\\GENE] phosphorylation, an effect blocked by [CHEMICAL]PD-98059[\\CHEMICAL] (MEK1/2 inhibitor).",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of [CHEMICAL]NO[\\CHEMICAL] synthesis) and [GENE]endothelial NO synthase[\\GENE] (eNOS) protein abundance, but did not alter eNOS phosphorylation.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of [CHEMICAL]NO[\\CHEMICAL] synthesis) and endothelial NO synthase ([GENE]eNOS[\\GENE]) protein abundance, but did not alter eNOS phosphorylation.",
        "label": 9,
        "major": 3,
        "len": 37
    },
    {
        "text": "We demonstrate that only treatment of HaCaT with GLA and EPA or a [GENE]PPARgamma[\\GENE] ligand ([CHEMICAL]roziglitazone[\\CHEMICAL]), induced COX-2 expression (protein and mRNA).",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "The inhibitory effects of [CHEMICAL]GW9662[\\CHEMICAL] and T0070907 (PPARgamma antagonists), on [GENE]COX-2[\\GENE] expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "The inhibitory effects of [CHEMICAL]GW9662[\\CHEMICAL] and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of [GENE]COX-2 promoter[\\GENE] activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "The inhibitory effects of GW9662 and [CHEMICAL]T0070907[\\CHEMICAL] (PPARgamma antagonists), on [GENE]COX-2[\\GENE] expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "The inhibitory effects of GW9662 and [CHEMICAL]T0070907[\\CHEMICAL] (PPARgamma antagonists), on COX-2 expression and on stimulation of [GENE]COX-2 promoter[\\GENE] activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of [GENE]COX-2 promoter[\\GENE] activity by [CHEMICAL]EPA[\\CHEMICAL] and GLA suggest that PPARgamma is implicated in COX-2 induction.",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of [GENE]COX-2 promoter[\\GENE] activity by EPA and [CHEMICAL]GLA[\\CHEMICAL] suggest that PPARgamma is implicated in COX-2 induction.",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the [CHEMICAL]PUFA[\\CHEMICAL] effects on [GENE]COX-2[\\GENE] induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "Moreover stimulation of [GENE]COX-2 promoter[\\GENE] activity was increased by those [CHEMICAL]PUFAs[\\CHEMICAL] or rosiglitazone.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "Moreover stimulation of [GENE]COX-2 promoter[\\GENE] activity was increased by those PUFAs or [CHEMICAL]rosiglitazone[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "[CHEMICAL]n-3 and n-6 polyunsaturated fatty acids[\\CHEMICAL] induce the expression of COX-2 via [GENE]PPARgamma[\\GENE] activation in human keratinocyte HaCaT cells.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of [CHEMICAL]AA[\\CHEMICAL] metabolites in [GENE]PPAR[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "These findings demonstrate that [CHEMICAL]n-3 and n-6 PUFA[\\CHEMICAL] increased [GENE]PPARgamma[\\GENE] activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "These findings demonstrate that [CHEMICAL]n-3 and n-6 PUFA[\\CHEMICAL] increased PPARgamma activity is necessary for the [GENE]COX-2[\\GENE] induction in HaCaT human keratinocyte cells.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Given the anti-inflammatory properties of EPA, we suggest that induction of [GENE]COX-2[\\GENE] in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of [CHEMICAL]PUFAs n-3[\\CHEMICAL] or n-6.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "We demonstrate that only treatment of HaCaT with [CHEMICAL]GLA[\\CHEMICAL] and EPA or a PPARgamma ligand (roziglitazone), induced [GENE]COX-2[\\GENE] expression (protein and mRNA).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "We demonstrate that only treatment of HaCaT with GLA and [CHEMICAL]EPA[\\CHEMICAL] or a PPARgamma ligand (roziglitazone), induced [GENE]COX-2[\\GENE] expression (protein and mRNA).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand ([CHEMICAL]roziglitazone[\\CHEMICAL]), induced [GENE]COX-2[\\GENE] expression (protein and mRNA).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]n-3 and n-6 polyunsaturated fatty acids[\\CHEMICAL] induce the expression of [GENE]COX-2[\\GENE] via PPARgamma activation in human keratinocyte HaCaT cells.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Finally, [GENE]PLA2[\\GENE] inhibitor methyl [CHEMICAL]arachidonyl fluorophosphonate[\\CHEMICAL] blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "Finally, PLA2 inhibitor methyl [CHEMICAL]arachidonyl fluorophosphonate[\\CHEMICAL] blocked the PUFA effects on [GENE]COX-2[\\GENE] induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "The inhibitory effects of [CHEMICAL]GW9662[\\CHEMICAL] and T0070907 ([GENE]PPARgamma[\\GENE] antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.",
        "label": 6,
        "major": 3,
        "len": 31
    },
    {
        "text": "The inhibitory effects of GW9662 and [CHEMICAL]T0070907[\\CHEMICAL] ([GENE]PPARgamma[\\GENE] antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.",
        "label": 6,
        "major": 3,
        "len": 31
    },
    {
        "text": "OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting [GENE]beta(2)-adrenergic[\\GENE] agonist that is the [R,R] isomer of formoterol) and [CHEMICAL]salmeterol xinafoate[\\CHEMICAL] versus placebo in patients with chronic obstructive pulmonary disease (COPD).",
        "label": 2,
        "major": 5,
        "len": 42
    },
    {
        "text": "OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting [GENE]beta(2)-adrenergic[\\GENE] agonist that is the [CHEMICAL][R,R] isomer of formoterol[\\CHEMICAL]) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).",
        "label": 5,
        "major": 5,
        "len": 42
    },
    {
        "text": "OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized [CHEMICAL]arformoterol tartrate[\\CHEMICAL] (a selective, long-acting [GENE]beta(2)-adrenergic[\\GENE] agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).",
        "label": 5,
        "major": 5,
        "len": 42
    },
    {
        "text": "The cytosolic [GENE]ACC1[\\GENE] is expressed primarily in liver and adipose tissue, and uses [CHEMICAL]malonyl-coenzyme A[\\CHEMICAL] as a key building block in fatty acid biosynthesis.",
        "label": 2,
        "major": -1,
        "len": 24
    },
    {
        "text": "The cytosolic [GENE]ACC1[\\GENE] is expressed primarily in liver and adipose tissue, and uses malonyl-coenzyme A as a key building block in [CHEMICAL]fatty acid[\\CHEMICAL] biosynthesis.",
        "label": 9,
        "major": -1,
        "len": 24
    },
    {
        "text": "The mitochondrial [GENE]ACC2[\\GENE] is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of [CHEMICAL]fatty acid[\\CHEMICAL] oxidation.",
        "label": 9,
        "major": -1,
        "len": 22
    },
    {
        "text": "[GENE]Acetyl-coenzyme A carboxylase[\\GENE] (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in [CHEMICAL]fatty acid[\\CHEMICAL] biosynthesis and oxidation.",
        "label": 9,
        "major": -1,
        "len": 22
    },
    {
        "text": "Acetyl-coenzyme A carboxylase ([GENE]ACC[\\GENE]) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in [CHEMICAL]fatty acid[\\CHEMICAL] biosynthesis and oxidation.",
        "label": 9,
        "major": -1,
        "len": 22
    },
    {
        "text": "Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, [GENE]ACC1[\\GENE] and ACC2, which play critical roles in [CHEMICAL]fatty acid[\\CHEMICAL] biosynthesis and oxidation.",
        "label": 9,
        "major": -1,
        "len": 22
    },
    {
        "text": "Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and [GENE]ACC2[\\GENE], which play critical roles in [CHEMICAL]fatty acid[\\CHEMICAL] biosynthesis and oxidation.",
        "label": 9,
        "major": -1,
        "len": 22
    },
    {
        "text": "In contrast, the [CHEMICAL]RA[\\CHEMICAL] catabolising enzymes [GENE]Cyp26A1[\\GENE] and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye.",
        "label": 9,
        "major": 10,
        "len": 24
    },
    {
        "text": "In contrast, the [CHEMICAL]RA[\\CHEMICAL] catabolising enzymes Cyp26A1 and [GENE]Cyp26B1[\\GENE] which are known to be RA-responsive were not expressed at all in the developing eye.",
        "label": 9,
        "major": 10,
        "len": 24
    },
    {
        "text": "In contrast, GLP-1 exerts glucoregulatory actions via slowing of gastric emptying and [CHEMICAL]glucose[\\CHEMICAL]-dependent inhibition of [GENE]glucagon[\\GENE] secretion.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "In contrast, [GENE]GLP-1[\\GENE] exerts glucoregulatory actions via slowing of gastric emptying and [CHEMICAL]glucose[\\CHEMICAL]-dependent inhibition of glucagon secretion.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "Incretin-receptor activation leads to [CHEMICAL]glucose[\\CHEMICAL]-dependent [GENE]insulin[\\GENE] secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "This report reviews published and unpublished data that suggest that [CHEMICAL]aripiprazole[\\CHEMICAL] acts as a selective partial agonist at the dopamine D(2) receptor and does not affect [GENE]5-HT receptors[\\GENE] at therapeutic doses.",
        "label": 10,
        "major": 10,
        "len": 31
    },
    {
        "text": "It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the [GENE]5-HT(2)[\\GENE] receptor contribute to the clinical profile of [CHEMICAL]aripiprazole[\\CHEMICAL], a so-called dopamine- and 5-HT stabiliser.",
        "label": 2,
        "major": 5,
        "len": 33
    },
    {
        "text": "This report reviews published and unpublished data that suggest that [CHEMICAL]aripiprazole[\\CHEMICAL] acts as a selective partial agonist at the [GENE]dopamine D(2) receptor[\\GENE] and does not affect 5-HT receptors at therapeutic doses.",
        "label": 5,
        "major": 10,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Mifepriston'e[\\CHEMICAL] blocks [GENE]glucocorticoid receptor[\\GENE] activation without modifying cortisol synthesis.",
        "label": 4,
        "major": 3,
        "len": 9
    },
    {
        "text": "Autoradiography studies with [CHEMICAL][(3)H](-)-CP 55,940[\\CHEMICAL] show that chronic treatment with SR 141716A for 15 days twice daily (1 mg/kg i.p.) significantly increases the density of [GENE]CB1 receptors[\\GENE] in the PVN.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "Autoradiography studies with [(3)H](-)-CP 55,940 show that chronic treatment with [CHEMICAL]SR 141716A[\\CHEMICAL] for 15 days twice daily (1 mg/kg i.p.) significantly increases the density of [GENE]CB1 receptors[\\GENE] in the PVN.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "The present findings confirm that PVN CB1 receptors, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of [GENE]CB1 receptors[\\GENE] by [CHEMICAL]SR 141716A[\\CHEMICAL] increases the density of these receptors in the PVN.",
        "label": 4,
        "major": 3,
        "len": 51
    },
    {
        "text": "[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] ([CHEMICAL]SR 141716A[\\CHEMICAL]), a selective [GENE]cannabinoid CB1 receptor[\\GENE] antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.",
        "label": 6,
        "major": 3,
        "len": 24
    },
    {
        "text": "[[CHEMICAL]N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide[\\CHEMICAL]] (SR 141716A), a selective [GENE]cannabinoid CB1 receptor[\\GENE] antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "[GENE]Amyloid[\\GENE] activates platelets through 2 pathways: one is through CD36, p38(MAPK), [CHEMICAL]thromboxane A2[\\CHEMICAL]-mediated induction of aggregation; the other is through glycoprotein Ib alpha-mediated aggregation and agglutination.",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "Modulation of the function of CD36 (CD36-/- mice), [GENE]p38[\\GENE](MAPK) ([CHEMICAL]SB203580[\\CHEMICAL]), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.",
        "label": 4,
        "major": 7,
        "len": 23
    },
    {
        "text": "Modulation of the function of CD36 (CD36-/- mice), p38([GENE]MAPK[\\GENE]) ([CHEMICAL]SB203580[\\CHEMICAL]), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.",
        "label": 4,
        "major": 7,
        "len": 23
    },
    {
        "text": "Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), [GENE]COX-1[\\GENE] ([CHEMICAL]indomethacin[\\CHEMICAL]), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.",
        "label": 4,
        "major": 7,
        "len": 23
    },
    {
        "text": "We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that [GENE]human type 12 RDH[\\GENE] reduces dihydrotestosterone to [CHEMICAL]androstanediol[\\CHEMICAL], and is thus also involved in steroid metabolism.",
        "label": 9,
        "major": 4,
        "len": 34
    },
    {
        "text": "The LS/SS genotype of the promoter for [GENE]SLC6A4[\\GENE] was associated with enhanced weight loss with [CHEMICAL]sibutramine[\\CHEMICAL].",
        "label": 2,
        "major": 10,
        "len": 16
    },
    {
        "text": "CONCLUSIONS: Weight reduction with [CHEMICAL]sibutramine[\\CHEMICAL] is associated with altered gastric functions and increased peptide YY and is significantly associated with [GENE]SLC6A4[\\GENE] genotype.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "The role of genetic variation in [GENE]SLC6A4[\\GENE] on weight loss in response to [CHEMICAL]sibutramine[\\CHEMICAL] deserves further study.",
        "label": 2,
        "major": -1,
        "len": 17
    },
    {
        "text": "The [CHEMICAL]sibutramine[\\CHEMICAL] group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial [GENE]peptide YY[\\GENE] compared with the placebo group.",
        "label": 3,
        "major": 4,
        "len": 31
    },
    {
        "text": "CONCLUSIONS: Weight reduction with [CHEMICAL]sibutramine[\\CHEMICAL] is associated with altered gastric functions and increased [GENE]peptide YY[\\GENE] and is significantly associated with SLC6A4 genotype.",
        "label": 3,
        "major": 10,
        "len": 22
    },
    {
        "text": "Multiple [GENE]rat brain calpastatin[\\GENE] forms are produced by distinct starting points and alternative splicing of the [CHEMICAL]N[\\CHEMICAL]-terminal exons.",
        "label": 1,
        "major": 9,
        "len": 18
    },
    {
        "text": "[CHEMICAL]GT-2331[\\CHEMICAL] [(+)-1] is one of the most potent members of a class of chiral drug substances used to regulate the synthesis and release of histamine by the [GENE]histamine H3 receptor[\\GENE], and as such, is an important biomarker for pharmaceutical companies conducting research in this field.",
        "label": 2,
        "major": -1,
        "len": 45
    },
    {
        "text": "An investigation of the absolute configuration of the potent [GENE]histamine H3 receptor[\\GENE] antagonist [CHEMICAL]GT-2331[\\CHEMICAL] using vibrational circular dichroism.",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of [CHEMICAL]atropine[\\CHEMICAL] induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant [GENE]human muscarinic M2 receptors[\\GENE] K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).",
        "label": 2,
        "major": 3,
        "len": 53
    },
    {
        "text": "In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [CHEMICAL][(3)H]N-methylscopolamine[\\CHEMICAL] dissociation from Chinese hamster ovary cells expressing recombinant [GENE]human muscarinic M2 receptors[\\GENE] K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).",
        "label": 2,
        "major": 3,
        "len": 53
    },
    {
        "text": "In this study the neuromuscular blocking drug [CHEMICAL]vecuronium[\\CHEMICAL] and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant [GENE]human muscarinic M2 receptors[\\GENE] K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).",
        "label": 4,
        "major": 3,
        "len": 53
    },
    {
        "text": "In this study the neuromuscular blocking drug vecuronium and the controls [CHEMICAL]gallamine[\\CHEMICAL] and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant [GENE]human muscarinic M2 receptors[\\GENE] K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).",
        "label": 4,
        "major": 3,
        "len": 53
    },
    {
        "text": "In this study the neuromuscular blocking drug vecuronium and the controls gallamine and [CHEMICAL]pancuronium[\\CHEMICAL] slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant [GENE]human muscarinic M2 receptors[\\GENE] K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).",
        "label": 4,
        "major": 3,
        "len": 53
    },
    {
        "text": "These data indicate that [CHEMICAL]vecuronium[\\CHEMICAL], gallamine and pancuronium interact with an allosteric site on the [GENE]muscarinic M2 receptor[\\GENE] (located on the heart) and this may explain some of their cardiac side effects.",
        "label": 7,
        "major": 7,
        "len": 32
    },
    {
        "text": "These data indicate that vecuronium, [CHEMICAL]gallamine[\\CHEMICAL] and pancuronium interact with an allosteric site on the [GENE]muscarinic M2 receptor[\\GENE] (located on the heart) and this may explain some of their cardiac side effects.",
        "label": 7,
        "major": 7,
        "len": 32
    },
    {
        "text": "These data indicate that vecuronium, gallamine and [CHEMICAL]pancuronium[\\CHEMICAL] interact with an allosteric site on the [GENE]muscarinic M2 receptor[\\GENE] (located on the heart) and this may explain some of their cardiac side effects.",
        "label": 7,
        "major": 2,
        "len": 32
    },
    {
        "text": "Allosteric interaction of the neuromuscular blockers [CHEMICAL]vecuronium[\\CHEMICAL] and pancuronium with recombinant [GENE]human muscarinic M2 receptors[\\GENE].",
        "label": 7,
        "major": 2,
        "len": 15
    },
    {
        "text": "Allosteric interaction of the neuromuscular blockers vecuronium and [CHEMICAL]pancuronium[\\CHEMICAL] with recombinant [GENE]human muscarinic M2 receptors[\\GENE].",
        "label": 7,
        "major": 2,
        "len": 15
    },
    {
        "text": "Since 10(-3)M H(2)O(2) oxidises methionine and tryptophan residues in proteins, we examined [CHEMICAL]calcium[\\CHEMICAL] binding to [GENE]calmodulin[\\GENE] in the presence and absence of H(2)O(2) utilising (45)calcium.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "The results showed that all four [CHEMICAL]calcium[\\CHEMICAL] atoms exchanged per molecule of [GENE]calmodulin[\\GENE].",
        "label": 2,
        "major": -1,
        "len": 13
    },
    {
        "text": "Hydrogen peroxide-mediated oxidative stress disrupts [CHEMICAL]calcium[\\CHEMICAL] binding on [GENE]calmodulin[\\GENE]: more evidence for oxidative stress in vitiligo.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Taken together H(2)O(2)-mediated oxidation affects [CHEMICAL]calcium[\\CHEMICAL] binding in [GENE]calmodulin[\\GENE] leading to perturbed calcium homeostasis and perturbed l-phenylalanine-uptake in the epidermis of acute vitiligo.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Since 10(-3)M H(2)O(2) oxidises methionine and tryptophan residues in proteins, we examined calcium binding to [GENE]calmodulin[\\GENE] in the presence and absence of [CHEMICAL]H(2)O(2)[\\CHEMICAL] utilising (45)calcium.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Hydrogen peroxide[\\CHEMICAL]-mediated oxidative stress disrupts calcium binding on [GENE]calmodulin[\\GENE]: more evidence for oxidative stress in vitiligo.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Taken together [CHEMICAL]H(2)O(2)[\\CHEMICAL]-mediated oxidation affects calcium binding in [GENE]calmodulin[\\GENE] leading to perturbed calcium homeostasis and perturbed l-phenylalanine-uptake in the epidermis of acute vitiligo.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Patients with acute vitiligo have low epidermal [GENE]catalase[\\GENE] expression/activities and accumulate 10(-3) M [CHEMICAL]H(2)O(2)[\\CHEMICAL].",
        "label": 9,
        "major": -1,
        "len": 14
    },
    {
        "text": "Moreover, the [GENE]CDO[\\GENE] active site is essentially unreactive toward [CHEMICAL]NO[\\CHEMICAL] in the absence of substrate, suggesting an obligate ordered binding of l-cysteine prior to NO.",
        "label": 10,
        "major": 9,
        "len": 25
    },
    {
        "text": "The active site coordination of [GENE]CDO[\\GENE] comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived [CHEMICAL]histidines[\\CHEMICAL], thus representing a new variant on the 2-histidine-1-carboxylate (2H1C) facial triad motif.",
        "label": 1,
        "major": -1,
        "len": 31
    },
    {
        "text": "The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the [CHEMICAL]NO[\\CHEMICAL]-bound [GENE]CDO[\\GENE] active site.",
        "label": 2,
        "major": 9,
        "len": 32
    },
    {
        "text": "The active site coordination of [GENE]CDO[\\GENE] comprises a mononuclear [CHEMICAL]iron[\\CHEMICAL] ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the 2-histidine-1-carboxylate (2H1C) facial triad motif.",
        "label": 2,
        "major": -1,
        "len": 31
    },
    {
        "text": "In these experiments, [GENE]CDO[\\GENE] exhibits an ordered binding of [CHEMICAL]l-cysteine[\\CHEMICAL] prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "In these experiments, CDO exhibits an ordered binding of [CHEMICAL]l-cysteine[\\CHEMICAL] prior to NO (and presumably O2) similar to that observed for the [GENE]2H1C class of non-heme iron enzymes[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "In these experiments, [GENE]CDO[\\GENE] exhibits an ordered binding of l-cysteine prior to [CHEMICAL]NO[\\CHEMICAL] (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "In these experiments, CDO exhibits an ordered binding of l-cysteine prior to [CHEMICAL]NO[\\CHEMICAL] (and presumably O2) similar to that observed for the [GENE]2H1C class of non-heme iron enzymes[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "In these experiments, [GENE]CDO[\\GENE] exhibits an ordered binding of l-cysteine prior to NO (and presumably [CHEMICAL]O2[\\CHEMICAL]) similar to that observed for the 2H1C class of non-heme iron enzymes.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "In these experiments, CDO exhibits an ordered binding of l-cysteine prior to NO (and presumably [CHEMICAL]O2[\\CHEMICAL]) similar to that observed for the [GENE]2H1C class of non-heme iron enzymes[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "Moreover, the [GENE]CDO[\\GENE] active site is essentially unreactive toward NO in the absence of substrate, suggesting an obligate ordered binding of [CHEMICAL]l-cysteine[\\CHEMICAL] prior to NO.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Moreover, the [GENE]CDO[\\GENE] active site is essentially unreactive toward NO in the absence of substrate, suggesting an obligate ordered binding of l-cysteine prior to [CHEMICAL]NO[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Characterization of the [CHEMICAL]nitrosyl[\\CHEMICAL] adduct of substrate-bound [GENE]mouse cysteine dioxygenase[\\GENE] by electron paramagnetic resonance: electronic structure of the active site and mechanistic implications.",
        "label": 2,
        "major": 9,
        "len": 23
    },
    {
        "text": "However, upon addition of [CHEMICAL]NO[\\CHEMICAL] to [GENE]CDO[\\GENE] in the presence of substrate l-cysteine, a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops.",
        "label": 2,
        "major": 9,
        "len": 32
    },
    {
        "text": "[GENE]Mammalian cysteine dioxygenase[\\GENE] (CDO) is a non-heme [CHEMICAL]iron[\\CHEMICAL] metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.",
        "label": 8,
        "major": 9,
        "len": 19
    },
    {
        "text": "Mammalian cysteine dioxygenase ([GENE]CDO[\\GENE]) is a non-heme [CHEMICAL]iron[\\CHEMICAL] metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.",
        "label": 8,
        "major": 9,
        "len": 19
    },
    {
        "text": "However, upon addition of NO to [GENE]CDO[\\GENE] in the presence of substrate [CHEMICAL]l-cysteine[\\CHEMICAL], a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "[GENE]Mammalian cysteine dioxygenase[\\GENE] (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative [CHEMICAL]cysteine[\\CHEMICAL] catabolism.",
        "label": 9,
        "major": 9,
        "len": 19
    },
    {
        "text": "Mammalian cysteine dioxygenase ([GENE]CDO[\\GENE]) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative [CHEMICAL]cysteine[\\CHEMICAL] catabolism.",
        "label": 9,
        "major": 9,
        "len": 19
    },
    {
        "text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by [CHEMICAL]Wy-14643[\\CHEMICAL] and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of [GENE]PPARalpha2[\\GENE], 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.",
        "label": 2,
        "major": -1,
        "len": 38
    },
    {
        "text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and [CHEMICAL]5,8,11,14-eicosatetraynoic acid[\\CHEMICAL] (ETYA) each at 10 microM, respectively, whereas that of [GENE]PPARalpha2[\\GENE], 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.",
        "label": 2,
        "major": -1,
        "len": 38
    },
    {
        "text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid ([CHEMICAL]ETYA[\\CHEMICAL]) each at 10 microM, respectively, whereas that of [GENE]PPARalpha2[\\GENE], 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.",
        "label": 2,
        "major": -1,
        "len": 38
    },
    {
        "text": "The transcriptional activity of torafugu [GENE]PPARalpha1[\\GENE] was enhanced 4.5- and 11.5-fold by [CHEMICAL]Wy-14643[\\CHEMICAL] and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.",
        "label": 3,
        "major": -1,
        "len": 38
    },
    {
        "text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by [CHEMICAL]Wy-14643[\\CHEMICAL] and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of [GENE]PPARalpha2[\\GENE], 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.",
        "label": 3,
        "major": -1,
        "len": 38
    },
    {
        "text": "The transcriptional activity of torafugu [GENE]PPARalpha1[\\GENE] was enhanced 4.5- and 11.5-fold by Wy-14643 and [CHEMICAL]5,8,11,14-eicosatetraynoic acid[\\CHEMICAL] (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.",
        "label": 3,
        "major": -1,
        "len": 38
    },
    {
        "text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and [CHEMICAL]5,8,11,14-eicosatetraynoic acid[\\CHEMICAL] (ETYA) each at 10 microM, respectively, whereas that of [GENE]PPARalpha2[\\GENE], 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.",
        "label": 3,
        "major": -1,
        "len": 38
    },
    {
        "text": "The transcriptional activity of torafugu [GENE]PPARalpha1[\\GENE] was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid ([CHEMICAL]ETYA[\\CHEMICAL]) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.",
        "label": 3,
        "major": -1,
        "len": 38
    },
    {
        "text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid ([CHEMICAL]ETYA[\\CHEMICAL]) each at 10 microM, respectively, whereas that of [GENE]PPARalpha2[\\GENE], 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.",
        "label": 3,
        "major": -1,
        "len": 38
    },
    {
        "text": "Furthermore, the activities of the two [GENE]torafugu PPARalphas[\\GENE] were enhanced 4.3- and 7.6-fold by [CHEMICAL]arachidonic acid[\\CHEMICAL], 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively.",
        "label": 3,
        "major": -1,
        "len": 34
    },
    {
        "text": "Furthermore, the activities of the two [GENE]torafugu PPARalphas[\\GENE] were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by [CHEMICAL]docosahexaenoic acid[\\CHEMICAL], and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively.",
        "label": 3,
        "major": -1,
        "len": 34
    },
    {
        "text": "Furthermore, the activities of the two [GENE]torafugu PPARalphas[\\GENE] were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by [CHEMICAL]eicosapentaenoic acid[\\CHEMICAL] each at 50 microM, respectively.",
        "label": 3,
        "major": -1,
        "len": 34
    },
    {
        "text": "Combination chemotherapy with a [GENE]substance P receptor[\\GENE] antagonist ([CHEMICAL]aprepitant[\\CHEMICAL]) and melarsoprol in a mouse model of human African trypanosomiasis.",
        "label": 6,
        "major": 6,
        "len": 19
    },
    {
        "text": "Combination chemotherapy with a [GENE]substance P receptor[\\GENE] antagonist (aprepitant) and [CHEMICAL]melarsoprol[\\CHEMICAL] in a mouse model of human African trypanosomiasis.",
        "label": 6,
        "major": 6,
        "len": 19
    },
    {
        "text": "In this study we investigated the effects of combination chemotherapy with melarsoprol and a [GENE]humanised SP receptor[\\GENE] antagonist [CHEMICAL]aprepitant[\\CHEMICAL] (EMEND) in this mouse model.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "In this study we investigated the effects of combination chemotherapy with melarsoprol and a [GENE]humanised SP receptor[\\GENE] antagonist aprepitant ([CHEMICAL]EMEND[\\CHEMICAL]) in this mouse model.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "PURPOSE: Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a [GENE]36-kDa water-soluble protein[\\GENE] with 316 [CHEMICAL]amino acids[\\CHEMICAL] found in the retinal pigment epithelium (RPE) and in retinal Muller cells.",
        "label": 1,
        "major": 1,
        "len": 31
    },
    {
        "text": "It is thought to play a critical role in the visual cycle by functioning as an acceptor of [CHEMICAL]11-cis-retinol[\\CHEMICAL] from the [GENE]isomerohydrolase[\\GENE] reaction.",
        "label": 9,
        "major": -1,
        "len": 23
    },
    {
        "text": "[GENE]Arginase[\\GENE] or nitric oxide synthase isoenzymes were not found to influence [CHEMICAL]L-citrulline[\\CHEMICAL] production.",
        "label": 10,
        "major": 9,
        "len": 13
    },
    {
        "text": "Arginase or [GENE]nitric oxide synthase[\\GENE] isoenzymes were not found to influence [CHEMICAL]L-citrulline[\\CHEMICAL] production.",
        "label": 10,
        "major": 9,
        "len": 13
    },
    {
        "text": "Using this assay, we found that both [CHEMICAL]superoxide[\\CHEMICAL] and nitric oxide inhibit renal cortical [GENE]DDAH[\\GENE] activity in vitro.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Using this assay, we found that both superoxide and [CHEMICAL]nitric oxide[\\CHEMICAL] inhibit renal cortical [GENE]DDAH[\\GENE] activity in vitro.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Our optimized [CHEMICAL]L-citrulline[\\CHEMICAL] production assay to measure [GENE]DDAH[\\GENE] activity correlated closely with the direct measure of the rate of asymmetric dimethylarginine consumption.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "[GENE]Dimethylarginine dimethylaminohydrolase[\\GENE] (DDAH) metabolizes asymmetric dimethylarginine to generate [CHEMICAL]L-citrulline[\\CHEMICAL] and is present in large quantities in the kidney.",
        "label": 9,
        "major": -1,
        "len": 18
    },
    {
        "text": "Dimethylarginine dimethylaminohydrolase ([GENE]DDAH[\\GENE]) metabolizes asymmetric dimethylarginine to generate [CHEMICAL]L-citrulline[\\CHEMICAL] and is present in large quantities in the kidney.",
        "label": 9,
        "major": -1,
        "len": 18
    },
    {
        "text": "We present a new study that optimizes the Prescott-Jones colorimetric assay to measure [GENE]DDAH[\\GENE]-dependent [CHEMICAL]L-citrulline[\\CHEMICAL] generation in kidney homogenates.",
        "label": 9,
        "major": -1,
        "len": 19
    },
    {
        "text": "Our optimized L-citrulline production assay to measure [GENE]DDAH[\\GENE] activity correlated closely with the direct measure of the rate of asymmetric [CHEMICAL]dimethylarginine[\\CHEMICAL] consumption.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "We found that the removal of [CHEMICAL]urea[\\CHEMICAL] with [GENE]urease[\\GENE] is necessary since urea also produces a positive reaction.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "[GENE]Dimethylarginine dimethylaminohydrolase[\\GENE] (DDAH) metabolizes asymmetric [CHEMICAL]dimethylarginine[\\CHEMICAL] to generate L-citrulline and is present in large quantities in the kidney.",
        "label": 9,
        "major": -1,
        "len": 18
    },
    {
        "text": "Dimethylarginine dimethylaminohydrolase ([GENE]DDAH[\\GENE]) metabolizes asymmetric [CHEMICAL]dimethylarginine[\\CHEMICAL] to generate L-citrulline and is present in large quantities in the kidney.",
        "label": 9,
        "major": -1,
        "len": 18
    },
    {
        "text": "A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, [GENE]HER2[\\GENE]/neu overexpressing breast cancer sequenced with chemotherapy including [CHEMICAL]doxorubicin[\\CHEMICAL], cyclophosphamide, and paclitaxel.",
        "label": 2,
        "major": -1,
        "len": 28
    },
    {
        "text": "A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/[GENE]neu[\\GENE] overexpressing breast cancer sequenced with chemotherapy including [CHEMICAL]doxorubicin[\\CHEMICAL], cyclophosphamide, and paclitaxel.",
        "label": 2,
        "major": -1,
        "len": 28
    },
    {
        "text": "A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, [GENE]HER2[\\GENE]/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, [CHEMICAL]cyclophosphamide[\\CHEMICAL], and paclitaxel.",
        "label": 2,
        "major": -1,
        "len": 28
    },
    {
        "text": "A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/[GENE]neu[\\GENE] overexpressing breast cancer sequenced with chemotherapy including doxorubicin, [CHEMICAL]cyclophosphamide[\\CHEMICAL], and paclitaxel.",
        "label": 2,
        "major": -1,
        "len": 28
    },
    {
        "text": "A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, [GENE]HER2[\\GENE]/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 2,
        "major": -1,
        "len": 28
    },
    {
        "text": "A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/[GENE]neu[\\GENE] overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 2,
        "major": -1,
        "len": 28
    },
    {
        "text": "The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting [GENE]HER2[\\GENE]/neu as well as the epidermal growth factor receptor (EGFR), [CHEMICAL]lapatinib[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/[GENE]neu[\\GENE] as well as the epidermal growth factor receptor (EGFR), [CHEMICAL]lapatinib[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/neu as well as the [GENE]epidermal growth factor receptor[\\GENE] (EGFR), [CHEMICAL]lapatinib[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/neu as well as the epidermal growth factor receptor ([GENE]EGFR[\\GENE]), [CHEMICAL]lapatinib[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas [CHEMICAL]l-glutamate[\\CHEMICAL] (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to [GENE]fibronectin[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 47
    },
    {
        "text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and [CHEMICAL]NMDA[\\CHEMICAL] (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to [GENE]fibronectin[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 47
    },
    {
        "text": "Exposure of Jurkat cells to either [CHEMICAL](5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine[\\CHEMICAL] [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective [GENE]NMDA receptor[\\GENE] antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",
        "label": 6,
        "major": 3,
        "len": 47
    },
    {
        "text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [[CHEMICAL](+)-MK 801[\\CHEMICAL]] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective [GENE]NMDA receptor[\\GENE] antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",
        "label": 6,
        "major": 3,
        "len": 47
    },
    {
        "text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or [CHEMICAL]D-(-)-2-amino-5-phosphonopentanoic acid[\\CHEMICAL] (D-AP5), two selective [GENE]NMDA receptor[\\GENE] antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",
        "label": 6,
        "major": 3,
        "len": 47
    },
    {
        "text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid ([CHEMICAL]D-AP5[\\CHEMICAL]), two selective [GENE]NMDA receptor[\\GENE] antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",
        "label": 6,
        "major": 3,
        "len": 47
    },
    {
        "text": "In an initial search for molecular features that differentially define antagonist binding determinants, we document that Val148 in [GENE]hNET transmembrane domain 3[\\GENE] selectively disrupts [CHEMICAL]NIS[\\CHEMICAL] binding but not that of DVS.",
        "label": 10,
        "major": 2,
        "len": 31
    },
    {
        "text": "Initial evaluation of the pharmacological properties of DVS (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the [GENE]hNET[\\GENE] expressed in membranes compared with whole cells when competing for [CHEMICAL][(3)H]nisoxetine[\\CHEMICAL] (NIS) binding.",
        "label": 2,
        "major": 4,
        "len": 34
    },
    {
        "text": "Initial evaluation of the pharmacological properties of DVS (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the [GENE]hNET[\\GENE] expressed in membranes compared with whole cells when competing for [(3)H]nisoxetine ([CHEMICAL]NIS[\\CHEMICAL]) binding.",
        "label": 2,
        "major": 4,
        "len": 34
    },
    {
        "text": "Using [GENE]hNET[\\GENE] in transfected human embryonic kidney-293 cells, this difference in potency for [CHEMICAL]DVS[\\CHEMICAL] at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
        "label": 2,
        "major": 6,
        "len": 51
    },
    {
        "text": "Using [GENE]hNET[\\GENE] in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [CHEMICAL][(3)H]NIS[\\CHEMICAL] was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
        "label": 2,
        "major": 6,
        "len": 51
    },
    {
        "text": "Using [GENE]hNET[\\GENE] in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the [CHEMICAL]DVS[\\CHEMICAL] analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "Using [GENE]hNET[\\GENE] in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog [CHEMICAL]rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol[\\CHEMICAL] (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "Using [GENE]hNET[\\GENE] in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol ([CHEMICAL]WY-46824[\\CHEMICAL]), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "Using [GENE]hNET[\\GENE] in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), [CHEMICAL]methylphenidate[\\CHEMICAL], and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "Using [GENE]hNET[\\GENE] in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the [CHEMICAL]cocaine[\\CHEMICAL] analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "Using [GENE]hNET[\\GENE] in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog [CHEMICAL]3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester[\\CHEMICAL] (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "Using [GENE]hNET[\\GENE] in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester ([CHEMICAL]RTI-55[\\CHEMICAL]) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other [GENE]hNET[\\GENE] antagonists, such as [CHEMICAL]NIS[\\CHEMICAL], mazindol, tricyclic antidepressants, and cocaine.",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other [GENE]hNET[\\GENE] antagonists, such as NIS, [CHEMICAL]mazindol[\\CHEMICAL], tricyclic antidepressants, and cocaine.",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "[CHEMICAL]Desvenlafaxine succinate[\\CHEMICAL] (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters ([GENE]hNET[\\GENE] and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",
        "label": 6,
        "major": 9,
        "len": 38
    },
    {
        "text": "[CHEMICAL]Desvenlafaxine succinate[\\CHEMICAL] (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and [GENE]hSERT[\\GENE], respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",
        "label": 6,
        "major": 9,
        "len": 38
    },
    {
        "text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other [GENE]hNET[\\GENE] antagonists, such as NIS, mazindol, [CHEMICAL]tricyclic[\\CHEMICAL] antidepressants, and cocaine.",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other [GENE]hNET[\\GENE] antagonists, such as NIS, mazindol, tricyclic antidepressants, and [CHEMICAL]cocaine[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "[CHEMICAL]Desvenlafaxine succinate[\\CHEMICAL] identifies novel antagonist binding determinants in the [GENE]human norepinephrine transporter[\\GENE].",
        "label": 6,
        "major": 6,
        "len": 12
    },
    {
        "text": "Desvenlafaxine succinate ([CHEMICAL]DVS[\\CHEMICAL]) is a recently introduced antagonist of the human norepinephrine and serotonin transporters ([GENE]hNET[\\GENE] and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",
        "label": 6,
        "major": 9,
        "len": 38
    },
    {
        "text": "Desvenlafaxine succinate ([CHEMICAL]DVS[\\CHEMICAL]) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and [GENE]hSERT[\\GENE], respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",
        "label": 6,
        "major": 6,
        "len": 38
    },
    {
        "text": "Using [GENE]hNET[\\GENE] in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish [CHEMICAL]DVS[\\CHEMICAL], the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "The key difference in structure of [GENE]Lp(a)[\\GENE] and plasminogen is replacement of [CHEMICAL]Arg[\\CHEMICAL] with Ser at position 560.",
        "label": 1,
        "major": 1,
        "len": 18
    },
    {
        "text": "The key difference in structure of Lp(a) and [GENE]plasminogen[\\GENE] is replacement of [CHEMICAL]Arg[\\CHEMICAL] with Ser at position 560.",
        "label": 1,
        "major": 1,
        "len": 18
    },
    {
        "text": "The key difference in structure of [GENE]Lp(a)[\\GENE] and plasminogen is replacement of Arg with [CHEMICAL]Ser[\\CHEMICAL] at position 560.",
        "label": 1,
        "major": 1,
        "len": 18
    },
    {
        "text": "The key difference in structure of Lp(a) and [GENE]plasminogen[\\GENE] is replacement of Arg with [CHEMICAL]Ser[\\CHEMICAL] at position 560.",
        "label": 1,
        "major": 1,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 ([GENE]VEGFR-2[\\GENE], VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, [GENE]VEGFR-3[\\GENE]) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and [GENE]platelet-derived growth factor receptor beta[\\GENE] (PDGFR-beta), while temsirolimus is an mTOR inhibitor.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta ([GENE]PDGFR-beta[\\GENE]), while temsirolimus is an mTOR inhibitor.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Sorafenib and [CHEMICAL]sunitinib[\\CHEMICAL] are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 ([GENE]VEGFR-2[\\GENE], VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Sorafenib and [CHEMICAL]sunitinib[\\CHEMICAL] are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, [GENE]VEGFR-3[\\GENE]) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Sorafenib and [CHEMICAL]sunitinib[\\CHEMICAL] are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and [GENE]platelet-derived growth factor receptor beta[\\GENE] (PDGFR-beta), while temsirolimus is an mTOR inhibitor.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Sorafenib and [CHEMICAL]sunitinib[\\CHEMICAL] are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta ([GENE]PDGFR-beta[\\GENE]), while temsirolimus is an mTOR inhibitor.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while [CHEMICAL]temsirolimus[\\CHEMICAL] is an [GENE]mTOR[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "One is that the binding of [CHEMICAL]retinoids[\\CHEMICAL] to nuclear [GENE]retinoic acid receptors[\\GENE] (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.",
        "label": 2,
        "major": 3,
        "len": 47
    },
    {
        "text": "One is that the binding of [CHEMICAL]retinoids[\\CHEMICAL] to nuclear retinoic acid receptors ([GENE]RARs[\\GENE]) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.",
        "label": 2,
        "major": 10,
        "len": 47
    },
    {
        "text": "One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas [CHEMICAL]tazarotene[\\CHEMICAL] preferentially binds to and activates RAR-beta and -gamma in preference to [GENE]RAR-alpha[\\GENE].",
        "label": 2,
        "major": 10,
        "len": 47
    },
    {
        "text": "One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas [CHEMICAL]tazarotene[\\CHEMICAL] preferentially binds to and activates RAR-beta and -gamma in preference to [GENE]RAR-alpha[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "In experimental models, [CHEMICAL]rasagiline[\\CHEMICAL] has been found to have neuroprotective properties that may be independent of [GENE]MAO-B[\\GENE] inhibition.",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "Rasagiline [[CHEMICAL]N-propargyl-l(R)-aminoindan[\\CHEMICAL]] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain [GENE]MAO-B[\\GENE] and is specifically designed for the treatment of Parkinson's disease (PD).",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation [CHEMICAL]propargylamine[\\CHEMICAL] pharmacophore that selectively and irreversibly inhibits brain [GENE]MAO-B[\\GENE] and is specifically designed for the treatment of Parkinson's disease (PD).",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Comprehensive review of [CHEMICAL]rasagiline[\\CHEMICAL], a second-generation [GENE]monoamine oxidase[\\GENE] inhibitor, for the treatment of Parkinson's disease.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Based on the results from those studies, we concluded that [CHEMICAL]rasagiline[\\CHEMICAL] PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited [GENE]MAO-B[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain [GENE]MAO-B[\\GENE] and is specifically designed for the treatment of Parkinson's disease (PD).",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "We postulate that this conserved [CHEMICAL]Gly[\\CHEMICAL] residue provides a flexible hinge within the [GENE]Top1p[\\GENE] catalytic pocket to facilitate linker dynamics and the structural alterations that accompany drug binding of the covalent enzyme-DNA intermediate.",
        "label": 1,
        "major": 2,
        "len": 33
    },
    {
        "text": "[GENE]Top1p[\\GENE] clamps around duplex DNA, wherein the core and [CHEMICAL]C[\\CHEMICAL]-terminal domains are connected by extended alpha-helices (linker domain), which position the active site Tyr of the C-terminal domain within the catalytic pocket.",
        "label": 1,
        "major": -1,
        "len": 32
    },
    {
        "text": "Top1p clamps around duplex DNA, wherein the core and [CHEMICAL]C[\\CHEMICAL]-terminal domains are connected by extended [GENE]alpha-helices[\\GENE] (linker domain), which position the active site Tyr of the C-terminal domain within the catalytic pocket.",
        "label": 1,
        "major": -1,
        "len": 32
    },
    {
        "text": "Top1p clamps around duplex DNA, wherein the core and [CHEMICAL]C[\\CHEMICAL]-terminal domains are connected by extended alpha-helices ([GENE]linker domain[\\GENE]), which position the active site Tyr of the C-terminal domain within the catalytic pocket.",
        "label": 1,
        "major": -1,
        "len": 32
    },
    {
        "text": "We report that mutation of this conserved [CHEMICAL]Gly[\\CHEMICAL] in [GENE]yeast Top1p[\\GENE] alters enzyme sensitivity to CPT.",
        "label": 1,
        "major": 1,
        "len": 16
    },
    {
        "text": "[GENE]Top1p[\\GENE] clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (linker domain), which position the active site [CHEMICAL]Tyr[\\CHEMICAL] of the C-terminal domain within the catalytic pocket.",
        "label": 1,
        "major": -1,
        "len": 32
    },
    {
        "text": "Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended [GENE]alpha-helices[\\GENE] (linker domain), which position the active site [CHEMICAL]Tyr[\\CHEMICAL] of the C-terminal domain within the catalytic pocket.",
        "label": 1,
        "major": -1,
        "len": 32
    },
    {
        "text": "[GENE]Top1p[\\GENE] clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (linker domain), which position the active site Tyr of the [CHEMICAL]C[\\CHEMICAL]-terminal domain within the catalytic pocket.",
        "label": 1,
        "major": -1,
        "len": 32
    },
    {
        "text": "Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices ([GENE]linker domain[\\GENE]), which position the active site Tyr of the [CHEMICAL]C[\\CHEMICAL]-terminal domain within the catalytic pocket.",
        "label": 1,
        "major": -1,
        "len": 32
    },
    {
        "text": "Crystallographic data reveal that a conserved [CHEMICAL]Gly[\\CHEMICAL] residue (located at the juncture between the linker and C-terminal domains) is at one end of a short [GENE]alpha-helix[\\GENE], which extends to the active site Tyr covalently linked to the DNA.",
        "label": 1,
        "major": -1,
        "len": 38
    },
    {
        "text": "Crystallographic data reveal that a conserved Gly residue (located at the juncture between the linker and [CHEMICAL]C[\\CHEMICAL]-terminal domains) is at one end of a short [GENE]alpha-helix[\\GENE], which extends to the active site Tyr covalently linked to the DNA.",
        "label": 1,
        "major": -1,
        "len": 38
    },
    {
        "text": "Crystallographic data reveal that a conserved Gly residue (located at the juncture between the linker and C-terminal domains) is at one end of a short [GENE]alpha-helix[\\GENE], which extends to the active site [CHEMICAL]Tyr[\\CHEMICAL] covalently linked to the DNA.",
        "label": 1,
        "major": -1,
        "len": 38
    },
    {
        "text": "In the presence of drug, the linker is rigid and this [GENE]alpha-helix[\\GENE] extends to include [CHEMICAL]Gly[\\CHEMICAL] and the preceding Leu.",
        "label": 1,
        "major": -1,
        "len": 20
    },
    {
        "text": "In the presence of drug, the linker is rigid and this [GENE]alpha-helix[\\GENE] extends to include Gly and the preceding [CHEMICAL]Leu[\\CHEMICAL].",
        "label": 1,
        "major": -1,
        "len": 20
    },
    {
        "text": "[GENE]Top1p[\\GENE] is the cellular target of the anti-cancer drug [CHEMICAL]camptothecin[\\CHEMICAL] (CPT), which reversibly stabilizes a covalent enzyme-DNA intermediate.",
        "label": 2,
        "major": -1,
        "len": 18
    },
    {
        "text": "[GENE]Top1p[\\GENE] is the cellular target of the anti-cancer drug camptothecin ([CHEMICAL]CPT[\\CHEMICAL]), which reversibly stabilizes a covalent enzyme-DNA intermediate.",
        "label": 2,
        "major": -1,
        "len": 18
    },
    {
        "text": "The physical connection of the linker with the [GENE]Top1p[\\GENE] clamp as well as linker flexibility affect enzyme sensitivity to [CHEMICAL]CPT[\\CHEMICAL].",
        "label": 2,
        "major": -1,
        "len": 20
    },
    {
        "text": "Mutation of Gly721 alters [GENE]DNA topoisomerase I[\\GENE] active site architecture and sensitivity to [CHEMICAL]camptothecin[\\CHEMICAL].",
        "label": 2,
        "major": 1,
        "len": 14
    },
    {
        "text": "We report that mutation of this conserved Gly in [GENE]yeast Top1p[\\GENE] alters enzyme sensitivity to [CHEMICAL]CPT[\\CHEMICAL].",
        "label": 2,
        "major": 1,
        "len": 16
    },
    {
        "text": "The binding of U46619 to the [GENE]PGIS[\\GENE] protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at [CHEMICAL]C-11[\\CHEMICAL], H2C, and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.",
        "label": 1,
        "major": 2,
        "len": 44
    },
    {
        "text": "The binding of U46619 to the [GENE]PGIS[\\GENE] protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, [CHEMICAL]H2C[\\CHEMICAL], and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.",
        "label": 1,
        "major": 2,
        "len": 44
    },
    {
        "text": "The binding of U46619 to the [GENE]PGIS[\\GENE] protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and [CHEMICAL]H20[\\CHEMICAL] of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.",
        "label": 1,
        "major": 2,
        "len": 44
    },
    {
        "text": "The binding of U46619 to the [GENE]PGIS[\\GENE] protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of [CHEMICAL]U46619[\\CHEMICAL] were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.",
        "label": 1,
        "major": 2,
        "len": 44
    },
    {
        "text": "The distances between the protons [CHEMICAL]H20[\\CHEMICAL] and H2, H18 and H2, and H18 and H4 are shorter following their binding to the [GENE]PGIS[\\GENE] in solution-down to within 5 A.",
        "label": 1,
        "major": 2,
        "len": 29
    },
    {
        "text": "The distances between the protons H20 and [CHEMICAL]H2[\\CHEMICAL], H18 and H2, and H18 and H4 are shorter following their binding to the [GENE]PGIS[\\GENE] in solution-down to within 5 A.",
        "label": 1,
        "major": 2,
        "len": 29
    },
    {
        "text": "The distances between the protons H20 and H2, [CHEMICAL]H18[\\CHEMICAL] and H2, and H18 and H4 are shorter following their binding to the [GENE]PGIS[\\GENE] in solution-down to within 5 A.",
        "label": 1,
        "major": 2,
        "len": 29
    },
    {
        "text": "The distances between the protons H20 and H2, H18 and [CHEMICAL]H2[\\CHEMICAL], and H18 and H4 are shorter following their binding to the [GENE]PGIS[\\GENE] in solution-down to within 5 A.",
        "label": 1,
        "major": 2,
        "len": 29
    },
    {
        "text": "The distances between the protons H20 and H2, H18 and H2, and [CHEMICAL]H18[\\CHEMICAL] and H4 are shorter following their binding to the [GENE]PGIS[\\GENE] in solution-down to within 5 A.",
        "label": 1,
        "major": 2,
        "len": 29
    },
    {
        "text": "The distances between the protons H20 and H2, H18 and H2, and H18 and [CHEMICAL]H4[\\CHEMICAL] are shorter following their binding to the [GENE]PGIS[\\GENE] in solution-down to within 5 A.",
        "label": 1,
        "major": 2,
        "len": 29
    },
    {
        "text": "The binding of [CHEMICAL]U46619[\\CHEMICAL] to the [GENE]PGIS[\\GENE] protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon [CHEMICAL]U46619[\\CHEMICAL] binding to the engineered [GENE]PGIS[\\GENE] in a concentration-dependent manner.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "The detailed conformational change and 3D structure of the [GENE]PGIS[\\GENE]-bound [CHEMICAL]U46619[\\CHEMICAL] were further demonstrated by 2D 1H NMR experiments using the transferred NOE technique.",
        "label": 2,
        "major": -1,
        "len": 24
    },
    {
        "text": "High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic ([CHEMICAL]U46619[\\CHEMICAL]) to the engineered [GENE]prostacyclin (PGI2) synthase[\\GENE] (PGIS) in solution.",
        "label": 2,
        "major": 9,
        "len": 25
    },
    {
        "text": "High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic ([CHEMICAL]U46619[\\CHEMICAL]) to the engineered prostacyclin (PGI2) synthase ([GENE]PGIS[\\GENE]) in solution.",
        "label": 2,
        "major": 9,
        "len": 25
    },
    {
        "text": "High-resolution NMR spectroscopy was used to determine the docking of a substrate ([CHEMICAL]prostaglandin H2[\\CHEMICAL]) mimic (U46619) to the engineered [GENE]prostacyclin (PGI2) synthase[\\GENE] (PGIS) in solution.",
        "label": 2,
        "major": 9,
        "len": 25
    },
    {
        "text": "High-resolution NMR spectroscopy was used to determine the docking of a substrate ([CHEMICAL]prostaglandin H2[\\CHEMICAL]) mimic (U46619) to the engineered prostacyclin (PGI2) synthase ([GENE]PGIS[\\GENE]) in solution.",
        "label": 2,
        "major": 9,
        "len": 25
    },
    {
        "text": "The bound conformation of [CHEMICAL]U46619[\\CHEMICAL] fits the crystal structure of the [GENE]PGIS[\\GENE] substrate binding pocket considerably better than that of the unbound U46619.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "For example, Trp282 could be one of the most important residues and is suspected to play a role in the determination of specific catalytic function, which has been established by the docking studies using the NMR structure of the [GENE]PGIS[\\GENE]-bound form of [CHEMICAL]U46619[\\CHEMICAL] and the PGIS crystal structure.",
        "label": 2,
        "major": -1,
        "len": 48
    },
    {
        "text": "For example, Trp282 could be one of the most important residues and is suspected to play a role in the determination of specific catalytic function, which has been established by the docking studies using the NMR structure of the PGIS-bound form of [CHEMICAL]U46619[\\CHEMICAL] and the [GENE]PGIS[\\GENE] crystal structure.",
        "label": 2,
        "major": -1,
        "len": 48
    },
    {
        "text": "The noted conformational changes where the C-6 position is closer to the C-9 position of [CHEMICAL]U46619[\\CHEMICAL] provided the first experimental data for understanding the molecular mechanism of the catalytic function of [GENE]PGIS[\\GENE] in the isomerization of PGH2 to prostacyclin.",
        "label": 2,
        "major": 10,
        "len": 39
    },
    {
        "text": "This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to [GENE]factor Xa[\\GENE] ([CHEMICAL]rivaroxaban[\\CHEMICAL] and apixaban) and IIa (dabigatran).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to [GENE]factor Xa[\\GENE] (rivaroxaban and [CHEMICAL]apixaban[\\CHEMICAL]) and IIa (dabigatran).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "INTERVENTIONS: In the 8-week run-in period, all participants received the [GENE]ACE[\\GENE] inhibitor [CHEMICAL]cilazapril[\\CHEMICAL] (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Two [CHEMICAL]imidazoquinoline[\\CHEMICAL] molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not [GENE]TLR8[\\GENE], was activated by the ligands.",
        "label": 10,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, [CHEMICAL]imiquimod[\\CHEMICAL] and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not [GENE]TLR8[\\GENE], was activated by the ligands.",
        "label": 10,
        "major": 3,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, imiquimod and [CHEMICAL]gardiquimod[\\CHEMICAL], markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not [GENE]TLR8[\\GENE], was activated by the ligands.",
        "label": 10,
        "major": 10,
        "len": 25
    },
    {
        "text": "Both [GENE]porcine TLR7[\\GENE] and TLR8 proteins were expressed in cell lines and were [CHEMICAL]N[\\CHEMICAL]-glycosylated.",
        "label": 1,
        "major": -1,
        "len": 14
    },
    {
        "text": "Both porcine TLR7 and [GENE]TLR8[\\GENE] proteins were expressed in cell lines and were [CHEMICAL]N[\\CHEMICAL]-glycosylated.",
        "label": 1,
        "major": -1,
        "len": 14
    },
    {
        "text": "Two [CHEMICAL]imidazoquinoline[\\CHEMICAL] molecules, imiquimod and gardiquimod, markedly activated both [GENE]porcine TLR7[\\GENE] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two [CHEMICAL]imidazoquinoline[\\CHEMICAL] molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and [GENE]TLR8[\\GENE] whereas only human TLR7, but not TLR8, was activated by the ligands.",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two [CHEMICAL]imidazoquinoline[\\CHEMICAL] molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only [GENE]human TLR7[\\GENE], but not TLR8, was activated by the ligands.",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two [CHEMICAL]imidazoquinoline[\\CHEMICAL] molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not [GENE]TLR8[\\GENE], was activated by the ligands.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, [CHEMICAL]imiquimod[\\CHEMICAL] and gardiquimod, markedly activated both [GENE]porcine TLR7[\\GENE] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, [CHEMICAL]imiquimod[\\CHEMICAL] and gardiquimod, markedly activated both porcine TLR7 and [GENE]TLR8[\\GENE] whereas only human TLR7, but not TLR8, was activated by the ligands.",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, [CHEMICAL]imiquimod[\\CHEMICAL] and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only [GENE]human TLR7[\\GENE], but not TLR8, was activated by the ligands.",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, [CHEMICAL]imiquimod[\\CHEMICAL] and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not [GENE]TLR8[\\GENE], was activated by the ligands.",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, imiquimod and [CHEMICAL]gardiquimod[\\CHEMICAL], markedly activated both [GENE]porcine TLR7[\\GENE] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, imiquimod and [CHEMICAL]gardiquimod[\\CHEMICAL], markedly activated both porcine TLR7 and [GENE]TLR8[\\GENE] whereas only human TLR7, but not TLR8, was activated by the ligands.",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, imiquimod and [CHEMICAL]gardiquimod[\\CHEMICAL], markedly activated both porcine TLR7 and TLR8 whereas only [GENE]human TLR7[\\GENE], but not TLR8, was activated by the ligands.",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, imiquimod and [CHEMICAL]gardiquimod[\\CHEMICAL], markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not [GENE]TLR8[\\GENE], was activated by the ligands.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Porcine TLR8 and TLR7 are both activated by a selective [GENE]TLR7[\\GENE] ligand, [CHEMICAL]imiquimod[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 13
    },
    {
        "text": "Two [CHEMICAL]imidazoquinoline[\\CHEMICAL] molecules, imiquimod and gardiquimod, markedly activated both [GENE]porcine TLR7[\\GENE] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.",
        "label": 3,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two [CHEMICAL]imidazoquinoline[\\CHEMICAL] molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and [GENE]TLR8[\\GENE] whereas only human TLR7, but not TLR8, was activated by the ligands.",
        "label": 3,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two [CHEMICAL]imidazoquinoline[\\CHEMICAL] molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only [GENE]human TLR7[\\GENE], but not TLR8, was activated by the ligands.",
        "label": 3,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, [CHEMICAL]imiquimod[\\CHEMICAL] and gardiquimod, markedly activated both [GENE]porcine TLR7[\\GENE] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.",
        "label": 3,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, [CHEMICAL]imiquimod[\\CHEMICAL] and gardiquimod, markedly activated both porcine TLR7 and [GENE]TLR8[\\GENE] whereas only human TLR7, but not TLR8, was activated by the ligands.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, [CHEMICAL]imiquimod[\\CHEMICAL] and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only [GENE]human TLR7[\\GENE], but not TLR8, was activated by the ligands.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, imiquimod and [CHEMICAL]gardiquimod[\\CHEMICAL], markedly activated both [GENE]porcine TLR7[\\GENE] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.",
        "label": 3,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, imiquimod and [CHEMICAL]gardiquimod[\\CHEMICAL], markedly activated both porcine TLR7 and [GENE]TLR8[\\GENE] whereas only human TLR7, but not TLR8, was activated by the ligands.",
        "label": 3,
        "major": 10,
        "len": 25
    },
    {
        "text": "Two imidazoquinoline molecules, imiquimod and [CHEMICAL]gardiquimod[\\CHEMICAL], markedly activated both porcine TLR7 and TLR8 whereas only [GENE]human TLR7[\\GENE], but not TLR8, was activated by the ligands.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Porcine TLR8 and [GENE]TLR7[\\GENE] are both activated by a selective TLR7 ligand, [CHEMICAL]imiquimod[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "Porcine [GENE]TLR8[\\GENE] and TLR7 are both activated by a selective TLR7 ligand, [CHEMICAL]imiquimod[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "Moreover, activation of transfected cells and porcine PBMC by [GENE]TLR7[\\GENE] ligands was inhibited by [CHEMICAL]bafilomycin A(1)[\\CHEMICAL] indicating the requirement of endosomal/lysosomal acidification for activation of the receptors.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for [CHEMICAL]4-iodopropofol[\\CHEMICAL], 4-bromopropofol and 4-chloropropofol in [GENE]Na(V)1.4[\\GENE], and 450 nM for 4-chloropropofol in Na(V)1.2.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, [CHEMICAL]4-bromopropofol[\\CHEMICAL] and 4-chloropropofol in [GENE]Na(V)1.4[\\GENE], and 450 nM for 4-chloropropofol in Na(V)1.2.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and [CHEMICAL]4-chloropropofol[\\CHEMICAL] in [GENE]Na(V)1.4[\\GENE], and 450 nM for 4-chloropropofol in Na(V)1.2.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for [CHEMICAL]4-chloropropofol[\\CHEMICAL] in [GENE]Na(V)1.2[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "CONCLUSIONS AND IMPLICATIONS: Halogenated propofol analogues constitute a novel class of [GENE]sodium channel[\\GENE]-blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug [CHEMICAL]lidocaine[\\CHEMICAL].",
        "label": 2,
        "major": -1,
        "len": 28
    },
    {
        "text": "The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for [CHEMICAL]4-chloropropofol[\\CHEMICAL] in [GENE]Na(V)1.2[\\GENE].",
        "label": 4,
        "major": -1,
        "len": 26
    },
    {
        "text": "Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for [CHEMICAL]4-iodopropofol[\\CHEMICAL], 4-bromopropofol and 4-chloropropofol in [GENE]Na(V)1.4[\\GENE], and 450 nM for 4-chloropropofol in Na(V)1.2.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "High-affinity blockade of [GENE]voltage-operated skeletal muscle and neuronal sodium channels[\\GENE] by [CHEMICAL]halogenated propofol[\\CHEMICAL] analogues.",
        "label": 4,
        "major": 2,
        "len": 14
    },
    {
        "text": "Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, [CHEMICAL]4-bromopropofol[\\CHEMICAL] and 4-chloropropofol in [GENE]Na(V)1.4[\\GENE], and 450 nM for 4-chloropropofol in Na(V)1.2.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and [CHEMICAL]4-chloropropofol[\\CHEMICAL] in [GENE]Na(V)1.4[\\GENE], and 450 nM for 4-chloropropofol in Na(V)1.2.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for [CHEMICAL]4-chloropropofol[\\CHEMICAL] in [GENE]Na(V)1.2[\\GENE].",
        "label": 4,
        "major": 2,
        "len": 29
    },
    {
        "text": "CONCLUSIONS AND IMPLICATIONS: [CHEMICAL]Halogenated propofol[\\CHEMICAL] analogues constitute a novel class of [GENE]sodium channel[\\GENE]-blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine.",
        "label": 4,
        "major": -1,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Irbesartan[\\CHEMICAL] (Aprovel, Avapro, Irbetan, Karvea), an [GENE]angiotensin II receptor type 1[\\GENE] antagonist, is approved in many countries worldwide for the treatment of hypertension.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "Irbesartan ([CHEMICAL]Aprovel[\\CHEMICAL], Avapro, Irbetan, Karvea), an [GENE]angiotensin II receptor type 1[\\GENE] antagonist, is approved in many countries worldwide for the treatment of hypertension.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "Irbesartan (Aprovel, [CHEMICAL]Avapro[\\CHEMICAL], Irbetan, Karvea), an [GENE]angiotensin II receptor type 1[\\GENE] antagonist, is approved in many countries worldwide for the treatment of hypertension.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "Irbesartan (Aprovel, Avapro, [CHEMICAL]Irbetan[\\CHEMICAL], Karvea), an [GENE]angiotensin II receptor type 1[\\GENE] antagonist, is approved in many countries worldwide for the treatment of hypertension.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "Irbesartan (Aprovel, Avapro, Irbetan, [CHEMICAL]Karvea[\\CHEMICAL]), an [GENE]angiotensin II receptor type 1[\\GENE] antagonist, is approved in many countries worldwide for the treatment of hypertension.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "When [GENE]RAD51[\\GENE], which is a central component of HR, was depleted by siRNA cells were sensitized to [CHEMICAL]raltitrexed[\\CHEMICAL] (RTX), which specifically inhibits TS.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "When [GENE]RAD51[\\GENE], which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed ([CHEMICAL]RTX[\\CHEMICAL]), which specifically inhibits TS.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]RTX[\\CHEMICAL] treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with [GENE]RPA2[\\GENE] foci varied.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "Phosphorylation of [GENE]replication protein A[\\GENE] (RPA2 subunit) and formation of damage-induced foci were strikingly evident following IC(50) doses of [CHEMICAL]RTX[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "Phosphorylation of replication protein A ([GENE]RPA2[\\GENE] subunit) and formation of damage-induced foci were strikingly evident following IC(50) doses of [CHEMICAL]RTX[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]RTX[\\CHEMICAL] treatment also induced foci of [GENE]RAD51[\\GENE], gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]RTX[\\CHEMICAL] treatment also induced foci of RAD51, [GENE]gamma-H2AX[\\GENE], phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]RTX[\\CHEMICAL] treatment also induced foci of RAD51, gamma-H2AX, [GENE]phospho-Chk1[\\GENE], and phospho-NBS1, although the extent of co-localization with RPA2 foci varied.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]RTX[\\CHEMICAL] treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and [GENE]phospho-NBS1[\\GENE], although the extent of co-localization with RPA2 foci varied.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed ([CHEMICAL]RTX[\\CHEMICAL]), which specifically inhibits [GENE]TS[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "DNA damage is accepted as a consequence of [CHEMICAL]thymidylate[\\CHEMICAL] deprivation induced by chemotherapeutic inhibitors of [GENE]thymidylate synthase[\\GENE] (TS), but the types of damage and signaling responses remain incompletely understood.",
        "label": 9,
        "major": 4,
        "len": 29
    },
    {
        "text": "DNA damage is accepted as a consequence of [CHEMICAL]thymidylate[\\CHEMICAL] deprivation induced by chemotherapeutic inhibitors of thymidylate synthase ([GENE]TS[\\GENE]), but the types of damage and signaling responses remain incompletely understood.",
        "label": 9,
        "major": 3,
        "len": 29
    },
    {
        "text": "These data support the concept that adipose tissue [GENE]NNMT[\\GENE] contributes to the increased plasma homocysteine levels in patients treated with [CHEMICAL]NA[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "Nicotinic acid ([CHEMICAL]NA[\\CHEMICAL]), a widely used drug to lower elevated plasma lipid levels, induced [GENE]NNMT[\\GENE] enzyme activity in white adipose tissue of mice.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Nicotinic acid[\\CHEMICAL] (NA), a widely used drug to lower elevated plasma lipid levels, induced [GENE]NNMT[\\GENE] enzyme activity in white adipose tissue of mice.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Homocysteine release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the [GENE]NNMT[\\GENE] inhibitor [CHEMICAL]1-methylnicotinamide[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[GENE]Nicotinamide N-methyltransferase[\\GENE] (NNMT) catalyses the conversion of nicotinamide to [CHEMICAL]1-methylnicotinamide[\\CHEMICAL] and plays an important role in hepatic detoxification reactions.",
        "label": 9,
        "major": 9,
        "len": 19
    },
    {
        "text": "Nicotinamide N-methyltransferase ([GENE]NNMT[\\GENE]) catalyses the conversion of nicotinamide to [CHEMICAL]1-methylnicotinamide[\\CHEMICAL] and plays an important role in hepatic detoxification reactions.",
        "label": 9,
        "major": 9,
        "len": 19
    },
    {
        "text": "These data support the concept that adipose tissue [GENE]NNMT[\\GENE] contributes to the increased plasma [CHEMICAL]homocysteine[\\CHEMICAL] levels in patients treated with NA.",
        "label": 9,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Homocysteine[\\CHEMICAL], the atherogenic product of the [GENE]NNMT[\\GENE]-catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Nicotinamide N-methyltransferase[\\GENE] (NNMT) catalyses the conversion of [CHEMICAL]nicotinamide[\\CHEMICAL] to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.",
        "label": 9,
        "major": 9,
        "len": 19
    },
    {
        "text": "Nicotinamide N-methyltransferase ([GENE]NNMT[\\GENE]) catalyses the conversion of [CHEMICAL]nicotinamide[\\CHEMICAL] to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.",
        "label": 9,
        "major": 9,
        "len": 19
    },
    {
        "text": "The L-type calcium channel ([GENE]LTCC[\\GENE]) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine ([CHEMICAL]DHP[\\CHEMICAL]) binding properties and are both expressed in mammalian brain.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "The [GENE]L-type calcium channel[\\GENE] (LTCC) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine ([CHEMICAL]DHP[\\CHEMICAL]) binding properties and are both expressed in mammalian brain.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "The L-type calcium channel (LTCC) isoforms [GENE]Ca(v)1.2[\\GENE] and Ca(v)1.3 display similar 1,4-dihydropyridine ([CHEMICAL]DHP[\\CHEMICAL]) binding properties and are both expressed in mammalian brain.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "The L-type calcium channel (LTCC) isoforms Ca(v)1.2 and [GENE]Ca(v)1.3[\\GENE] display similar 1,4-dihydropyridine ([CHEMICAL]DHP[\\CHEMICAL]) binding properties and are both expressed in mammalian brain.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Inhibition of [CHEMICAL](+)-[(3)H]isradipine[\\CHEMICAL] binding to Ca(v)1.2DHP(-/-) (predominantly [GENE]Ca(v)1.3[\\GENE]) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and nifedipine for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.",
        "label": 2,
        "major": 4,
        "len": 40
    },
    {
        "text": "Inhibition of [CHEMICAL](+)-[(3)H]isradipine[\\CHEMICAL] binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly [GENE]Ca(v)1.2[\\GENE]) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and nifedipine for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.",
        "label": 2,
        "major": 2,
        "len": 40
    },
    {
        "text": "Inhibition of (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of [CHEMICAL]nitrendipine[\\CHEMICAL] and nifedipine for the [GENE]Ca(v)1.2[\\GENE] binding pocket, a finding further confirmed with heterologously expressed channels.",
        "label": 2,
        "major": 2,
        "len": 40
    },
    {
        "text": "Inhibition of (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and [CHEMICAL]nifedipine[\\CHEMICAL] for the [GENE]Ca(v)1.2[\\GENE] binding pocket, a finding further confirmed with heterologously expressed channels.",
        "label": 2,
        "major": 4,
        "len": 40
    },
    {
        "text": "[CHEMICAL](+)-[(3)H]isradipine[\\CHEMICAL] binding to Ca(v)1.2DHP(-/-) and [GENE]Ca(v)[\\GENE]-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "[CHEMICAL](+)-[(3)H]isradipine[\\CHEMICAL] binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that [GENE]Ca(v)1.3[\\GENE] accounts for 10.7% of brain LTCCs.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "[CHEMICAL](+)-[(3)H]isradipine[\\CHEMICAL] binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain [GENE]LTCCs[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The L-type calcium channel ([GENE]LTCC[\\GENE]) isoforms Ca(v)1.2 and Ca(v)1.3 display similar [CHEMICAL]1,4-dihydropyridine[\\CHEMICAL] (DHP) binding properties and are both expressed in mammalian brain.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "The [GENE]L-type calcium channel[\\GENE] (LTCC) isoforms Ca(v)1.2 and Ca(v)1.3 display similar [CHEMICAL]1,4-dihydropyridine[\\CHEMICAL] (DHP) binding properties and are both expressed in mammalian brain.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "The L-type calcium channel (LTCC) isoforms [GENE]Ca(v)1.2[\\GENE] and Ca(v)1.3 display similar [CHEMICAL]1,4-dihydropyridine[\\CHEMICAL] (DHP) binding properties and are both expressed in mammalian brain.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "The L-type calcium channel (LTCC) isoforms Ca(v)1.2 and [GENE]Ca(v)1.3[\\GENE] display similar [CHEMICAL]1,4-dihydropyridine[\\CHEMICAL] (DHP) binding properties and are both expressed in mammalian brain.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Expression and [CHEMICAL]1,4-dihydropyridine[\\CHEMICAL]-binding properties of brain [GENE]L-type calcium channel[\\GENE] isoforms.",
        "label": 2,
        "major": 2,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Bosutinib[\\CHEMICAL] did not inhibit [GENE]KIT[\\GENE] or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked STE20 kinases.",
        "label": 10,
        "major": 10,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Bosutinib[\\CHEMICAL] did not inhibit KIT or [GENE]platelet-derived growth factor receptor[\\GENE], but prominently targeted the apoptosis-linked STE20 kinases.",
        "label": 10,
        "major": 10,
        "len": 17
    },
    {
        "text": "Although in vivo [CHEMICAL]bosutinib[\\CHEMICAL] is inactive against [GENE]ABL[\\GENE] T315I, we found this clinically important mutant to be enzymatically inhibited in the mid-nanomolar range.",
        "label": 10,
        "major": 1,
        "len": 23
    },
    {
        "text": "Although in vivo [CHEMICAL]bosutinib[\\CHEMICAL] is inactive against ABL [GENE]T315I[\\GENE], we found this clinically important mutant to be enzymatically inhibited in the mid-nanomolar range.",
        "label": 10,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Bosutinib[\\CHEMICAL] did not inhibit KIT or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked [GENE]STE20 kinases[\\GENE].",
        "label": 2,
        "major": 10,
        "len": 17
    },
    {
        "text": "A comparison of bosutinib with [CHEMICAL]dasatinib[\\CHEMICAL] across the whole [GENE]kinase[\\GENE] panel revealed overlapping, but distinct, inhibition profiles.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Global target profile of the [GENE]kinase[\\GENE] inhibitor [CHEMICAL]bosutinib[\\CHEMICAL] in primary chronic myeloid leukemia cells.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Finally, [CHEMICAL]bosutinib[\\CHEMICAL] is the first [GENE]kinase[\\GENE] inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Finally, [CHEMICAL]bosutinib[\\CHEMICAL] is the first kinase inhibitor shown to target [GENE]CAMK2G[\\GENE], recently implicated in myeloid leukemia cell proliferation.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Here, we characterized the target profile of the dual [GENE]SRC[\\GENE]/ABL inhibitor [CHEMICAL]bosutinib[\\CHEMICAL] employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.",
        "label": 4,
        "major": 2,
        "len": 46
    },
    {
        "text": "Here, we characterized the target profile of the dual SRC/[GENE]ABL[\\GENE] inhibitor [CHEMICAL]bosutinib[\\CHEMICAL] employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.",
        "label": 4,
        "major": 2,
        "len": 46
    },
    {
        "text": "A comparison of [CHEMICAL]bosutinib[\\CHEMICAL] with dasatinib across the whole [GENE]kinase[\\GENE] panel revealed overlapping, but distinct, inhibition profiles.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib ([CHEMICAL]SU 11248[\\CHEMICAL], Sutent) specific for [GENE]VEGF receptor[\\GENE] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib ([CHEMICAL]SU 11248[\\CHEMICAL], Sutent) specific for VEGF receptor [GENE]kinase[\\GENE], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, [CHEMICAL]Sutent[\\CHEMICAL]) specific for [GENE]VEGF receptor[\\GENE] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, [CHEMICAL]Sutent[\\CHEMICAL]) specific for VEGF receptor [GENE]kinase[\\GENE], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, [CHEMICAL]AMN107[\\CHEMICAL] (Nilotinib) and INNO-406 (NS-187) specific for [GENE]c-KIT[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 ([CHEMICAL]Nilotinib[\\CHEMICAL]) and INNO-406 (NS-187) specific for [GENE]c-KIT[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and [CHEMICAL]INNO-406[\\CHEMICAL] (NS-187) specific for [GENE]c-KIT[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 ([CHEMICAL]NS-187[\\CHEMICAL]) specific for [GENE]c-KIT[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: [CHEMICAL]Lapatinib[\\CHEMICAL] (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib ([CHEMICAL]Lapatinib ditosylate[\\CHEMICAL], Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, [CHEMICAL]Tykerb[\\CHEMICAL], GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, [CHEMICAL]GW-572016[\\CHEMICAL]), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), [CHEMICAL]Canertinib[\\CHEMICAL] (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib ([CHEMICAL]CI-1033[\\CHEMICAL]), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), [CHEMICAL]Zactima[\\CHEMICAL] (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima ([CHEMICAL]ZD6474[\\CHEMICAL]), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), [CHEMICAL]Vatalanib[\\CHEMICAL] (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib ([CHEMICAL]PTK787[\\CHEMICAL]/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/[CHEMICAL]ZK 222584[\\CHEMICAL]), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), [CHEMICAL]Sorafenib[\\CHEMICAL] (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib ([CHEMICAL]Bay 43-9006[\\CHEMICAL], Nexavar), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]), and Leflunomide (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include [CHEMICAL]Dasatinib[\\CHEMICAL] (BMS-354825) specific for [GENE]ABL[\\GENE] non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include [CHEMICAL]Dasatinib[\\CHEMICAL] (BMS-354825) specific for ABL [GENE]non-receptor cytoplasmic kinase[\\GENE], Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and [CHEMICAL]Leflunomide[\\CHEMICAL] (SU101, Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide ([CHEMICAL]SU101[\\CHEMICAL], Arava).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The following [GENE]TK[\\GENE] blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, [CHEMICAL]Arava[\\CHEMICAL]).",
        "label": 4,
        "major": -1,
        "len": 34
    },
    {
        "text": "The most successful example of [GENE]kinase[\\GENE] blockers is [CHEMICAL]Imatinib[\\CHEMICAL] (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The most successful example of kinase blockers is [CHEMICAL]Imatinib[\\CHEMICAL] (Imatinib mesylate, Gleevec, STI571), the inhibitor of [GENE]Bcr[\\GENE]/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The most successful example of kinase blockers is [CHEMICAL]Imatinib[\\CHEMICAL] (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/[GENE]Abl[\\GENE] oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The most successful example of [GENE]kinase[\\GENE] blockers is Imatinib ([CHEMICAL]Imatinib mesylate[\\CHEMICAL], Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The most successful example of kinase blockers is Imatinib ([CHEMICAL]Imatinib mesylate[\\CHEMICAL], Gleevec, STI571), the inhibitor of [GENE]Bcr[\\GENE]/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The most successful example of kinase blockers is Imatinib ([CHEMICAL]Imatinib mesylate[\\CHEMICAL], Gleevec, STI571), the inhibitor of Bcr/[GENE]Abl[\\GENE] oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The most successful example of [GENE]kinase[\\GENE] blockers is Imatinib (Imatinib mesylate, [CHEMICAL]Gleevec[\\CHEMICAL], STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The most successful example of kinase blockers is Imatinib (Imatinib mesylate, [CHEMICAL]Gleevec[\\CHEMICAL], STI571), the inhibitor of [GENE]Bcr[\\GENE]/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The most successful example of kinase blockers is Imatinib (Imatinib mesylate, [CHEMICAL]Gleevec[\\CHEMICAL], STI571), the inhibitor of Bcr/[GENE]Abl[\\GENE] oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The most successful example of [GENE]kinase[\\GENE] blockers is Imatinib (Imatinib mesylate, Gleevec, [CHEMICAL]STI571[\\CHEMICAL]), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, [CHEMICAL]STI571[\\CHEMICAL]), the inhibitor of [GENE]Bcr[\\GENE]/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, [CHEMICAL]STI571[\\CHEMICAL]), the inhibitor of Bcr/[GENE]Abl[\\GENE] oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib ([CHEMICAL]BMS-354825[\\CHEMICAL]) specific for [GENE]ABL[\\GENE] non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, [CHEMICAL]Gefitinib[\\CHEMICAL] (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for [GENE]VEGF receptor[\\GENE] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, [CHEMICAL]Gefitinib[\\CHEMICAL] (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor [GENE]kinase[\\GENE], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib ([CHEMICAL]Iressa[\\CHEMICAL]), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for [GENE]VEGF receptor[\\GENE] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib ([CHEMICAL]Iressa[\\CHEMICAL]), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor [GENE]kinase[\\GENE], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), [CHEMICAL]Erlotinib[\\CHEMICAL] (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for [GENE]VEGF receptor[\\GENE] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), [CHEMICAL]Erlotinib[\\CHEMICAL] (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor [GENE]kinase[\\GENE], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib ([CHEMICAL]OSI-774[\\CHEMICAL], Tarceva) and Sunitinib (SU 11248, Sutent) specific for [GENE]VEGF receptor[\\GENE] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib ([CHEMICAL]OSI-774[\\CHEMICAL], Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor [GENE]kinase[\\GENE], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, [CHEMICAL]Tarceva[\\CHEMICAL]) and Sunitinib (SU 11248, Sutent) specific for [GENE]VEGF receptor[\\GENE] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, [CHEMICAL]Tarceva[\\CHEMICAL]) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor [GENE]kinase[\\GENE], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and [CHEMICAL]Sunitinib[\\CHEMICAL] (SU 11248, Sutent) specific for [GENE]VEGF receptor[\\GENE] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and [CHEMICAL]Sunitinib[\\CHEMICAL] (SU 11248, Sutent) specific for VEGF receptor [GENE]kinase[\\GENE], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Currently, the use of orally administered [GENE]MAO[\\GENE] inhibitor antidepressants (eg, phenelzine, tranylcypromine) is limited by the risk of [CHEMICAL]tyramine[\\CHEMICAL]-provoked events (eg, acute hypertension and headache, also known as the \"cheese reaction\") when combined with dietary tyramine.",
        "label": 2,
        "major": 4,
        "len": 36
    },
    {
        "text": "Currently, the use of orally administered [GENE]MAO[\\GENE] inhibitor antidepressants (eg, [CHEMICAL]phenelzine[\\CHEMICAL], tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the \"cheese reaction\") when combined with dietary tyramine.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Currently, the use of orally administered [GENE]MAO[\\GENE] inhibitor antidepressants (eg, phenelzine, [CHEMICAL]tranylcypromine[\\CHEMICAL]) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the \"cheese reaction\") when combined with dietary tyramine.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "[CHEMICAL]Atomoxetine[\\CHEMICAL] has a high affinity and selectivity for norepinephrine transporters, but little or no affinity for various [GENE]neurotransmitter receptors[\\GENE].",
        "label": 10,
        "major": 2,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Atomoxetine[\\CHEMICAL] has a high affinity and selectivity for [GENE]norepinephrine transporters[\\GENE], but little or no affinity for various neurotransmitter receptors.",
        "label": 2,
        "major": 9,
        "len": 19
    },
    {
        "text": "[GENE]CYP2D6[\\GENE] inhibitors, such as [CHEMICAL]paroxetine[\\CHEMICAL], are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "It undergoes extensive biotransformation, which is affected by poor metabolism by [GENE]cytochrome P450 (CYP) 2D6[\\GENE] in a small percentage of the population; these patients have greater exposure to and slower elimination of [CHEMICAL]atomoxetine[\\CHEMICAL] than extensive metabolizers.",
        "label": 9,
        "major": -1,
        "len": 36
    },
    {
        "text": "CYP2D6 inhibitors, such as paroxetine, are associated with changes in [CHEMICAL]atomoxetine[\\CHEMICAL] pharmacokinetics similar to those observed among poor [GENE]CYP2D6[\\GENE] metabolizers.",
        "label": 9,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Atomoxetine[\\CHEMICAL] appeared better tolerated among extensive [GENE]CYP2D6[\\GENE] metabolizers than among poor metabolizers.",
        "label": 9,
        "major": -1,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Hexachlorophene[\\CHEMICAL] forms a ring around the internal cavity in [GENE]GDH[\\GENE] through aromatic stacking interactions between the drug and GDH as well as between the drug molecules themselves.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Hexachlorophene[\\CHEMICAL] forms a ring around the internal cavity in GDH through aromatic stacking interactions between the drug and [GENE]GDH[\\GENE] as well as between the drug molecules themselves.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "[GENE]Mammalian glutamate dehydrogenase[\\GENE] (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using [CHEMICAL]NAD(P)(+)[\\CHEMICAL] as coenzyme.",
        "label": 2,
        "major": 9,
        "len": 22
    },
    {
        "text": "Mammalian glutamate dehydrogenase ([GENE]GDH[\\GENE]) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using [CHEMICAL]NAD(P)(+)[\\CHEMICAL] as coenzyme.",
        "label": 2,
        "major": 9,
        "len": 22
    },
    {
        "text": "The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by [CHEMICAL]GTP[\\CHEMICAL] causes excessive secretion of [GENE]insulin[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of [GENE]GDH[\\GENE] are inhibited by the green tea polyphenols, [CHEMICAL]epigallocatechin gallate[\\CHEMICAL] and epicatechin gallate.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of [GENE]GDH[\\GENE] are inhibited by the green tea polyphenols, epigallocatechin gallate and [CHEMICAL]epicatechin gallate[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of [GENE]GDH[\\GENE] by [CHEMICAL]GTP[\\CHEMICAL] causes excessive secretion of insulin.",
        "label": 7,
        "major": 7,
        "len": 21
    },
    {
        "text": "[GENE]Mammalian glutamate dehydrogenase[\\GENE] (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to [CHEMICAL]2-oxoglutarate[\\CHEMICAL] using NAD(P)(+) as coenzyme.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Mammalian glutamate dehydrogenase ([GENE]GDH[\\GENE]) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to [CHEMICAL]2-oxoglutarate[\\CHEMICAL] using NAD(P)(+) as coenzyme.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "[GENE]Mammalian glutamate dehydrogenase[\\GENE] (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of [CHEMICAL]l-glutamate[\\CHEMICAL] to 2-oxoglutarate using NAD(P)(+) as coenzyme.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Mammalian glutamate dehydrogenase ([GENE]GDH[\\GENE]) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of [CHEMICAL]l-glutamate[\\CHEMICAL] to 2-oxoglutarate using NAD(P)(+) as coenzyme.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Systemic [CHEMICAL]bupivacaine[\\CHEMICAL] did not modify either the hyperalgesia and local inflammation or [GENE]COX[\\GENE] expression.",
        "label": 10,
        "major": 10,
        "len": 14
    },
    {
        "text": "BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord [GENE]COX-2[\\GENE] (cyclooxygenase-2), with a subsequent increase in central [CHEMICAL]prostaglandin E2[\\CHEMICAL] (PGE2) levels associated with the development of hyperalgesia.",
        "label": 9,
        "major": 3,
        "len": 30
    },
    {
        "text": "BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 ([GENE]cyclooxygenase-2[\\GENE]), with a subsequent increase in central [CHEMICAL]prostaglandin E2[\\CHEMICAL] (PGE2) levels associated with the development of hyperalgesia.",
        "label": 9,
        "major": 3,
        "len": 30
    },
    {
        "text": "BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord [GENE]COX-2[\\GENE] (cyclooxygenase-2), with a subsequent increase in central prostaglandin E2 ([CHEMICAL]PGE2[\\CHEMICAL]) levels associated with the development of hyperalgesia.",
        "label": 9,
        "major": 3,
        "len": 30
    },
    {
        "text": "BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 ([GENE]cyclooxygenase-2[\\GENE]), with a subsequent increase in central prostaglandin E2 ([CHEMICAL]PGE2[\\CHEMICAL]) levels associated with the development of hyperalgesia.",
        "label": 9,
        "major": 3,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Ambrisentan[\\CHEMICAL] is an [GENE]endothelin receptor[\\GENE] antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH).",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Ambrisentan[\\CHEMICAL] is the first [GENE]ET(A)[\\GENE] selective ERA approved for use in the US.",
        "label": 6,
        "major": -1,
        "len": 13
    },
    {
        "text": "A series of 4,5-diaryloxazole analogs were designed and the interaction between [CHEMICAL]oxaprozin[\\CHEMICAL] and [GENE]cyclooxygenase-2[\\GENE] studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of oxaprozin.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, [CHEMICAL]promegestone[\\CHEMICAL], nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking [GENE]sulfatase[\\GENE] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, [CHEMICAL]promegestone[\\CHEMICAL], nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and [GENE]17beta-hydroxysteroid-dehydrogenase type 1[\\GENE] activities.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, [CHEMICAL]nomegestrol acetate[\\CHEMICAL] and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking [GENE]sulfatase[\\GENE] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, [CHEMICAL]nomegestrol acetate[\\CHEMICAL] and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and [GENE]17beta-hydroxysteroid-dehydrogenase type 1[\\GENE] activities.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and [CHEMICAL]norelgestromin[\\CHEMICAL] can reduce intratissular levels of estradiol in breast cancer by blocking [GENE]sulfatase[\\GENE] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and [CHEMICAL]norelgestromin[\\CHEMICAL] can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and [GENE]17beta-hydroxysteroid-dehydrogenase type 1[\\GENE] activities.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "As discussed in this review, various [CHEMICAL]progestogens[\\CHEMICAL] including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking [GENE]sulfatase[\\GENE] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "As discussed in this review, various [CHEMICAL]progestogens[\\CHEMICAL] including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and [GENE]17beta-hydroxysteroid-dehydrogenase type 1[\\GENE] activities.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "As discussed in this review, various progestogens including [CHEMICAL]dydrogesterone[\\CHEMICAL] and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking [GENE]sulfatase[\\GENE] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "As discussed in this review, various progestogens including [CHEMICAL]dydrogesterone[\\CHEMICAL] and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and [GENE]17beta-hydroxysteroid-dehydrogenase type 1[\\GENE] activities.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, [CHEMICAL]medrogestone[\\CHEMICAL], promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking [GENE]sulfatase[\\GENE] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, [CHEMICAL]medrogestone[\\CHEMICAL], promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and [GENE]17beta-hydroxysteroid-dehydrogenase type 1[\\GENE] activities.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of [CHEMICAL]estradiol[\\CHEMICAL] in breast cancer by blocking [GENE]sulfatase[\\GENE] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.",
        "label": 9,
        "major": 4,
        "len": 35
    },
    {
        "text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of [CHEMICAL]estradiol[\\CHEMICAL] in breast cancer by blocking sulfatase and [GENE]17beta-hydroxysteroid-dehydrogenase type 1[\\GENE] activities.",
        "label": 9,
        "major": 4,
        "len": 35
    },
    {
        "text": "OBJECTIVE: [CHEMICAL]Mitiglinide[\\CHEMICAL], a rapid- and short-acting insulinotropic [GENE]sulfonylurea receptor[\\GENE] ligand, exhibits hypoglycemic action unlike other sulfonylureas.",
        "label": 2,
        "major": 10,
        "len": 16
    },
    {
        "text": "OBJECTIVE: Mitiglinide, a rapid- and short-acting insulinotropic [GENE]sulfonylurea receptor[\\GENE] ligand, exhibits hypoglycemic action unlike other [CHEMICAL]sulfonylureas[\\CHEMICAL].",
        "label": 2,
        "major": 10,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Mitiglinide[\\CHEMICAL] reduced fasting plasma glucose and [GENE]GA[\\GENE] levels after 4 weeks and Hb(A1c) levels after 8 weeks.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Mitiglinide[\\CHEMICAL] reduced fasting plasma glucose and GA levels after 4 weeks and [GENE]Hb(A1c)[\\GENE] levels after 8 weeks.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Cyan fluorescent protein was fused to the [CHEMICAL]C[\\CHEMICAL] terminus of the [GENE]M(2) muscarinic receptor[\\GENE], and a specific binding sequence for the small fluorescent compound fluorescein arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH.",
        "label": 1,
        "major": 2,
        "len": 48
    },
    {
        "text": "Cyan fluorescent protein was fused to the C terminus of the [GENE]M(2) muscarinic receptor[\\GENE], and a specific binding sequence for the small fluorescent compound [CHEMICAL]fluorescein[\\CHEMICAL] arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH.",
        "label": 2,
        "major": 2,
        "len": 48
    },
    {
        "text": "Because these speeds are significantly faster than the responses to antagonists, these data indicate that [CHEMICAL]gallamine[\\CHEMICAL] and dimethyl-W84 are allosteric ligands and actively induce a conformation of the [GENE]M(2) receptor[\\GENE] with a reduced affinity for its agonists.",
        "label": 7,
        "major": 6,
        "len": 37
    },
    {
        "text": "Because these speeds are significantly faster than the responses to antagonists, these data indicate that gallamine and [CHEMICAL]dimethyl-W84[\\CHEMICAL] are allosteric ligands and actively induce a conformation of the [GENE]M(2) receptor[\\GENE] with a reduced affinity for its agonists.",
        "label": 7,
        "major": 2,
        "len": 37
    },
    {
        "text": "Here, we report that the transcription factor [GENE]peroxisome proliferator-activated receptor gamma[\\GENE] (PPARgamma) is essential for coupling [CHEMICAL]ibuprofen[\\CHEMICAL] to RhoA inhibition and subsequent neurite growth promotion in neurons.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma ([GENE]PPARgamma[\\GENE]) is essential for coupling [CHEMICAL]ibuprofen[\\CHEMICAL] to RhoA inhibition and subsequent neurite growth promotion in neurons.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "Moreover, the effect of [CHEMICAL]ibuprofen[\\CHEMICAL] on [GENE]RhoA[\\GENE] activity and neurite growth in neuronal cultures is prevented by selective PPARgamma inhibition.",
        "label": 2,
        "major": 4,
        "len": 20
    },
    {
        "text": "Moreover, the effect of [CHEMICAL]ibuprofen[\\CHEMICAL] on RhoA activity and neurite growth in neuronal cultures is prevented by selective [GENE]PPARgamma[\\GENE] inhibition.",
        "label": 2,
        "major": 4,
        "len": 20
    },
    {
        "text": "These findings support that [GENE]PPARgamma[\\GENE] plays an essential role in mediating the RhoA-inhibiting effect of [CHEMICAL]ibuprofen[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Ibuprofen[\\CHEMICAL] activates [GENE]PPARgamma[\\GENE] in neuron-like PC12 and B104 cells.",
        "label": 3,
        "major": 3,
        "len": 9
    },
    {
        "text": "In addition, another study suggests that [CHEMICAL]ibuprofen[\\CHEMICAL] reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate [GENE]amyloid-beta42[\\GENE] formation by direct inhibition of the gamma-secretase complex.",
        "label": 3,
        "major": 4,
        "len": 31
    },
    {
        "text": "Recently, we have demonstrated that [CHEMICAL]ibuprofen[\\CHEMICAL] inhibits intracellular signaling of [GENE]RhoA[\\GENE] and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "In addition, another study suggests that [CHEMICAL]ibuprofen[\\CHEMICAL] reduces generation of [GENE]amyloid-beta42[\\GENE] peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In addition, another study suggests that [CHEMICAL]ibuprofen[\\CHEMICAL] reduces generation of amyloid-beta42 peptide via inactivation of [GENE]RhoA[\\GENE] signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The molecular mechanisms by which [CHEMICAL]ibuprofen[\\CHEMICAL] inhibits the [GENE]RhoA[\\GENE] signal in neurons, however, remain unclear.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling [CHEMICAL]ibuprofen[\\CHEMICAL] to [GENE]RhoA[\\GENE] inhibition and subsequent neurite growth promotion in neurons.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "A molecular mechanism for [CHEMICAL]ibuprofen[\\CHEMICAL]-mediated [GENE]RhoA[\\GENE] inhibition in neurons.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "[CHEMICAL]Ibuprofen[\\CHEMICAL] is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of [GENE]cyclooxygenases[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Activation of PPARgamma with traditional agonists mimics the [GENE]RhoA[\\GENE]-inhibiting properties of [CHEMICAL]ibuprofen[\\CHEMICAL] in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "These findings support that PPARgamma plays an essential role in mediating the [GENE]RhoA[\\GENE]-inhibiting effect of [CHEMICAL]ibuprofen[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Elucidation of the novel molecular mechanisms linking [CHEMICAL]ibuprofen[\\CHEMICAL] to [GENE]RhoA[\\GENE] inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "In addition, another study suggests that [CHEMICAL]ibuprofen[\\CHEMICAL] reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the [GENE]gamma-secretase complex[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Of these, the [GENE]thrombin[\\GENE] inhibitor [CHEMICAL]dabigatran[\\CHEMICAL] and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Of these, the thrombin inhibitor dabigatran and [GENE]factor Xa[\\GENE] inhibitor [CHEMICAL]rivaroxaban[\\CHEMICAL] have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "In addition, the [GENE]factor Xa[\\GENE] inhibitor [CHEMICAL]apixaban[\\CHEMICAL] is in late-stage clinical development.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "We determined whether an angiotensin-converting enzyme (ACE) inhibitor, captopril, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the [GENE]MMP-2[\\GENE]-[CHEMICAL]captopril[\\CHEMICAL] complex.",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "Molecular models of the [GENE]MMP-2[\\GENE]-[CHEMICAL]captopril[\\CHEMICAL] complex were simulated by 1000 iterations of random docking and energy minimization.",
        "label": 2,
        "major": -1,
        "len": 17
    },
    {
        "text": "RESULTS: Captopril directly inhibited MMP-2 activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that [CHEMICAL]captopril[\\CHEMICAL] binding to the [GENE]MMP-2[\\GENE] active site could be formed in each complex model without molecular distortion.",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "We determined whether an [GENE]angiotensin-converting enzyme[\\GENE] (ACE) inhibitor, [CHEMICAL]captopril[\\CHEMICAL], inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "We determined whether an angiotensin-converting enzyme ([GENE]ACE[\\GENE]) inhibitor, [CHEMICAL]captopril[\\CHEMICAL], inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "METHODS: The inhibitory effect of [CHEMICAL]captopril[\\CHEMICAL] on [GENE]MMP-2[\\GENE] activity was measured in peritoneal effluents from 17 patients on CAPD.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "RESULTS: [CHEMICAL]Captopril[\\CHEMICAL] directly inhibited [GENE]MMP-2[\\GENE] activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that captopril binding to the MMP-2 active site could be formed in each complex model without molecular distortion.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "CONCLUSION: ACE inhibitors, such as [CHEMICAL]captopril[\\CHEMICAL], may be applied as important compounds for [GENE]MMP-2[\\GENE] inhibition in inflammation caused by CAPD.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "CONCLUSION: [GENE]ACE[\\GENE] inhibitors, such as [CHEMICAL]captopril[\\CHEMICAL], may be applied as important compounds for MMP-2 inhibition in inflammation caused by CAPD.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Captopril[\\CHEMICAL] directly inhibits [GENE]matrix metalloproteinase-2[\\GENE] activity in continuous ambulatory peritoneal dialysis therapy.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Phenformin but not [CHEMICAL]metformin[\\CHEMICAL] inhibits a number of variants of [GENE]K(ATP)[\\GENE] including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).",
        "label": 10,
        "major": 10,
        "len": 31
    },
    {
        "text": "Phenformin but not [CHEMICAL]metformin[\\CHEMICAL] inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle ([GENE]Kir6.1[\\GENE]/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).",
        "label": 10,
        "major": 4,
        "len": 31
    },
    {
        "text": "Phenformin but not [CHEMICAL]metformin[\\CHEMICAL] inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/[GENE]SUR2B[\\GENE] and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).",
        "label": 10,
        "major": 10,
        "len": 31
    },
    {
        "text": "Phenformin but not [CHEMICAL]metformin[\\CHEMICAL] inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and [GENE]Kir6.2[\\GENE]/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).",
        "label": 10,
        "major": 4,
        "len": 31
    },
    {
        "text": "Phenformin but not [CHEMICAL]metformin[\\CHEMICAL] inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/[GENE]SUR2B[\\GENE]) and pancreatic beta-cells (Kir6.2/SUR1).",
        "label": 10,
        "major": 4,
        "len": 31
    },
    {
        "text": "Phenformin but not [CHEMICAL]metformin[\\CHEMICAL] inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells ([GENE]Kir6.2[\\GENE]/SUR1).",
        "label": 10,
        "major": 10,
        "len": 31
    },
    {
        "text": "Phenformin but not [CHEMICAL]metformin[\\CHEMICAL] inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/[GENE]SUR1[\\GENE]).",
        "label": 10,
        "major": 10,
        "len": 31
    },
    {
        "text": "These findings suggest that [CHEMICAL]phenformin[\\CHEMICAL] interacts directly with the pore-forming [GENE]Kir6.0[\\GENE] subunit however the sulphonylurea receptor is able to significantly modulate the affinity.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Additionally, [CHEMICAL]phenformin[\\CHEMICAL] inhibited the current elicited through the Kir6.2DeltaC26 (functional without [GENE]SUR[\\GENE]) channel with an IC50 of 1.78 mM.",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "These findings suggest that [CHEMICAL]phenformin[\\CHEMICAL] interacts directly with the pore-forming Kir6.0 subunit however the [GENE]sulphonylurea receptor[\\GENE] is able to significantly modulate the affinity.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Phenformin[\\CHEMICAL] reduced the open probability of [GENE]Kir6.1[\\GENE]/SUR2B channels by approximately 90% in inside-out patches.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Phenformin[\\CHEMICAL] reduced the open probability of Kir6.1/[GENE]SUR2B[\\GENE] channels by approximately 90% in inside-out patches.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Phenformin[\\CHEMICAL] but not metformin inhibits a number of variants of [GENE]K(ATP)[\\GENE] including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).",
        "label": 4,
        "major": 10,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Phenformin[\\CHEMICAL] but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle ([GENE]Kir6.1[\\GENE]/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Phenformin[\\CHEMICAL] but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/[GENE]SUR2B[\\GENE] and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Phenformin[\\CHEMICAL] but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and [GENE]Kir6.2[\\GENE]/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Phenformin[\\CHEMICAL] but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/[GENE]SUR2B[\\GENE]) and pancreatic beta-cells (Kir6.2/SUR1).",
        "label": 4,
        "major": 10,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Phenformin[\\CHEMICAL] but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells ([GENE]Kir6.2[\\GENE]/SUR1).",
        "label": 4,
        "major": 10,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Phenformin[\\CHEMICAL] but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/[GENE]SUR1[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Phenformin[\\CHEMICAL] has a direct inhibitory effect on the [GENE]ATP-sensitive potassium channel[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "The extent and rate of inhibition are similar to that seen with the known [GENE]K(ATP)[\\GENE] blocker [CHEMICAL]PNU 37883A[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Additionally, [CHEMICAL]phenformin[\\CHEMICAL] inhibited the current elicited through the [GENE]Kir6.2DeltaC26[\\GENE] (functional without SUR) channel with an IC50 of 1.78 mM.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "In pig parathyroid cells, [CHEMICAL]paricalcitol[\\CHEMICAL] and the active form of doxercalciferol induced [GENE]VDR[\\GENE] translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively.",
        "label": 2,
        "major": 4,
        "len": 42
    },
    {
        "text": "In pig parathyroid cells, paricalcitol and the active form of [CHEMICAL]doxercalciferol[\\CHEMICAL] induced [GENE]VDR[\\GENE] translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively.",
        "label": 2,
        "major": 3,
        "len": 42
    },
    {
        "text": "Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum [CHEMICAL]Ca[\\CHEMICAL] regulates PTH secretion mediated by the [GENE]Ca-sensing receptor[\\GENE] (CaSR).",
        "label": 2,
        "major": -1,
        "len": 31
    },
    {
        "text": "Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum [CHEMICAL]Ca[\\CHEMICAL] regulates PTH secretion mediated by the Ca-sensing receptor ([GENE]CaSR[\\GENE]).",
        "label": 2,
        "major": -1,
        "len": 31
    },
    {
        "text": "In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although [CHEMICAL]paricalcitol[\\CHEMICAL] induced the expression of [GENE]CaSR[\\GENE] mRNA more effectively.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum [CHEMICAL]Ca[\\CHEMICAL] regulates [GENE]PTH[\\GENE] secretion mediated by the Ca-sensing receptor (CaSR).",
        "label": 3,
        "major": -1,
        "len": 31
    },
    {
        "text": "Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum [GENE]PTH[\\GENE] effectively in the 5/6 NX rats, but [CHEMICAL]paricalcitol[\\CHEMICAL] was less potent in raising serum Ca than doxercalciferol.",
        "label": 4,
        "major": -1,
        "len": 32
    },
    {
        "text": "Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum [GENE]PTH[\\GENE] effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than [CHEMICAL]doxercalciferol[\\CHEMICAL].",
        "label": 4,
        "major": -1,
        "len": 32
    },
    {
        "text": "Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed [GENE]PTH[\\GENE] mRNA expression and serum PTH effectively in the 5/6 NX rats, but [CHEMICAL]paricalcitol[\\CHEMICAL] was less potent in raising serum Ca than doxercalciferol.",
        "label": 4,
        "major": -1,
        "len": 32
    },
    {
        "text": "Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed [GENE]PTH[\\GENE] mRNA expression and serum PTH effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than [CHEMICAL]doxercalciferol[\\CHEMICAL].",
        "label": 4,
        "major": -1,
        "len": 32
    },
    {
        "text": "In pig parathyroid cells, [CHEMICAL]paricalcitol[\\CHEMICAL] and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed [GENE]PTH[\\GENE] mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "In pig parathyroid cells, paricalcitol and the active form of [CHEMICAL]doxercalciferol[\\CHEMICAL] induced VDR translocation from the cytoplasm into the nucleus, suppressed [GENE]PTH[\\GENE] mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL] initiates its teratogenic effects by binding to [GENE]CRBN[\\GENE] and inhibiting the associated ubiquitin ligase activity.",
        "label": 2,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL] initiates its teratogenic effects by binding to CRBN and inhibiting the associated [GENE]ubiquitin ligase[\\GENE] activity.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Telmisartan[\\CHEMICAL] is an [GENE]angiotensin II receptor[\\GENE] blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "With the pentapeptide linked through the C7alpha position of [CHEMICAL]estradiol[\\CHEMICAL], the resulting PROTAC shows the most effective ER degradation and highest affinity for the [GENE]estrogen receptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The [GENE]ER[\\GENE]-targeting PROTACs are composed of an [CHEMICAL]estradiol[\\CHEMICAL] on one end and a hypoxia-inducing factor 1alpha (HIF-1alpha)-derived synthetic pentapeptide on the other.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "With the pentapeptide linked through the C7alpha position of [CHEMICAL]estradiol[\\CHEMICAL], the resulting PROTAC shows the most effective [GENE]ER[\\GENE] degradation and highest affinity for the estrogen receptor.",
        "label": 4,
        "major": 2,
        "len": 26
    },
    {
        "text": "Recent studies indicate that [CHEMICAL]tamoxifen[\\CHEMICAL] initially acts as an antagonist, but later functions as an [GENE]ER[\\GENE] agonist, promoting tumor growth.",
        "label": 5,
        "major": 5,
        "len": 20
    },
    {
        "text": "Recent studies indicate that [CHEMICAL]tamoxifen[\\CHEMICAL] initially acts as an antagonist, but later functions as an [GENE]ER[\\GENE] agonist, promoting tumor growth.",
        "label": 6,
        "major": 6,
        "len": 20
    },
    {
        "text": "denopamine for beta(1); clenbuterol, AZ 40140d, [CHEMICAL]salbutamol[\\CHEMICAL] for [GENE]beta(2)[\\GENE]) were found to have subtype-selective intrinsic efficacy.",
        "label": 2,
        "major": -1,
        "len": 16
    },
    {
        "text": "[CHEMICAL]denopamine[\\CHEMICAL] for [GENE]beta(1)[\\GENE]; clenbuterol, AZ 40140d, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy.",
        "label": 2,
        "major": -1,
        "len": 16
    },
    {
        "text": "denopamine for beta(1); [CHEMICAL]clenbuterol[\\CHEMICAL], AZ 40140d, salbutamol for [GENE]beta(2)[\\GENE]) were found to have subtype-selective intrinsic efficacy.",
        "label": 2,
        "major": -1,
        "len": 16
    },
    {
        "text": "denopamine for beta(1); clenbuterol, [CHEMICAL]AZ 40140d[\\CHEMICAL], salbutamol for [GENE]beta(2)[\\GENE]) were found to have subtype-selective intrinsic efficacy.",
        "label": 2,
        "major": -1,
        "len": 16
    },
    {
        "text": "[CHEMICAL]salmeterol[\\CHEMICAL] and formoterol, for the [GENE]beta(2)-adrenoceptor[\\GENE] over the beta(1) or beta(3)), while others (e.g.",
        "label": 5,
        "major": -1,
        "len": 14
    },
    {
        "text": "[CHEMICAL]salmeterol[\\CHEMICAL] and formoterol, for the beta(2)-adrenoceptor over the [GENE]beta(1)[\\GENE] or beta(3)), while others (e.g.",
        "label": 5,
        "major": -1,
        "len": 14
    },
    {
        "text": "salmeterol and [CHEMICAL]formoterol[\\CHEMICAL], for the [GENE]beta(2)-adrenoceptor[\\GENE] over the beta(1) or beta(3)), while others (e.g.",
        "label": 5,
        "major": -1,
        "len": 14
    },
    {
        "text": "salmeterol and [CHEMICAL]formoterol[\\CHEMICAL], for the beta(2)-adrenoceptor over the beta(1) or [GENE]beta(3)[\\GENE]), while others (e.g.",
        "label": 5,
        "major": -1,
        "len": 14
    },
    {
        "text": "salmeterol and formoterol, for the [GENE]beta(2)-adrenoceptor[\\GENE] over the beta(1) or beta(3)), while others (e.g. [CHEMICAL]isoprenaline[\\CHEMICAL]) had little affinity-selectivity.",
        "label": 5,
        "major": 2,
        "len": 18
    },
    {
        "text": "salmeterol and formoterol, for the beta(2)-adrenoceptor over the [GENE]beta(1)[\\GENE] or beta(3)), while others (e.g. [CHEMICAL]isoprenaline[\\CHEMICAL]) had little affinity-selectivity.",
        "label": 5,
        "major": 2,
        "len": 18
    },
    {
        "text": "salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or [GENE]beta(3)[\\GENE]), while others (e.g. [CHEMICAL]isoprenaline[\\CHEMICAL]) had little affinity-selectivity.",
        "label": 5,
        "major": 2,
        "len": 18
    },
    {
        "text": "However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the [CHEMICAL]N-propargyl[\\CHEMICAL] moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating [GENE]Bcl-2[\\GENE] family proteins.",
        "label": 3,
        "major": 4,
        "len": 52
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL]: a novel anti-Parkinsonian [GENE]monoamine oxidase-B[\\GENE] inhibitor with neuroprotective activity.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible [GENE]monoamine oxidase (MAO)-B[\\GENE] inhibitor, anti-Parkinsonian drug.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Rasagiline ([CHEMICAL]N-propargyl-1-(R)-aminoindan[\\CHEMICAL]) is a novel, highly potent irreversible [GENE]monoamine oxidase (MAO)-B[\\GENE] inhibitor, anti-Parkinsonian drug.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Its S-isomer, [CHEMICAL]TVP1022[\\CHEMICAL] is thousand times less potent as an [GENE]MAO-B[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of [CHEMICAL]rasagiline[\\CHEMICAL] does not depend on inhibition of [GENE]MAO-B[\\GENE], but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins.",
        "label": 4,
        "major": 10,
        "len": 52
    },
    {
        "text": "Supplementation with [CHEMICAL]levothyroxine[\\CHEMICAL] at a dose of >350 microg/day did not normalize the serum [GENE]TSH[\\GENE] level; however, the patient showed normal growth and intelligence at 14 years of age.",
        "label": 10,
        "major": 10,
        "len": 29
    },
    {
        "text": "Consistent with the results of a computer analysis, the binding of [GENE]R316C[\\GENE] to triiodothyronine ([CHEMICAL]T3[\\CHEMICAL]) was significantly decreased to 38% that of the wild type.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Consistent with the results of a computer analysis, the binding of [GENE]R316C[\\GENE] to [CHEMICAL]triiodothyronine[\\CHEMICAL] (T3) was significantly decreased to 38% that of the wild type.",
        "label": 2,
        "major": 4,
        "len": 25
    },
    {
        "text": "However, a glutathione-S-transferase pull-down assay showed reduced binding of [GENE]R316C[\\GENE] with NCoR in the absence of T3 and impaired release in the presence of [CHEMICAL]T3[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 25
    },
    {
        "text": "However, a glutathione-S-transferase pull-down assay showed reduced binding of R316C with [GENE]NCoR[\\GENE] in the absence of T3 and impaired release in the presence of [CHEMICAL]T3[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum [GENE]TSH[\\GENE] level with high dose of [CHEMICAL]levothyroxine[\\CHEMICAL] might be optimum for normal growth.",
        "label": 3,
        "major": 4,
        "len": 40
    },
    {
        "text": "With exposure to [CHEMICAL]rofecoxib[\\CHEMICAL], a selective [GENE]COX-2[\\GENE] inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "With exposure to [CHEMICAL]rofecoxib[\\CHEMICAL], a selective COX-2 inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective [GENE]COX-2[\\GENE] inhibitors in breast cancer prophylaxis.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "METHODS: We conducted a case-control study to measure the association between selective [GENE]cox-2[\\GENE] inhibitors, particularly [CHEMICAL]celecoxib[\\CHEMICAL], rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "METHODS: We conducted a case-control study to measure the association between selective [GENE]cox-2[\\GENE] inhibitors, particularly celecoxib, [CHEMICAL]rofecoxib[\\CHEMICAL], valdecoxib and non-specific NSAID subgroups, and breast cancer risk.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "METHODS: We conducted a case-control study to measure the association between selective [GENE]cox-2[\\GENE] inhibitors, particularly celecoxib, rofecoxib, [CHEMICAL]valdecoxib[\\CHEMICAL] and non-specific NSAID subgroups, and breast cancer risk.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-[CHEMICAL]steroidal[\\CHEMICAL] anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of [GENE]cyclooxygenase-2[\\GENE] (COX-2).",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-[CHEMICAL]steroidal[\\CHEMICAL] anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 ([GENE]COX-2[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "The altered genes associated with [CHEMICAL]chlorcyclizine[\\CHEMICAL]-induced cleft palate included Wnt5a, [GENE]Bmp2[\\GENE], Bmp4, Fgf10, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "The altered genes associated with [CHEMICAL]chlorcyclizine[\\CHEMICAL]-induced cleft palate included Wnt5a, Bmp2, [GENE]Bmp4[\\GENE], Fgf10, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "The altered genes associated with [CHEMICAL]chlorcyclizine[\\CHEMICAL]-induced cleft palate included Wnt5a, Bmp2, Bmp4, [GENE]Fgf10[\\GENE], Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "The altered genes associated with [CHEMICAL]chlorcyclizine[\\CHEMICAL]-induced cleft palate included Wnt5a, Bmp2, Bmp4, Fgf10, [GENE]Fgfr2[\\GENE], Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "The altered genes associated with [CHEMICAL]chlorcyclizine[\\CHEMICAL]-induced cleft palate included Wnt5a, Bmp2, Bmp4, Fgf10, Fgfr2, [GENE]Msx1[\\GENE], and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "The altered genes associated with [CHEMICAL]chlorcyclizine[\\CHEMICAL]-induced cleft palate included Wnt5a, Bmp2, Bmp4, Fgf10, Fgfr2, Msx1, and [GENE]Insig1[\\GENE] but the magnitude of the change was relatively small (1.5- to 2-fold).",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "The altered genes associated with [CHEMICAL]chlorcyclizine[\\CHEMICAL]-induced cleft palate included [GENE]Wnt5a[\\GENE], Bmp2, Bmp4, Fgf10, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "BACKGROUND: The effects of [GENE]histamine H1[\\GENE] antagonist [CHEMICAL]chlorcyclizine[\\CHEMICAL] on rat palate development were characterized following in utero exposure.",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "Effects of the [GENE]histamine H1[\\GENE] antagonist [CHEMICAL]chlorcyclizine[\\CHEMICAL] on rat fetal palate development.",
        "label": 6,
        "major": 6,
        "len": 12
    },
    {
        "text": "Using a photo incorporable analogue of the general anesthetic, R(+)etomidate, we identified two transmembrane [CHEMICAL]amino acids[\\CHEMICAL] that were affinity labelled in purified [GENE]bovine brain GABA(A)-R[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "PRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate [GENE]GABA(A)-R[\\GENE]-mediated inhibitory transmission, site-directed mutagenesis comparing sequences of GABA(A)-R subunits of varying sensitivity led to identification of [CHEMICAL]amino acid[\\CHEMICAL] residues in the transmembrane domain that are critical for the drug actions in vitro.",
        "label": 1,
        "major": 7,
        "len": 44
    },
    {
        "text": "PRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate GABA(A)-R-mediated inhibitory transmission, site-directed mutagenesis comparing sequences of [GENE]GABA(A)-R[\\GENE] subunits of varying sensitivity led to identification of [CHEMICAL]amino acid[\\CHEMICAL] residues in the transmembrane domain that are critical for the drug actions in vitro.",
        "label": 1,
        "major": 7,
        "len": 44
    },
    {
        "text": "Using a photo incorporable analogue of the general anesthetic, [CHEMICAL]R(+)etomidate[\\CHEMICAL], we identified two transmembrane amino acids that were affinity labelled in purified [GENE]bovine brain GABA(A)-R[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement [CHEMICAL]spermine[\\CHEMICAL] and this can be accomplished by breeding with CAG-[GENE]SMS[\\GENE] mice that express SpmS from a ubiquitous promoter.",
        "label": 9,
        "major": 1,
        "len": 42
    },
    {
        "text": "An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement [CHEMICAL]spermine[\\CHEMICAL] and this can be accomplished by breeding with CAG-SMS mice that express [GENE]SpmS[\\GENE] from a ubiquitous promoter.",
        "label": 9,
        "major": 10,
        "len": 42
    },
    {
        "text": "Importantly, treatment with [CHEMICAL]cabozantinib[\\CHEMICAL] did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of VEGF signaling that do not target [GENE]MET[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 30
    },
    {
        "text": "Importantly, treatment with [CHEMICAL]cabozantinib[\\CHEMICAL] did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of [GENE]VEGF[\\GENE] signaling that do not target MET.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Collectively, these data suggest that [CHEMICAL]cabozantinib[\\CHEMICAL] is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated [GENE]MET[\\GENE] and VEGFR signaling.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Collectively, these data suggest that [CHEMICAL]cabozantinib[\\CHEMICAL] is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and [GENE]VEGFR[\\GENE] signaling.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Cabozantinib[\\CHEMICAL] (XL184) is a small-molecule [GENE]kinase[\\GENE] inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Cabozantinib[\\CHEMICAL] (XL184) is a small-molecule kinase inhibitor with potent activity toward [GENE]MET[\\GENE] and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Cabozantinib[\\CHEMICAL] (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and [GENE]VEGF receptor 2[\\GENE] (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Cabozantinib[\\CHEMICAL] (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 ([GENE]VEGFR2[\\GENE]), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Cabozantinib[\\CHEMICAL] (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other [GENE]receptor tyrosine kinases[\\GENE] that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Cabozantinib[\\CHEMICAL] (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including [GENE]RET[\\GENE], KIT, AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Cabozantinib[\\CHEMICAL] (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, [GENE]KIT[\\GENE], AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Cabozantinib[\\CHEMICAL] (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, [GENE]AXL[\\GENE], and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Cabozantinib[\\CHEMICAL] (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and [GENE]FLT3[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Cabozantinib ([CHEMICAL]XL184[\\CHEMICAL]) is a small-molecule [GENE]kinase[\\GENE] inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Cabozantinib ([CHEMICAL]XL184[\\CHEMICAL]) is a small-molecule kinase inhibitor with potent activity toward [GENE]MET[\\GENE] and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Cabozantinib ([CHEMICAL]XL184[\\CHEMICAL]) is a small-molecule kinase inhibitor with potent activity toward MET and [GENE]VEGF receptor 2[\\GENE] (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Cabozantinib ([CHEMICAL]XL184[\\CHEMICAL]) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 ([GENE]VEGFR2[\\GENE]), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Cabozantinib ([CHEMICAL]XL184[\\CHEMICAL]) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other [GENE]receptor tyrosine kinases[\\GENE] that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Cabozantinib ([CHEMICAL]XL184[\\CHEMICAL]) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including [GENE]RET[\\GENE], KIT, AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Cabozantinib ([CHEMICAL]XL184[\\CHEMICAL]) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, [GENE]KIT[\\GENE], AXL, and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Cabozantinib ([CHEMICAL]XL184[\\CHEMICAL]) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, [GENE]AXL[\\GENE], and FLT3.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Cabozantinib ([CHEMICAL]XL184[\\CHEMICAL]) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and [GENE]FLT3[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Treatment with [CHEMICAL]cabozantinib[\\CHEMICAL] inhibited [GENE]MET[\\GENE] and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Treatment with [CHEMICAL]cabozantinib[\\CHEMICAL] inhibited MET and [GENE]VEGFR2[\\GENE] phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Cabozantinib[\\CHEMICAL] (XL184), a novel [GENE]MET[\\GENE] and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Cabozantinib[\\CHEMICAL] (XL184), a novel MET and [GENE]VEGFR2[\\GENE] inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Cabozantinib ([CHEMICAL]XL184[\\CHEMICAL]), a novel [GENE]MET[\\GENE] and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Cabozantinib ([CHEMICAL]XL184[\\CHEMICAL]), a novel MET and [GENE]VEGFR2[\\GENE] inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "KEY RESULTS: [CHEMICAL]Thiocolchicoside[\\CHEMICAL] suppressed osteoclastogenesis induced by [GENE]RANKL[\\GENE], and by breast cancer and multiple myeloma cells.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Thiocolchicoside[\\CHEMICAL] suppresses osteoclastogenesis induced by [GENE]RANKL[\\GENE] and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "Inhibition of the NF-kappaB pathway was responsible for this effect since the [CHEMICAL]colchicoside[\\CHEMICAL] inhibited RANKL-induced [GENE]NF-kappaB[\\GENE] activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Inhibition of the NF-kappaB pathway was responsible for this effect since the [CHEMICAL]colchicoside[\\CHEMICAL] inhibited RANKL-induced NF-kappaB activation, activation of [GENE]IkappaB kinase[\\GENE] (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Inhibition of the NF-kappaB pathway was responsible for this effect since the [CHEMICAL]colchicoside[\\CHEMICAL] inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase ([GENE]IKK[\\GENE]) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Inhibition of the NF-kappaB pathway was responsible for this effect since the [CHEMICAL]colchicoside[\\CHEMICAL] inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of [GENE]NF-kappaBalpha[\\GENE] (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Inhibition of the NF-kappaB pathway was responsible for this effect since the [CHEMICAL]colchicoside[\\CHEMICAL] inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha ([GENE]IkappaBalpha[\\GENE]) phosphorylation and degradation, an inhibitor of NF-kappaB.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Inhibition of the NF-kappaB pathway was responsible for this effect since the [CHEMICAL]colchicoside[\\CHEMICAL] inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of [GENE]NF-kappaB[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Inhibition of the NF-kappaB pathway was responsible for this effect since the [CHEMICAL]colchicoside[\\CHEMICAL] inhibited [GENE]RANKL[\\GENE]-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that [CHEMICAL]thiocolchicoside[\\CHEMICAL] significantly suppressed osteoclastogenesis induced by [GENE]RANKL[\\GENE] and tumour cells via the NF-kappaB signalling pathway.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that [CHEMICAL]thiocolchicoside[\\CHEMICAL] significantly suppressed osteoclastogenesis induced by RANKL and tumour cells via the [GENE]NF-kappaB[\\GENE] signalling pathway.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Our findings show evidence that [GENE]eNOS[\\GENE] polymorphisms affect the responses of PED and clinical ED patients to [CHEMICAL]sildenafil[\\CHEMICAL].",
        "label": 2,
        "major": -1,
        "len": 18
    },
    {
        "text": "Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous NO formation, there is little information about how [GENE]eNOS[\\GENE] polymorphisms and haplotypes affect the responses to [CHEMICAL]sildenafil[\\CHEMICAL].",
        "label": 2,
        "major": -1,
        "len": 31
    },
    {
        "text": "[GENE]Endothelial nitric oxide synthase[\\GENE] genotypes and haplotypes modify the responses to [CHEMICAL]sildenafil[\\CHEMICAL] in patients with erectile dysfunction.",
        "label": 2,
        "major": 10,
        "len": 17
    },
    {
        "text": "Although genetic polymorphisms in the endothelial nitric oxide synthase ([GENE]eNOS[\\GENE]) gene may impair endogenous [CHEMICAL]NO[\\CHEMICAL] formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil.",
        "label": 9,
        "major": -1,
        "len": 31
    },
    {
        "text": "Although genetic polymorphisms in the [GENE]endothelial nitric oxide synthase[\\GENE] (eNOS) gene may impair endogenous [CHEMICAL]NO[\\CHEMICAL] formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil.",
        "label": 9,
        "major": -1,
        "len": 31
    },
    {
        "text": "Here, we report biochemical evidence that [CHEMICAL]mercury[\\CHEMICAL] alone induces [GENE]NF-\u03baB[\\GENE] activation, resulting in the induced expression of COX-2 and iNOS.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Here, we report biochemical evidence that [CHEMICAL]mercury[\\CHEMICAL] alone induces NF-\u03baB activation, resulting in the induced expression of [GENE]COX-2[\\GENE] and iNOS.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Here, we report biochemical evidence that [CHEMICAL]mercury[\\CHEMICAL] alone induces NF-\u03baB activation, resulting in the induced expression of COX-2 and [GENE]iNOS[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Mercury[\\CHEMICAL] induces the expression of [GENE]cyclooxygenase-2[\\GENE] and inducible nitric oxide synthase.",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Mercury[\\CHEMICAL] induces the expression of cyclooxygenase-2 and [GENE]inducible nitric oxide synthase[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "Unexpectedly, both the [GENE]mGluR(5)[\\GENE]specific agonist, [CHEMICAL]CHPG[\\CHEMICAL], and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization.",
        "label": 5,
        "major": 3,
        "len": 20
    },
    {
        "text": "Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the [GENE]group II mGluR[\\GENE] (mGlu(2/3)) agonist, [CHEMICAL]LY379268[\\CHEMICAL] (LY), induced a TTX-insensitive outward current/hyperpolarization.",
        "label": 5,
        "major": 3,
        "len": 20
    },
    {
        "text": "Both outward currents were significantly reduced by the [GENE]mGluR[\\GENE] antagonist [CHEMICAL]MCPG[\\CHEMICAL] and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP.",
        "label": 6,
        "major": 4,
        "len": 23
    },
    {
        "text": "Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific [GENE]mGluR(5)[\\GENE] antagonist [CHEMICAL]MTEP[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "We have examined the effectiveness of two novel [GENE]Chk1[\\GENE] selective inhibitors, [CHEMICAL]AR323[\\CHEMICAL] and AR678, in a panel of melanoma cell lines and normal cell types.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "We have examined the effectiveness of two novel [GENE]Chk1[\\GENE] selective inhibitors, AR323 and [CHEMICAL]AR678[\\CHEMICAL], in a panel of melanoma cell lines and normal cell types.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and [GENE]AMPK[\\GENE]-independent mechanisms of [CHEMICAL]aspirin[\\CHEMICAL]-induced inhibition of mTOR.",
        "label": 10,
        "major": 3,
        "len": 24
    },
    {
        "text": "mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating [GENE]AMPK[\\GENE]-dependent and AMPK-independent mechanisms of [CHEMICAL]aspirin[\\CHEMICAL]-induced inhibition of mTOR.",
        "label": 2,
        "major": 4,
        "len": 24
    },
    {
        "text": "Aspirin and [CHEMICAL]metformin[\\CHEMICAL] (an activator of [GENE]AMPK[\\GENE]) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "CONCLUSIONS: [CHEMICAL]Aspirin[\\CHEMICAL] is an inhibitor of mTOR and an activator of [GENE]AMPK[\\GENE], targeting regulators of intracellular energy homeostasis and metabolism.",
        "label": 3,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Aspirin[\\CHEMICAL] inhibits mTOR signaling, activates [GENE]AMP-activated protein kinase[\\GENE], and induces autophagy in colorectal cancer cells.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Aspirin[\\CHEMICAL] changed nucleotide ratios and activated [GENE]AMPK[\\GENE] in CRC cells.",
        "label": 3,
        "major": 3,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Aspirin[\\CHEMICAL] and metformin (an activator of [GENE]AMPK[\\GENE]) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "RESULTS: [CHEMICAL]Aspirin[\\CHEMICAL] reduced [GENE]mTOR[\\GENE] signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Aspirin[\\CHEMICAL] inhibits [GENE]mTOR[\\GENE] signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Aspirin and [CHEMICAL]metformin[\\CHEMICAL] (an activator of AMPK) increased inhibition of [GENE]mTOR[\\GENE] and Akt, as well as autophagy in CRC cells.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Aspirin and [CHEMICAL]metformin[\\CHEMICAL] (an activator of AMPK) increased inhibition of mTOR and [GENE]Akt[\\GENE], as well as autophagy in CRC cells.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Rectal mucosal samples from patients given [CHEMICAL]aspirin[\\CHEMICAL] had reduced phosphorylation of [GENE]S6K1[\\GENE] and S6.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Rectal mucosal samples from patients given [CHEMICAL]aspirin[\\CHEMICAL] had reduced phosphorylation of S6K1 and [GENE]S6[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "CONCLUSIONS: [CHEMICAL]Aspirin[\\CHEMICAL] is an inhibitor of [GENE]mTOR[\\GENE] and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "RESULTS: [CHEMICAL]Aspirin[\\CHEMICAL] reduced mTOR signaling in CRC cells by inhibiting the [GENE]mTOR[\\GENE] effectors S6K1 and 4E-BP1.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "RESULTS: [CHEMICAL]Aspirin[\\CHEMICAL] reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors [GENE]S6K1[\\GENE] and 4E-BP1.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "RESULTS: [CHEMICAL]Aspirin[\\CHEMICAL] reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and [GENE]4E-BP1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[GENE]mTOR[\\GENE] was still inhibited by [CHEMICAL]aspirin[\\CHEMICAL] in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of [CHEMICAL]aspirin[\\CHEMICAL]-induced inhibition of [GENE]mTOR[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Aspirin[\\CHEMICAL] induced autophagy, a feature of [GENE]mTOR[\\GENE] inhibition.",
        "label": 4,
        "major": 4,
        "len": 8
    },
    {
        "text": "[CHEMICAL]Aspirin[\\CHEMICAL] and metformin (an activator of AMPK) increased inhibition of [GENE]mTOR[\\GENE] and Akt, as well as autophagy in CRC cells.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Aspirin[\\CHEMICAL] and metformin (an activator of AMPK) increased inhibition of mTOR and [GENE]Akt[\\GENE], as well as autophagy in CRC cells.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Oncogenic [GENE]K-ras[\\GENE] expression is associated with derangement of the cAMP/PKA pathway and [CHEMICAL]forskolin[\\CHEMICAL]-reversible alterations of mitochondrial dynamics and respiration.",
        "label": 2,
        "major": -1,
        "len": 19
    },
    {
        "text": "These findings support the notion that [CHEMICAL]glucose[\\CHEMICAL] shortage-induced apoptosis, specific of [GENE]K-ras[\\GENE]-transformed cells, is associated to a derangement of PKA signaling that leads to mitochondrial complex I decrease, reduction of ATP formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.",
        "label": 2,
        "major": 4,
        "len": 48
    },
    {
        "text": "Exogenous stimulation of PKA activity, achieved by [CHEMICAL]forskolin[\\CHEMICAL] treatment, protected [GENE]K-ras[\\GENE]-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "Oncogenic K-ras expression is associated with derangement of the cAMP/[GENE]PKA[\\GENE] pathway and [CHEMICAL]forskolin[\\CHEMICAL]-reversible alterations of mitochondrial dynamics and respiration.",
        "label": 2,
        "major": -1,
        "len": 19
    },
    {
        "text": "Exogenous stimulation of [GENE]PKA[\\GENE] activity, achieved by [CHEMICAL]forskolin[\\CHEMICAL] treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "Exogenous stimulation of PKA activity, achieved by [CHEMICAL]forskolin[\\CHEMICAL] treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced [GENE]complex I[\\GENE] activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected [GENE]K-ras[\\GENE]-transformed cells from apoptosis induced by [CHEMICAL]glucose[\\CHEMICAL] deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "[CHEMICAL]Berberine[\\CHEMICAL] exerts suppressive effects on phenotype changes and ECM production in NPDFs via [GENE]p38[\\GENE] signaling pathway interference.",
        "label": 2,
        "major": 10,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Berberine[\\CHEMICAL] inhibits myofibroblast differentiation in nasal polyp-derived fibroblasts via the [GENE]p38[\\GENE] pathway.",
        "label": 2,
        "major": 4,
        "len": 12
    },
    {
        "text": "[CHEMICAL]SB203580[\\CHEMICAL] (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of [GENE]collagen type I[\\GENE] and \u03b1-SMA in TGF-\u03b21-induced NPDFs.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]SB203580[\\CHEMICAL] (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and [GENE]\u03b1-SMA[\\GENE] in TGF-\u03b21-induced NPDFs.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]SB203580[\\CHEMICAL] (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and \u03b1-SMA in [GENE]TGF-\u03b21[\\GENE]-induced NPDFs.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "In [GENE]TGF-\u03b21[\\GENE]-induced NPDFs, [CHEMICAL]berberine[\\CHEMICAL] significantly inhibited the expression of \u03b1-SMA and collagen type I mRNA and reduced \u03b1-SMA and collagen protein levels.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "In TGF-\u03b21-induced NPDFs, [CHEMICAL]berberine[\\CHEMICAL] significantly inhibited the expression of [GENE]\u03b1-SMA[\\GENE] and collagen type I mRNA and reduced \u03b1-SMA and collagen protein levels.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "In TGF-\u03b21-induced NPDFs, [CHEMICAL]berberine[\\CHEMICAL] significantly inhibited the expression of \u03b1-SMA and [GENE]collagen type I[\\GENE] mRNA and reduced \u03b1-SMA and collagen protein levels.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "In TGF-\u03b21-induced NPDFs, [CHEMICAL]berberine[\\CHEMICAL] significantly inhibited the expression of \u03b1-SMA and collagen type I mRNA and reduced [GENE]\u03b1-SMA[\\GENE] and collagen protein levels.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "In TGF-\u03b21-induced NPDFs, [CHEMICAL]berberine[\\CHEMICAL] significantly inhibited the expression of \u03b1-SMA and collagen type I mRNA and reduced \u03b1-SMA and [GENE]collagen[\\GENE] protein levels.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Berberine[\\CHEMICAL] only suppressed the expression of [GENE]pp38[\\GENE] among the evaluated signaling molecules.",
        "label": 4,
        "major": -1,
        "len": 12
    },
    {
        "text": "[CHEMICAL]SB203580[\\CHEMICAL] (a specific inhibitor of [GENE]p38[\\GENE] kinase) markedly suppressed the increased expression of collagen type I and \u03b1-SMA in TGF-\u03b21-induced NPDFs.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]SB203580[\\CHEMICAL] (a specific inhibitor of p38 [GENE]kinase[\\GENE]) markedly suppressed the increased expression of collagen type I and \u03b1-SMA in TGF-\u03b21-induced NPDFs.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Lenalidomide[\\CHEMICAL] and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective [GENE]CRBN[\\GENE](YW/AA).",
        "label": 10,
        "major": 4,
        "len": 20
    },
    {
        "text": "Lenalidomide and [CHEMICAL]pomalidomide[\\CHEMICAL] inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective [GENE]CRBN[\\GENE](YW/AA).",
        "label": 10,
        "major": 10,
        "len": 20
    },
    {
        "text": "Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, [CHEMICAL]pomalidomide[\\CHEMICAL], bound endogenous [GENE]CRBN[\\GENE] and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.",
        "label": 2,
        "major": 7,
        "len": 22
    },
    {
        "text": "Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, [CHEMICAL]pomalidomide[\\CHEMICAL], bound endogenous CRBN and recombinant [GENE]CRBN[\\GENE]-DNA damage binding protein-1 (DDB1) complexes.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, [CHEMICAL]pomalidomide[\\CHEMICAL], bound endogenous CRBN and recombinant CRBN-[GENE]DNA damage binding protein-1[\\GENE] (DDB1) complexes.",
        "label": 2,
        "major": 10,
        "len": 22
    },
    {
        "text": "Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, [CHEMICAL]pomalidomide[\\CHEMICAL], bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 ([GENE]DDB1[\\GENE]) complexes.",
        "label": 2,
        "major": 7,
        "len": 22
    },
    {
        "text": "Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing [CHEMICAL]thalidomide[\\CHEMICAL]-binding competent wild-type [GENE]CRBN[\\GENE], but not thalidomide-binding defective CRBN(YW/AA).",
        "label": 2,
        "major": 4,
        "len": 20
    },
    {
        "text": "Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not [CHEMICAL]thalidomide[\\CHEMICAL]-binding defective [GENE]CRBN[\\GENE](YW/AA).",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "Our studies demonstrate that [CHEMICAL]thalidomide[\\CHEMICAL], lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous [GENE]CRBN[\\GENE] and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Our studies demonstrate that [CHEMICAL]thalidomide[\\CHEMICAL], lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant [GENE]CRBN[\\GENE]-DNA damage binding protein-1 (DDB1) complexes.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Our studies demonstrate that [CHEMICAL]thalidomide[\\CHEMICAL], lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-[GENE]DNA damage binding protein-1[\\GENE] (DDB1) complexes.",
        "label": 2,
        "major": 10,
        "len": 22
    },
    {
        "text": "Our studies demonstrate that [CHEMICAL]thalidomide[\\CHEMICAL], lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 ([GENE]DDB1[\\GENE]) complexes.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Our studies demonstrate that thalidomide, [CHEMICAL]lenalidomide[\\CHEMICAL] and another immunomodulatory drug, pomalidomide, bound endogenous [GENE]CRBN[\\GENE] and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.",
        "label": 2,
        "major": 7,
        "len": 22
    },
    {
        "text": "Our studies demonstrate that thalidomide, [CHEMICAL]lenalidomide[\\CHEMICAL] and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant [GENE]CRBN[\\GENE]-DNA damage binding protein-1 (DDB1) complexes.",
        "label": 2,
        "major": 7,
        "len": 22
    },
    {
        "text": "Our studies demonstrate that thalidomide, [CHEMICAL]lenalidomide[\\CHEMICAL] and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-[GENE]DNA damage binding protein-1[\\GENE] (DDB1) complexes.",
        "label": 2,
        "major": 7,
        "len": 22
    },
    {
        "text": "Our studies demonstrate that thalidomide, [CHEMICAL]lenalidomide[\\CHEMICAL] and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 ([GENE]DDB1[\\GENE]) complexes.",
        "label": 2,
        "major": 7,
        "len": 22
    },
    {
        "text": "[GENE]CRBN[\\GENE] mediated antiproliferative activities of [CHEMICAL]lenalidomide[\\CHEMICAL] and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "[GENE]CRBN[\\GENE] mediated antiproliferative activities of lenalidomide and [CHEMICAL]pomalidomide[\\CHEMICAL] in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "[GENE]Cereblon[\\GENE] is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and [CHEMICAL]pomalidomide[\\CHEMICAL].",
        "label": 2,
        "major": 7,
        "len": 15
    },
    {
        "text": "[GENE]Cereblon[\\GENE] is a direct protein target for immunomodulatory and antiproliferative activities of [CHEMICAL]lenalidomide[\\CHEMICAL] and pomalidomide.",
        "label": 2,
        "major": 7,
        "len": 15
    },
    {
        "text": "Our biophysical, biochemical and gene silencing studies show that [GENE]CRBN[\\GENE] is a proximate, therapeutically important molecular target of [CHEMICAL]lenalidomide[\\CHEMICAL] and pomalidomide.",
        "label": 2,
        "major": -1,
        "len": 21
    },
    {
        "text": "Our biophysical, biochemical and gene silencing studies show that [GENE]CRBN[\\GENE] is a proximate, therapeutically important molecular target of lenalidomide and [CHEMICAL]pomalidomide[\\CHEMICAL].",
        "label": 2,
        "major": -1,
        "len": 21
    },
    {
        "text": "The ubiquitously expressed E3 ligase protein [GENE]cereblon[\\GENE] (CRBN) has been identified as the primary teratogenic target of [CHEMICAL]thalidomide[\\CHEMICAL].",
        "label": 2,
        "major": -1,
        "len": 18
    },
    {
        "text": "The ubiquitously expressed E3 ligase protein cereblon ([GENE]CRBN[\\GENE]) has been identified as the primary teratogenic target of [CHEMICAL]thalidomide[\\CHEMICAL].",
        "label": 2,
        "major": -1,
        "len": 18
    },
    {
        "text": "CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as [CHEMICAL]lenalidomide[\\CHEMICAL]- and pomalidomide-induced [GENE]cytokine[\\GENE] production in T cells.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and [CHEMICAL]pomalidomide[\\CHEMICAL]-induced [GENE]cytokine[\\GENE] production in T cells.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified [CHEMICAL]pomalidomide[\\CHEMICAL]-mediated reductions in c-myc and IRF4 expression and increases in p21([GENE]WAF-1[\\GENE]) expression.",
        "label": 3,
        "major": 10,
        "len": 27
    },
    {
        "text": "Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified [CHEMICAL]pomalidomide[\\CHEMICAL]-mediated reductions in c-myc and IRF4 expression and increases in [GENE]p21[\\GENE](WAF-1) expression.",
        "label": 3,
        "major": 1,
        "len": 27
    },
    {
        "text": "Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified [CHEMICAL]pomalidomide[\\CHEMICAL]-mediated reductions in [GENE]c-myc[\\GENE] and IRF4 expression and increases in p21(WAF-1) expression.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified [CHEMICAL]pomalidomide[\\CHEMICAL]-mediated reductions in c-myc and [GENE]IRF4[\\GENE] expression and increases in p21(WAF-1) expression.",
        "label": 4,
        "major": 10,
        "len": 27
    },
    {
        "text": "Long-term selection for [CHEMICAL]lenalidomide[\\CHEMICAL] resistance in H929 myeloma cell lines was accompanied by a reduction in [GENE]CRBN[\\GENE], while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Lenalidomide[\\CHEMICAL] and pomalidomide inhibited autoubiquitination of [GENE]CRBN[\\GENE] in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA).",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Lenalidomide[\\CHEMICAL] and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type [GENE]CRBN[\\GENE], but not thalidomide-binding defective CRBN(YW/AA).",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Lenalidomide and [CHEMICAL]pomalidomide[\\CHEMICAL] inhibited autoubiquitination of [GENE]CRBN[\\GENE] in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA).",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Lenalidomide and [CHEMICAL]pomalidomide[\\CHEMICAL] inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type [GENE]CRBN[\\GENE], but not thalidomide-binding defective CRBN(YW/AA).",
        "label": 4,
        "major": 10,
        "len": 20
    },
    {
        "text": "These [CHEMICAL]polyphenols[\\CHEMICAL], but not GvEx, showed a certain level of inhibition of human-cDNA-expressed [GENE]CYPs[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Emerging data suggest that [CHEMICAL]crizotinib[\\CHEMICAL] may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the [GENE]MET[\\GENE] oncogene, or translocation of the ROS1 oncogene.",
        "label": 2,
        "major": 1,
        "len": 31
    },
    {
        "text": "Emerging data suggest that [CHEMICAL]crizotinib[\\CHEMICAL] may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the MET oncogene, or translocation of the [GENE]ROS1[\\GENE] oncogene.",
        "label": 2,
        "major": 1,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Crizotinib[\\CHEMICAL] has demonstrated efficacy against [GENE]ALK[\\GENE]-rearranged NSCLC, and has potential for broader application in select subsets of lung cancer.",
        "label": 2,
        "major": -1,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Crizotinib[\\CHEMICAL] is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing [GENE]ALK[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Crizotinib[\\CHEMICAL] is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the [GENE]ALK[\\GENE] fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Crizotinib[\\CHEMICAL] is an oral [GENE]tyrosine kinase[\\GENE] inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Celastrol[\\CHEMICAL] highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic [GENE]TGF-\u03b2[\\GENE]-NF-\u03baB signal pathway.",
        "label": 2,
        "major": -1,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Celastrol[\\CHEMICAL] highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic TGF-\u03b2-[GENE]NF-\u03baB[\\GENE] signal pathway.",
        "label": 2,
        "major": -1,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Celastrol[\\CHEMICAL] also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and [GENE]Annexin V[\\GENE] markers of apoptosis.",
        "label": 3,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Celastrol[\\CHEMICAL], a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased [GENE]TGF-\u03b21[\\GENE]-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Celastrol[\\CHEMICAL], a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, [GENE]TGF-\u03b21[\\GENE]- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Celastrol[\\CHEMICAL], a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and [GENE]tumor necrosis factor-alpha[\\GENE] (TNF-\u03b1)-induced NF-\u03baB reporter gene activity.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Celastrol[\\CHEMICAL], a [GENE]TAK1[\\GENE] inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Celastrol[\\CHEMICAL], a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of [GENE]TAK1[\\GENE] and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Celastrol[\\CHEMICAL], a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and [GENE]RELA[\\GENE], and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Celastrol[\\CHEMICAL], a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced [GENE]NF-\u03baB[\\GENE] reporter gene activity.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Celastrol[\\CHEMICAL] highlights the therapeutic potential of agents targeting [GENE]TAK1[\\GENE] as a key node in this pro-oncogenic TGF-\u03b2-NF-\u03baB signal pathway.",
        "label": 4,
        "major": -1,
        "len": 19
    },
    {
        "text": "When combined, mianserin antagonized the effects of the full [GENE]kappa-opioid receptor[\\GENE] agonists in [CHEMICAL][(35)S]GTPgammaS[\\CHEMICAL] assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "In [CHEMICAL][(35)S]GTPgammaS[\\CHEMICAL] assays, mianserin selectively activated [GENE]kappa-opioid receptors[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 8
    },
    {
        "text": "In rat striatum and nucleus accumbens, mianserin stimulated [CHEMICAL][35S]GTPgammaS[\\CHEMICAL] binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full [GENE]kappa-opioid[\\GENE] agonists (-)-U50,488 and dynorphin A.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Mianserin[\\CHEMICAL] and mirtazapine increased ERK1/2 phosphorylation in CHO cells expressing [GENE]kappa-opioid receptors[\\GENE] and C6 cells, and these effects were antagonized by nor-BNI.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Mianserin and [CHEMICAL]mirtazapine[\\CHEMICAL] increased ERK1/2 phosphorylation in CHO cells expressing [GENE]kappa-opioid receptors[\\GENE] and C6 cells, and these effects were antagonized by nor-BNI.",
        "label": 2,
        "major": 6,
        "len": 22
    },
    {
        "text": "Mianserin and mirtazapine increased ERK1/2 phosphorylation in CHO cells expressing [GENE]kappa-opioid receptors[\\GENE] and C6 cells, and these effects were antagonized by [CHEMICAL]nor-BNI[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "In rat striatum and nucleus accumbens, [CHEMICAL]mianserin[\\CHEMICAL] stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full [GENE]kappa-opioid[\\GENE] agonists (-)-U50,488 and dynorphin A.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a [CHEMICAL]nor-BNI[\\CHEMICAL]-sensitive manner with maximal effects lower than those of the full [GENE]kappa-opioid[\\GENE] agonists (-)-U50,488 and dynorphin A.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of [GENE]p38[\\GENE] MAPK and ERK1/2 phosphorylation by [CHEMICAL]dynorphin A[\\CHEMICAL].",
        "label": 3,
        "major": 6,
        "len": 28
    },
    {
        "text": "When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 [GENE]MAPK[\\GENE] and ERK1/2 phosphorylation by [CHEMICAL]dynorphin A[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "CONCLUSIONS AND IMPLICATIONS: In different cell systems, [CHEMICAL]mianserin[\\CHEMICAL] directly activates [GENE]kappa-opioid receptors[\\GENE], displaying partial agonist activity at brain receptors.",
        "label": 3,
        "major": 5,
        "len": 19
    },
    {
        "text": "In [(35)S]GTPgammaS assays, [CHEMICAL]mianserin[\\CHEMICAL] selectively activated [GENE]kappa-opioid receptors[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 8
    },
    {
        "text": "The agonist activity was antagonized by the selective [GENE]kappa-opioid[\\GENE] blocker [CHEMICAL]nor-binaltorphimine[\\CHEMICAL] (nor-BNI).",
        "label": 4,
        "major": 6,
        "len": 12
    },
    {
        "text": "The agonist activity was antagonized by the selective [GENE]kappa-opioid[\\GENE] blocker nor-binaltorphimine ([CHEMICAL]nor-BNI[\\CHEMICAL]).",
        "label": 4,
        "major": 6,
        "len": 12
    },
    {
        "text": "When combined, [CHEMICAL]mianserin[\\CHEMICAL] antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of [GENE]p38[\\GENE] MAPK and ERK1/2 phosphorylation by dynorphin A.",
        "label": 4,
        "major": 5,
        "len": 28
    },
    {
        "text": "When combined, [CHEMICAL]mianserin[\\CHEMICAL] antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 [GENE]MAPK[\\GENE] and ERK1/2 phosphorylation by dynorphin A.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "We previously reported that [CHEMICAL]tricyclic[\\CHEMICAL] antidepressants act as agonists at distinct [GENE]opioid receptors[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 13
    },
    {
        "text": "CONCLUSIONS AND IMPLICATIONS: In different cell systems, [CHEMICAL]mianserin[\\CHEMICAL] directly activates [GENE]kappa-opioid receptors[\\GENE], displaying partial agonist activity at brain receptors.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "The [CHEMICAL]mianserin[\\CHEMICAL] analogue mirtazapine also displayed [GENE]kappa-opioid[\\GENE] agonist activity.",
        "label": 5,
        "major": 5,
        "len": 9
    },
    {
        "text": "The mianserin analogue [CHEMICAL]mirtazapine[\\CHEMICAL] also displayed [GENE]kappa-opioid[\\GENE] agonist activity.",
        "label": 5,
        "major": 5,
        "len": 9
    },
    {
        "text": "The atypical antidepressant [CHEMICAL]mianserin[\\CHEMICAL] exhibits agonist activity at [GENE]kappa-opioid receptors[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 10
    },
    {
        "text": "In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full [GENE]kappa-opioid[\\GENE] agonists [CHEMICAL](-)-U50,488[\\CHEMICAL] and dynorphin A.",
        "label": 5,
        "major": 2,
        "len": 29
    },
    {
        "text": "In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full [GENE]kappa-opioid[\\GENE] agonists (-)-U50,488 and [CHEMICAL]dynorphin A[\\CHEMICAL].",
        "label": 5,
        "major": 3,
        "len": 29
    },
    {
        "text": "The agonist activity was antagonized by the selective [GENE]kappa-opioid[\\GENE] blocker [CHEMICAL]nor-binaltorphimine[\\CHEMICAL] (nor-BNI).",
        "label": 6,
        "major": 6,
        "len": 12
    },
    {
        "text": "The agonist activity was antagonized by the selective [GENE]kappa-opioid[\\GENE] blocker nor-binaltorphimine ([CHEMICAL]nor-BNI[\\CHEMICAL]).",
        "label": 6,
        "major": 5,
        "len": 12
    },
    {
        "text": "When combined, [CHEMICAL]mianserin[\\CHEMICAL] antagonized the effects of the full [GENE]kappa-opioid receptor[\\GENE] agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A.",
        "label": 6,
        "major": 3,
        "len": 28
    },
    {
        "text": "In the present study we tested whether [CHEMICAL]propranolol[\\CHEMICAL], a [GENE]\u03b2-receptor[\\GENE] antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8).",
        "label": 6,
        "major": 3,
        "len": 33
    },
    {
        "text": "Effect of [CHEMICAL]chalcones[\\CHEMICAL] on lipid peroxidation, [GENE]heme oxygenase 1[\\GENE](HO-1), cyclooxygenase (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.",
        "label": 2,
        "major": -1,
        "len": 27
    },
    {
        "text": "Effect of [CHEMICAL]chalcones[\\CHEMICAL] on lipid peroxidation, heme oxygenase 1([GENE]HO-1[\\GENE]), cyclooxygenase (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.",
        "label": 2,
        "major": -1,
        "len": 27
    },
    {
        "text": "Effect of [CHEMICAL]chalcones[\\CHEMICAL] on lipid peroxidation, heme oxygenase 1(HO-1), [GENE]cyclooxygenase[\\GENE] (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.",
        "label": 2,
        "major": -1,
        "len": 27
    },
    {
        "text": "Effect of [CHEMICAL]chalcones[\\CHEMICAL] on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase ([GENE]COX[\\GENE]), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.",
        "label": 2,
        "major": -1,
        "len": 27
    },
    {
        "text": "Effect of [CHEMICAL]chalcones[\\CHEMICAL] on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (COX), [GENE]interleukin 5[\\GENE] (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.",
        "label": 2,
        "major": -1,
        "len": 27
    },
    {
        "text": "Effect of [CHEMICAL]chalcones[\\CHEMICAL] on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (COX), interleukin 5 ([GENE]IL-5[\\GENE]), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.",
        "label": 2,
        "major": -1,
        "len": 27
    },
    {
        "text": "The purpose of this review is to summarize current knowledge about oxysterol-dependent activation by LXR of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of [CHEMICAL]oxysterol[\\CHEMICAL] generation for expression of [GENE]LXR[\\GENE]-dependent genes.",
        "label": 2,
        "major": 3,
        "len": 45
    },
    {
        "text": "The purpose of this review is to summarize current knowledge about [CHEMICAL]oxysterol[\\CHEMICAL]-dependent activation by [GENE]LXR[\\GENE] of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of LXR-dependent genes.",
        "label": 3,
        "major": 3,
        "len": 45
    },
    {
        "text": "[GENE]LXRs[\\GENE] are thought to be activated predominantly by [CHEMICAL]oxysterols[\\CHEMICAL] generated enzymatically from cholesterol in different cell organelles.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in [GENE]sterol-27-hydroxylase[\\GENE] activity lead to specific blocks in [CHEMICAL]oxysterol[\\CHEMICAL] production and impaired LXR-dependent gene activation.",
        "label": 9,
        "major": 3,
        "len": 29
    },
    {
        "text": "Mass spectral analysis of CBDP-inhibited [GENE]BChE[\\GENE] digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on [CHEMICAL]lysine[\\CHEMICAL] 499, a residue far from the active site, but not on His-438.",
        "label": 1,
        "major": 10,
        "len": 28
    },
    {
        "text": "Mass spectral analysis of CBDP-inhibited [GENE]BChE[\\GENE] digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on [CHEMICAL]His[\\CHEMICAL]-438.",
        "label": 1,
        "major": 4,
        "len": 28
    },
    {
        "text": "Cresyl saligenin phosphate makes multiple adducts on free histidine, but does not form an adduct on [CHEMICAL]histidine[\\CHEMICAL] 438 of [GENE]human butyrylcholinesterase[\\GENE].",
        "label": 1,
        "major": 10,
        "len": 21
    },
    {
        "text": "CBDP irreversibly inhibits [GENE]butyrylcholinesterase[\\GENE] (BChE) in human plasma by forming adducts on the active site [CHEMICAL]serine[\\CHEMICAL] (Ser-198).",
        "label": 1,
        "major": 4,
        "len": 17
    },
    {
        "text": "CBDP irreversibly inhibits butyrylcholinesterase ([GENE]BChE[\\GENE]) in human plasma by forming adducts on the active site [CHEMICAL]serine[\\CHEMICAL] (Ser-198).",
        "label": 1,
        "major": 4,
        "len": 17
    },
    {
        "text": "CBDP irreversibly inhibits [GENE]butyrylcholinesterase[\\GENE] (BChE) in human plasma by forming adducts on the active site serine ([CHEMICAL]Ser[\\CHEMICAL]-198).",
        "label": 1,
        "major": 4,
        "len": 17
    },
    {
        "text": "CBDP irreversibly inhibits butyrylcholinesterase ([GENE]BChE[\\GENE]) in human plasma by forming adducts on the active site serine ([CHEMICAL]Ser[\\CHEMICAL]-198).",
        "label": 1,
        "major": 4,
        "len": 17
    },
    {
        "text": "Mass spectral analysis of CBDP-inhibited [GENE]BChE[\\GENE] digested with Glu-C showed an [CHEMICAL]o-hydroxybenzyl[\\CHEMICAL] adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438.",
        "label": 2,
        "major": 10,
        "len": 28
    },
    {
        "text": "Mass spectral analysis of CBDP-inhibited [GENE]BChE[\\GENE] digested with [CHEMICAL]Glu[\\CHEMICAL]-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Cresyl saligenin phosphate[\\CHEMICAL] makes multiple adducts on free histidine, but does not form an adduct on histidine 438 of [GENE]human butyrylcholinesterase[\\GENE].",
        "label": 2,
        "major": 10,
        "len": 21
    },
    {
        "text": "Mass spectral analysis of [CHEMICAL]CBDP[\\CHEMICAL]-inhibited [GENE]BChE[\\GENE] digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]CBDP[\\CHEMICAL] irreversibly inhibits [GENE]butyrylcholinesterase[\\GENE] (BChE) in human plasma by forming adducts on the active site serine (Ser-198).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]CBDP[\\CHEMICAL] irreversibly inhibits butyrylcholinesterase ([GENE]BChE[\\GENE]) in human plasma by forming adducts on the active site serine (Ser-198).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by [CHEMICAL]\u03b1-tocopherol[\\CHEMICAL] in the rat dentate gyrus, increasing [GENE]cyclic adenosine monophosphate response element binding protein[\\GENE] phosphorylation.",
        "label": 3,
        "major": 2,
        "len": 31
    },
    {
        "text": "After [CHEMICAL]SU5416[\\CHEMICAL] treatment, cell viability, [GENE]PARP-1[\\GENE], and caspase-3 protein levels were not changed.",
        "label": 10,
        "major": 10,
        "len": 13
    },
    {
        "text": "After [CHEMICAL]SU5416[\\CHEMICAL] treatment, cell viability, PARP-1, and [GENE]caspase-3[\\GENE] protein levels were not changed.",
        "label": 10,
        "major": 10,
        "len": 13
    },
    {
        "text": "[GENE]CCAAT/Enhancer-binding protein-homologous protein[\\GENE] sensitizes to [CHEMICAL]SU5416[\\CHEMICAL] by modulating p21 and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "CCAAT/Enhancer-binding protein-homologous protein sensitizes to [CHEMICAL]SU5416[\\CHEMICAL] by modulating [GENE]p21[\\GENE] and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.",
        "label": 2,
        "major": 7,
        "len": 19
    },
    {
        "text": "CCAAT/Enhancer-binding protein-homologous protein sensitizes to [CHEMICAL]SU5416[\\CHEMICAL] by modulating p21 and [GENE]PI3K[\\GENE]/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.",
        "label": 2,
        "major": 7,
        "len": 19
    },
    {
        "text": "CCAAT/Enhancer-binding protein-homologous protein sensitizes to [CHEMICAL]SU5416[\\CHEMICAL] by modulating p21 and PI3K/[GENE]Akt[\\GENE] signal pathway in FRO anaplastic thyroid carcinoma cells.",
        "label": 2,
        "major": 7,
        "len": 19
    },
    {
        "text": "In conclusion, these results suggest that CHOP may sensitize FRO ATC cells to [CHEMICAL]SU5416[\\CHEMICAL] thereby inhibiting cell survival by modulating [GENE]p21[\\GENE] and PI3K/Akt signal pathway.",
        "label": 2,
        "major": 4,
        "len": 25
    },
    {
        "text": "In conclusion, these results suggest that CHOP may sensitize FRO ATC cells to [CHEMICAL]SU5416[\\CHEMICAL] thereby inhibiting cell survival by modulating p21 and [GENE]PI3K[\\GENE]/Akt signal pathway.",
        "label": 2,
        "major": 7,
        "len": 25
    },
    {
        "text": "In conclusion, these results suggest that CHOP may sensitize FRO ATC cells to [CHEMICAL]SU5416[\\CHEMICAL] thereby inhibiting cell survival by modulating p21 and PI3K/[GENE]Akt[\\GENE] signal pathway.",
        "label": 2,
        "major": 4,
        "len": 25
    },
    {
        "text": "Furthermore, these findings imply that [GENE]CHOP[\\GENE] may be a possible candidate as the chemosensitizing factor for induction of cytotoxicity in ATC cells exposed to [CHEMICAL]SU5416[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Moreover, we investigated the roles of [GENE]CHOP[\\GENE] in cell survival under condition of [CHEMICAL]SU5416[\\CHEMICAL] treatment in FRO ATC cells.",
        "label": 2,
        "major": -1,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Galantamine[\\CHEMICAL] is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of [GENE]nicotinic acetylcholine receptors[\\GENE] (nAChR-APL) that shares many common structural elements with morphinan-based opioids.",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Galantamine[\\CHEMICAL] is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors ([GENE]nAChR[\\GENE]-APL) that shares many common structural elements with morphinan-based opioids.",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "The structurally diverse opioids [CHEMICAL]codeine[\\CHEMICAL] and eseroline, like galantamine, are also [GENE]nAChR[\\GENE]-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "The structurally diverse opioids [CHEMICAL]codeine[\\CHEMICAL] and eseroline, like galantamine, are also nAChR-APL that have greatly diminished affinity for [GENE]AChE[\\GENE], representing potential lead compounds for selective nAChR-APL development.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "The structurally diverse opioids codeine and [CHEMICAL]eseroline[\\CHEMICAL], like galantamine, are also [GENE]nAChR[\\GENE]-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "The structurally diverse opioids codeine and [CHEMICAL]eseroline[\\CHEMICAL], like galantamine, are also nAChR-APL that have greatly diminished affinity for [GENE]AChE[\\GENE], representing potential lead compounds for selective nAChR-APL development.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "The structurally diverse opioids codeine and eseroline, like [CHEMICAL]galantamine[\\CHEMICAL], are also [GENE]nAChR[\\GENE]-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "The structurally diverse opioids codeine and eseroline, like [CHEMICAL]galantamine[\\CHEMICAL], are also nAChR-APL that have greatly diminished affinity for [GENE]AChE[\\GENE], representing potential lead compounds for selective nAChR-APL development.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Galantamine[\\CHEMICAL] is a reversible, competitive [GENE]acetylcholinesterase[\\GENE] (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids.",
        "label": 4,
        "major": 7,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Galantamine[\\CHEMICAL] is a reversible, competitive acetylcholinesterase ([GENE]AChE[\\GENE]) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids.",
        "label": 4,
        "major": 7,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Galantamine[\\CHEMICAL] is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of [GENE]nicotinic acetylcholine receptors[\\GENE] (nAChR-APL) that shares many common structural elements with morphinan-based opioids.",
        "label": 7,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Galantamine[\\CHEMICAL] is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors ([GENE]nAChR[\\GENE]-APL) that shares many common structural elements with morphinan-based opioids.",
        "label": 7,
        "major": 7,
        "len": 26
    },
    {
        "text": "The structurally diverse opioids [CHEMICAL]codeine[\\CHEMICAL] and eseroline, like galantamine, are also [GENE]nAChR[\\GENE]-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.",
        "label": 7,
        "major": 2,
        "len": 27
    },
    {
        "text": "The structurally diverse opioids [CHEMICAL]codeine[\\CHEMICAL] and eseroline, like galantamine, are also nAChR-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective [GENE]nAChR[\\GENE]-APL development.",
        "label": 7,
        "major": 2,
        "len": 27
    },
    {
        "text": "The structurally diverse opioids codeine and [CHEMICAL]eseroline[\\CHEMICAL], like galantamine, are also [GENE]nAChR[\\GENE]-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.",
        "label": 7,
        "major": 2,
        "len": 27
    },
    {
        "text": "The structurally diverse opioids codeine and [CHEMICAL]eseroline[\\CHEMICAL], like galantamine, are also nAChR-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective [GENE]nAChR[\\GENE]-APL development.",
        "label": 7,
        "major": 2,
        "len": 27
    },
    {
        "text": "The structurally diverse opioids codeine and eseroline, like [CHEMICAL]galantamine[\\CHEMICAL], are also [GENE]nAChR[\\GENE]-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.",
        "label": 7,
        "major": 2,
        "len": 27
    },
    {
        "text": "The structurally diverse opioids codeine and eseroline, like [CHEMICAL]galantamine[\\CHEMICAL], are also nAChR-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective [GENE]nAChR[\\GENE]-APL development.",
        "label": 7,
        "major": 2,
        "len": 27
    },
    {
        "text": "Treatment options for DUB are: combined oral contraceptives (COCs), progestogens, non steroidal anti inflammatory drugs (NSAIDs), tranexamic acid (anti-fibrinolytic), [GENE]GnRH[\\GENE] analogues, [CHEMICAL]Danazol[\\CHEMICAL] and Levonorgestrel releasing intra uterine system (LNG IUS).",
        "label": 2,
        "major": -1,
        "len": 30
    },
    {
        "text": "Treatment options for DUB are: combined oral contraceptives (COCs), progestogens, non steroidal anti inflammatory drugs (NSAIDs), tranexamic acid (anti-fibrinolytic), [GENE]GnRH[\\GENE] analogues, Danazol and [CHEMICAL]Levonorgestrel[\\CHEMICAL] releasing intra uterine system (LNG IUS).",
        "label": 2,
        "major": -1,
        "len": 30
    },
    {
        "text": "These results suggest that the regulation of nitrergic system by [GENE]ERs[\\GENE] may play a role in the control of [CHEMICAL]oestrogen[\\CHEMICAL]-dependent physiological mechanisms regulated by the SON and the PVN.",
        "label": 2,
        "major": -1,
        "len": 29
    },
    {
        "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective [GENE]ER\u03b2[\\GENE] agonist-[CHEMICAL]DPN[\\CHEMICAL] [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
        "label": 5,
        "major": 5,
        "len": 41
    },
    {
        "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective [GENE]ER\u03b2[\\GENE] agonist-DPN [[CHEMICAL]2,3-bis(4-hydroxyphenyl)-propionitrile[\\CHEMICAL]], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
        "label": 5,
        "major": 6,
        "len": 41
    },
    {
        "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective [GENE]ER\u03b1[\\GENE] agonist-[CHEMICAL]PPT[\\CHEMICAL] [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
        "label": 5,
        "major": 5,
        "len": 41
    },
    {
        "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective [GENE]ER\u03b1[\\GENE] agonist-PPT [[CHEMICAL]4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol[\\CHEMICAL]], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
        "label": 5,
        "major": 5,
        "len": 41
    },
    {
        "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective [GENE]ER\u03b1[\\GENE] antagonist-[CHEMICAL]MPP[\\CHEMICAL] [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
        "label": 6,
        "major": 6,
        "len": 41
    },
    {
        "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective [GENE]ER\u03b1[\\GENE] antagonist-MPP [[CHEMICAL]1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol[\\CHEMICAL]]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
        "label": 6,
        "major": 5,
        "len": 41
    },
    {
        "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective [GENE]ER\u03b1[\\GENE] antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-[CHEMICAL]1H-pyrazole dihydrochloride[\\CHEMICAL]] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
        "label": 6,
        "major": 6,
        "len": 41
    },
    {
        "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective [GENE]ER\u03b2[\\GENE] antagonist-[CHEMICAL]PHTPP[\\CHEMICAL] (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",
        "label": 6,
        "major": 6,
        "len": 41
    },
    {
        "text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective [GENE]ER\u03b2[\\GENE] antagonist-PHTPP ([CHEMICAL]4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol[\\CHEMICAL]).",
        "label": 6,
        "major": 5,
        "len": 41
    },
    {
        "text": "Modulation of the [CHEMICAL]nitric oxide[\\CHEMICAL] producing system (demonstrated via the [GENE]NADPH-diaphorase[\\GENE] histochemical reaction) by oestradiol has been established in several structures of the rat brain.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "The residence time of a stoichiometric bioscavenger, human butyrylcholinesterase ([GENE]huBuChE[\\GENE]), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs ([CHEMICAL]oxime[\\CHEMICAL], anti-muscarinic, anticonvulsant).",
        "label": 2,
        "major": -1,
        "len": 31
    },
    {
        "text": "The residence time of a stoichiometric bioscavenger, [GENE]human butyrylcholinesterase[\\GENE] (huBuChE), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs ([CHEMICAL]oxime[\\CHEMICAL], anti-muscarinic, anticonvulsant).",
        "label": 2,
        "major": -1,
        "len": 31
    },
    {
        "text": "A combination of nerve agent therapy drugs ([CHEMICAL]oxime[\\CHEMICAL], anti-muscarinic, anticonvulsant) with [GENE]huBuChE[\\GENE] (i.m.)",
        "label": 2,
        "major": -1,
        "len": 13
    },
    {
        "text": "Therefore, we examined whether [CHEMICAL]verrucarin A[\\CHEMICAL] (VA) sensitize [GENE]TRAIL[\\GENE]-induced apoptosis in cancer cells by induction of ER stress.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Verrucarin A[\\CHEMICAL] sensitizes [GENE]TRAIL[\\GENE]-induced apoptosis via the upregulation of DR5 in an eIF2\u03b1/CHOP-dependent manner.",
        "label": 2,
        "major": 3,
        "len": 14
    },
    {
        "text": "Furthermore, [CHEMICAL]salubrinal[\\CHEMICAL], a specific [GENE]eIF2\u03b1[\\GENE] phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Furthermore, [CHEMICAL]salubrinal[\\CHEMICAL], a specific eIF2\u03b1 phosphorylation-inducing agent, increased [GENE]CHOP[\\GENE] and DR5 expression in the presence of VA.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Furthermore, [CHEMICAL]salubrinal[\\CHEMICAL], a specific eIF2\u03b1 phosphorylation-inducing agent, increased CHOP and [GENE]DR5[\\GENE] expression in the presence of VA.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Verrucarin A[\\CHEMICAL] sensitizes TRAIL-induced apoptosis via the upregulation of [GENE]DR5[\\GENE] in an eIF2\u03b1/CHOP-dependent manner.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Verrucarin A[\\CHEMICAL] sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an [GENE]eIF2\u03b1[\\GENE]/CHOP-dependent manner.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Verrucarin A[\\CHEMICAL] sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2\u03b1/[GENE]CHOP[\\GENE]-dependent manner.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "Though microtubule mediated actin remodeling through PKC\u03b6, reorganization of microtubule depended on [CHEMICAL]tyrosine[\\CHEMICAL] phosphorylation of [GENE]insulin receptor[\\GENE], the mechanism is different from insulin-induced actin remodeling, which relied on the activity of PI3-kinase and PKC\u03b6.",
        "label": 1,
        "major": 3,
        "len": 34
    },
    {
        "text": "Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface [GENE]glucose transporter isoform 4[\\GENE] (GLUT4) and [CHEMICAL]glucose[\\CHEMICAL] uptake.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 ([GENE]GLUT4[\\GENE]) and [CHEMICAL]glucose[\\CHEMICAL] uptake.",
        "label": 9,
        "major": 4,
        "len": 24
    },
    {
        "text": "Androstanol and [CHEMICAL]androstenol[\\CHEMICAL], estrone, 17\u03b2-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both [GENE]CARs[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Androstanol and androstenol, [CHEMICAL]estrone[\\CHEMICAL], 17\u03b2-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both [GENE]CARs[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Androstanol and androstenol, estrone, [CHEMICAL]17\u03b2-estradiol[\\CHEMICAL], TCPOBOP, and CITCO showed compound-specific but similar affinities for both [GENE]CARs[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Androstanol and androstenol, estrone, 17\u03b2-estradiol, [CHEMICAL]TCPOBOP[\\CHEMICAL], and CITCO showed compound-specific but similar affinities for both [GENE]CARs[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Androstanol and androstenol, estrone, 17\u03b2-estradiol, TCPOBOP, and [CHEMICAL]CITCO[\\CHEMICAL] showed compound-specific but similar affinities for both [GENE]CARs[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Androstanol[\\CHEMICAL] and androstenol, estrone, 17\u03b2-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both [GENE]CARs[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Other groups received either an infusion of the selective [GENE]NMDA receptor[\\GENE] antagonist (AP7; 10 nmol; intra-mPFC) or vehicle, 10 min prior to [CHEMICAL]PILO[\\CHEMICAL] preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).",
        "label": 2,
        "major": 6,
        "len": 37
    },
    {
        "text": "Our results show that PILO converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, PILO does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that [GENE]NMDA receptor[\\GENE] pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by [CHEMICAL]PILO[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 74
    },
    {
        "text": "Our results show that PILO converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, PILO does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that [GENE]NMDA receptor[\\GENE] pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since [CHEMICAL]AP7[\\CHEMICAL] microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO.",
        "label": 4,
        "major": 9,
        "len": 74
    },
    {
        "text": "Other groups received either an infusion of the selective [GENE]NMDA receptor[\\GENE] antagonist ([CHEMICAL]AP7[\\CHEMICAL]; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).",
        "label": 6,
        "major": 6,
        "len": 37
    },
    {
        "text": "The acetylation of [CHEMICAL]TETA[\\CHEMICAL] is increased in [GENE]SSAT1[\\GENE]-overexpressing mice compared with wild-type mice.",
        "label": 9,
        "major": 3,
        "len": 13
    },
    {
        "text": "However, SSAT1-deficient mice metabolize [CHEMICAL]TETA[\\CHEMICAL] at the same rate as the wild-type mice, indicating the existence of another [GENE]N-acetylase[\\GENE] respons 2ible for its metabolism in mice.",
        "label": 9,
        "major": 10,
        "len": 26
    },
    {
        "text": "Here, we show that siRNA-mediated knockdown of [GENE]SSAT2[\\GENE] in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of [CHEMICAL]TETA[\\CHEMICAL] to MAT.",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "By contrast, [CHEMICAL]1,12-diamino-3,6,9-triazadodecane[\\CHEMICAL](SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by [GENE]SSAT1[\\GENE] in HEPG2 cells and in wild-type primary hepatocytes.",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "By contrast, [CHEMICAL]1,12-diamino-3,6,9-triazadodecane[\\CHEMICAL](SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of [GENE]human recombinant SSAT2[\\GENE] and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "By contrast, 1,12-diamino-3,6,9-triazadodecane([CHEMICAL]SpmTrien[\\CHEMICAL]), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by [GENE]SSAT1[\\GENE] in HEPG2 cells and in wild-type primary hepatocytes.",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "By contrast, 1,12-diamino-3,6,9-triazadodecane([CHEMICAL]SpmTrien[\\CHEMICAL]), a charge-deficient spermine analog, was an extremely poor substrate of [GENE]human recombinant SSAT2[\\GENE] and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient [CHEMICAL]spermine[\\CHEMICAL] analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by [GENE]SSAT1[\\GENE] in HEPG2 cells and in wild-type primary hepatocytes.",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient [CHEMICAL]spermine[\\CHEMICAL] analog, was an extremely poor substrate of [GENE]human recombinant SSAT2[\\GENE] and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "Metabolism of [CHEMICAL]triethylenetetramine[\\CHEMICAL] and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and [GENE]thialysine acetyltransferase[\\GENE].",
        "label": 9,
        "major": -1,
        "len": 11
    },
    {
        "text": "Metabolism of [CHEMICAL]triethylenetetramine[\\CHEMICAL] and 1,12-diamino-3,6,9-triazadodecane by the [GENE]spermidine/spermine-N(1)-acetyltransferase[\\GENE] and thialysine acetyltransferase.",
        "label": 9,
        "major": -1,
        "len": 11
    },
    {
        "text": "Metabolism of triethylenetetramine and [CHEMICAL]1,12-diamino-3,6,9-triazadodecane[\\CHEMICAL] by the spermidine/spermine-N(1)-acetyltransferase and [GENE]thialysine acetyltransferase[\\GENE].",
        "label": 9,
        "major": -1,
        "len": 11
    },
    {
        "text": "Metabolism of triethylenetetramine and [CHEMICAL]1,12-diamino-3,6,9-triazadodecane[\\CHEMICAL] by the [GENE]spermidine/spermine-N(1)-acetyltransferase[\\GENE] and thialysine acetyltransferase.",
        "label": 9,
        "major": -1,
        "len": 11
    },
    {
        "text": "Thus, despite the similar structures of TETA and SpmTrien, [GENE]SSAT2[\\GENE] is the main acetylator of [CHEMICAL]TETA[\\CHEMICAL], whereas SpmTrien is primarily acetylated by SSAT1.",
        "label": 9,
        "major": -1,
        "len": 23
    },
    {
        "text": "Thus, despite the similar structures of TETA and SpmTrien, SSAT2 is the main acetylator of TETA, whereas [CHEMICAL]SpmTrien[\\CHEMICAL] is primarily acetylated by [GENE]SSAT1[\\GENE].",
        "label": 9,
        "major": -1,
        "len": 23
    },
    {
        "text": "We recently showed that [CHEMICAL]TETA[\\CHEMICAL] is metabolized in vitro by polyamine catabolic enzyme [GENE]spermidine/spermine-N(1)-acetyltransferase[\\GENE] (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).",
        "label": 9,
        "major": -1,
        "len": 25
    },
    {
        "text": "We recently showed that [CHEMICAL]TETA[\\CHEMICAL] is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase ([GENE]SSAT1[\\GENE]) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).",
        "label": 9,
        "major": -1,
        "len": 25
    },
    {
        "text": "We recently showed that [CHEMICAL]TETA[\\CHEMICAL] is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by [GENE]thialysine acetyltransferase[\\GENE] (SSAT2) to its monoacetylated derivative (MAT).",
        "label": 9,
        "major": -1,
        "len": 25
    },
    {
        "text": "We recently showed that [CHEMICAL]TETA[\\CHEMICAL] is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase ([GENE]SSAT2[\\GENE]) to its monoacetylated derivative (MAT).",
        "label": 9,
        "major": -1,
        "len": 25
    },
    {
        "text": "We recently showed that TETA is metabolized in vitro by [CHEMICAL]polyamine[\\CHEMICAL] catabolic enzyme [GENE]spermidine/spermine-N(1)-acetyltransferase[\\GENE] (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).",
        "label": 9,
        "major": -1,
        "len": 25
    },
    {
        "text": "We recently showed that TETA is metabolized in vitro by [CHEMICAL]polyamine[\\CHEMICAL] catabolic enzyme spermidine/spermine-N(1)-acetyltransferase ([GENE]SSAT1[\\GENE]) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).",
        "label": 9,
        "major": -1,
        "len": 25
    },
    {
        "text": "[GENE]Cytochrome b5[\\GENE] has shown to be an essential component in P450 3A4 catalyzed [CHEMICAL]5-hydroxyelzasonan[\\CHEMICAL] formation and provides insights on the disconnect between human liver microsomes data and that of rCYP.",
        "label": 2,
        "major": 9,
        "len": 30
    },
    {
        "text": "In vitro metabolism of the [GENE]5-hydroxytryptamine1B[\\GENE] receptor antagonist [CHEMICAL]elzasonan[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 9
    },
    {
        "text": "Cytochrome b5 has shown to be an essential component in [GENE]P450 3A4[\\GENE] catalyzed [CHEMICAL]5-hydroxyelzasonan[\\CHEMICAL] formation and provides insights on the disconnect between human liver microsomes data and that of rCYP.",
        "label": 9,
        "major": 9,
        "len": 30
    },
    {
        "text": "The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each [GENE]rCYP[\\GENE] in the metabolism of [CHEMICAL]elzasonan[\\CHEMICAL].",
        "label": 9,
        "major": -1,
        "len": 31
    },
    {
        "text": "The mutant Fc domain ([GENE]AglycoT-Fc1004[\\GENE]) contained a total of 5 [CHEMICAL]amino acid[\\CHEMICAL] substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131:Fc\u03b3RIIb).",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "The mutant Fc domain (AglycoT-Fc1004) contained a total of 5 [CHEMICAL]amino acid[\\CHEMICAL] substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; [GENE]FcyRIIa[\\GENE]-R131:Fc\u03b3RIIb).",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "The mutant Fc domain (AglycoT-Fc1004) contained a total of 5 [CHEMICAL]amino acid[\\CHEMICAL] substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131:[GENE]Fc\u03b3RIIb[\\GENE]).",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "The mutant [GENE]Fc domain[\\GENE] (AglycoT-Fc1004) contained a total of 5 [CHEMICAL]amino acid[\\CHEMICAL] substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131:Fc\u03b3RIIb).",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "In contrast, [CHEMICAL]VPD[\\CHEMICAL] had little effect on limb morphology and no significant effect on [GENE]HDAC[\\GENE] activity or the expression of marker genes.",
        "label": 10,
        "major": -1,
        "len": 22
    },
    {
        "text": "Disturbances in these signaling pathways are likely to be a consequence of [GENE]HDAC[\\GENE] inhibition because [CHEMICAL]VPD[\\CHEMICAL] did not affect their expressions.",
        "label": 10,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Valpromide[\\CHEMICAL] (VPD), the amide derivative of VPA, does not inhibit [GENE]HDAC[\\GENE] activity and is a weak teratogen in vivo.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Valpromide ([CHEMICAL]VPD[\\CHEMICAL]), the amide derivative of VPA, does not inhibit [GENE]HDAC[\\GENE] activity and is a weak teratogen in vivo.",
        "label": 10,
        "major": 4,
        "len": 19
    },
    {
        "text": "Valpromide (VPD), the [CHEMICAL]amide[\\CHEMICAL] derivative of VPA, does not inhibit [GENE]HDAC[\\GENE] activity and is a weak teratogen in vivo.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Valpromide (VPD), the amide derivative of [CHEMICAL]VPA[\\CHEMICAL], does not inhibit [GENE]HDAC[\\GENE] activity and is a weak teratogen in vivo.",
        "label": 10,
        "major": 4,
        "len": 19
    },
    {
        "text": "The signaling of both [GENE]Sox9[\\GENE] and Runx2, key regulators of chondrogenesis, was downregulated by [CHEMICAL]VPA[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "The signaling of both Sox9 and [GENE]Runx2[\\GENE], key regulators of chondrogenesis, was downregulated by [CHEMICAL]VPA[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]VPA[\\CHEMICAL] caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its [GENE]HDAC[\\GENE] inhibitory effect.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "In utero exposure to [CHEMICAL]valproic acid[\\CHEMICAL] (VPA), a [GENE]histone deacetylase[\\GENE] (HDAC) inhibitor, causes neural tube, heart, and limb defects.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "In utero exposure to [CHEMICAL]valproic acid[\\CHEMICAL] (VPA), a histone deacetylase ([GENE]HDAC[\\GENE]) inhibitor, causes neural tube, heart, and limb defects.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "In utero exposure to valproic acid ([CHEMICAL]VPA[\\CHEMICAL]), a [GENE]histone deacetylase[\\GENE] (HDAC) inhibitor, causes neural tube, heart, and limb defects.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "In utero exposure to valproic acid ([CHEMICAL]VPA[\\CHEMICAL]), a histone deacetylase ([GENE]HDAC[\\GENE]) inhibitor, causes neural tube, heart, and limb defects.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "In summary, activation of [GENE]caspases[\\GENE] and oxidative stress were observed after [CHEMICAL]AMD[\\CHEMICAL]/TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated AMD/TNF-induced cytotoxicity.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]\u03b1-TOCO[\\CHEMICAL] plus a [GENE]pancaspase[\\GENE] inhibitor completely abolished AMD/TNF-induced cytotoxicity.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "Studies have indicated that the three-dimensional structure and the domains of [GENE]HuBChE[\\GENE] ([CHEMICAL]acyl[\\CHEMICAL] pocket, lip of the active center gorge, and the anionic substrate-binding domain) that are critical for the binding of substrate are also essential for the selectivity and binding of inhibitors including OPs.",
        "label": 1,
        "major": 4,
        "len": 45
    },
    {
        "text": "[CHEMICAL]Amino acid[\\CHEMICAL] residues at the N- and C-termini are essential for the folding of active [GENE]human butyrylcholinesterase[\\GENE] polypeptide.",
        "label": 1,
        "major": 1,
        "len": 18
    },
    {
        "text": "Human serum butyrylcholinesterase ([GENE]HuBChE[\\GENE]) is currently the most suitable bioscavenger for the prophylaxis of highly toxic [CHEMICAL]organophosphate[\\CHEMICAL] (OP) nerve agents.",
        "label": 9,
        "major": -1,
        "len": 20
    },
    {
        "text": "[GENE]Human serum butyrylcholinesterase[\\GENE] (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic [CHEMICAL]organophosphate[\\CHEMICAL] (OP) nerve agents.",
        "label": 9,
        "major": -1,
        "len": 20
    },
    {
        "text": "Claudin-3 and claudin-4 regulate sensitivity to [CHEMICAL]cisplatin[\\CHEMICAL] by controlling expression of the copper and cisplatin influx transporter [GENE]CTR1[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 18
    },
    {
        "text": "Claudin-3 and claudin-4 regulate sensitivity to [CHEMICAL]cisplatin[\\CHEMICAL] by controlling expression of the [GENE]copper and cisplatin influx transporter[\\GENE] CTR1.",
        "label": 2,
        "major": 9,
        "len": 18
    },
    {
        "text": "[GENE]Claudin-3[\\GENE] and claudin-4 regulate sensitivity to [CHEMICAL]cisplatin[\\CHEMICAL] by controlling expression of the copper and cisplatin influx transporter CTR1.",
        "label": 2,
        "major": 9,
        "len": 18
    },
    {
        "text": "Claudin-3 and [GENE]claudin-4[\\GENE] regulate sensitivity to [CHEMICAL]cisplatin[\\CHEMICAL] by controlling expression of the copper and cisplatin influx transporter CTR1.",
        "label": 2,
        "major": 9,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Cu[\\CHEMICAL]-dependent [GENE]tyrosinase[\\GENE] activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate l-DOPA.",
        "label": 2,
        "major": 9,
        "len": 20
    },
    {
        "text": "Cu-dependent [GENE]tyrosinase[\\GENE] activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate [CHEMICAL]l-DOPA[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "Protein expression of [GENE]Ugt1a6[\\GENE] also decreased and corresponded with reduced in vitro glucuronidation of [CHEMICAL]bisphenol A[\\CHEMICAL] in S9 fractions from livers of pregnant mice.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as [GENE]NQO1[\\GENE], HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of [CHEMICAL]DMF[\\CHEMICAL] on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.",
        "label": 2,
        "major": 4,
        "len": 44
    },
    {
        "text": "However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, [GENE]HO-1[\\GENE] and glutathione S-transferase (GST) did not reverse the inhibitory effect of [CHEMICAL]DMF[\\CHEMICAL] on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.",
        "label": 2,
        "major": 4,
        "len": 44
    },
    {
        "text": "However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and [GENE]glutathione S-transferase[\\GENE] (GST) did not reverse the inhibitory effect of [CHEMICAL]DMF[\\CHEMICAL] on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.",
        "label": 2,
        "major": 4,
        "len": 44
    },
    {
        "text": "However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase ([GENE]GST[\\GENE]) did not reverse the inhibitory effect of [CHEMICAL]DMF[\\CHEMICAL] on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.",
        "label": 2,
        "major": 4,
        "len": 44
    },
    {
        "text": "However, downregulation of the [GENE]antioxidant response element[\\GENE] (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of [CHEMICAL]DMF[\\CHEMICAL] on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.",
        "label": 2,
        "major": 4,
        "len": 44
    },
    {
        "text": "However, downregulation of the antioxidant response element ([GENE]ARE[\\GENE])-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of [CHEMICAL]DMF[\\CHEMICAL] on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.",
        "label": 2,
        "major": 3,
        "len": 44
    },
    {
        "text": "However, downregulation of the antioxidant response element (ARE)-driven [GENE]Nrf2[\\GENE] target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of [CHEMICAL]DMF[\\CHEMICAL] on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.",
        "label": 2,
        "major": 3,
        "len": 44
    },
    {
        "text": "However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an [GENE]ARE[\\GENE]-independent anti-fibrotic activity of [CHEMICAL]DMF[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 44
    },
    {
        "text": "In summary, [CHEMICAL]DMF[\\CHEMICAL] attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta/Smad3 signaling in an [GENE]ARE[\\GENE]-independent manner, suggesting that DMF could be used to treat renal fibrosis.",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "Results showed that DMF increased nuclear levels of Nrf2, and both [CHEMICAL]DMF[\\CHEMICAL] and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in [GENE]TGF-beta[\\GENE]-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).",
        "label": 2,
        "major": 4,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Dimethylfumarate[\\CHEMICAL] attenuates renal fibrosis via [GENE]NF-E2-related factor 2[\\GENE]-mediated inhibition of transforming growth factor-beta/Smad signaling.",
        "label": 2,
        "major": 4,
        "len": 14
    },
    {
        "text": "In summary, [CHEMICAL]DMF[\\CHEMICAL] attenuated renal fibrosis via the [GENE]Nrf2[\\GENE]-mediated inhibition of TGF-beta/Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "Results showed that [CHEMICAL]DMF[\\CHEMICAL] increased nuclear levels of [GENE]Nrf2[\\GENE], and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).",
        "label": 3,
        "major": 4,
        "len": 41
    },
    {
        "text": "Results showed that DMF increased nuclear levels of Nrf2, and both [CHEMICAL]DMF[\\CHEMICAL] and adenovirus-mediated overexpression of [GENE]Nrf2[\\GENE] (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).",
        "label": 3,
        "major": 4,
        "len": 41
    },
    {
        "text": "Finally, [CHEMICAL]DMF[\\CHEMICAL] suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of [GENE]Nrf2[\\GENE] and phospho-Smad3, respectively.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "Additionally, [CHEMICAL]DMF[\\CHEMICAL] and Ad-Nrf2 repressed [GENE]TGF-beta[\\GENE]-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of [CHEMICAL]DMF[\\CHEMICAL] on [GENE]TGF-beta[\\GENE]-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Results showed that DMF increased nuclear levels of Nrf2, and both [CHEMICAL]DMF[\\CHEMICAL] and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased [GENE]PAI-1[\\GENE], alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "Results showed that DMF increased nuclear levels of Nrf2, and both [CHEMICAL]DMF[\\CHEMICAL] and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, [GENE]alpha-smooth muscle actin[\\GENE] (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Results showed that DMF increased nuclear levels of Nrf2, and both [CHEMICAL]DMF[\\CHEMICAL] and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin ([GENE]alpha-SMA[\\GENE]), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Results showed that DMF increased nuclear levels of Nrf2, and both [CHEMICAL]DMF[\\CHEMICAL] and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), [GENE]fibronectin[\\GENE] and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "Results showed that DMF increased nuclear levels of Nrf2, and both [CHEMICAL]DMF[\\CHEMICAL] and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and [GENE]type 1 collagen[\\GENE] expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Dimethylfumarate[\\CHEMICAL] attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/[GENE]Smad[\\GENE] signaling.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Dimethylfumarate[\\CHEMICAL] attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of [GENE]transforming growth factor-beta[\\GENE]/Smad signaling.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Finally, [CHEMICAL]DMF[\\CHEMICAL] suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and [GENE]alpha-SMA[\\GENE], fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Finally, [CHEMICAL]DMF[\\CHEMICAL] suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, [GENE]fibronectin[\\GENE] and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Finally, [CHEMICAL]DMF[\\CHEMICAL] suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and [GENE]type 1 collagen[\\GENE] expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Finally, [CHEMICAL]DMF[\\CHEMICAL] suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and [GENE]phospho-Smad3[\\GENE], respectively.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "In summary, [CHEMICAL]DMF[\\CHEMICAL] attenuated renal fibrosis via the Nrf2-mediated inhibition of [GENE]TGF-beta[\\GENE]/Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "In summary, [CHEMICAL]DMF[\\CHEMICAL] attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta/[GENE]Smad3[\\GENE] signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Additionally, [CHEMICAL]DMF[\\CHEMICAL] and Ad-Nrf2 repressed TGF-beta-stimulated [GENE]Smad3[\\GENE] activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Additionally, [CHEMICAL]DMF[\\CHEMICAL] and Ad-Nrf2 repressed TGF-beta-stimulated Smad3 activity by inhibiting [GENE]Smad3[\\GENE] phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while [GENE]osteocalcin[\\GENE] (OCN) was augmented in CCL3(-/-) and [CHEMICAL]Met[\\CHEMICAL]-RANTES-treated mice.",
        "label": 3,
        "major": 4,
        "len": 25
    },
    {
        "text": "The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin ([GENE]OCN[\\GENE]) was augmented in CCL3(-/-) and [CHEMICAL]Met[\\CHEMICAL]-RANTES-treated mice.",
        "label": 3,
        "major": 4,
        "len": 25
    },
    {
        "text": "The expression of the osteoblast markers runt-related transcription factor 2 ([GENE]RUNX2[\\GENE]) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and [CHEMICAL]Met[\\CHEMICAL]-RANTES-treated mice.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and [GENE]periostin[\\GENE] was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and [CHEMICAL]Met[\\CHEMICAL]-RANTES-treated mice.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "The expression of the osteoblast markers [GENE]runt-related transcription factor 2[\\GENE] (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and [CHEMICAL]Met[\\CHEMICAL]-RANTES-treated mice.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "mRNA levels of [GENE]receptor activator of nuclear factor kappa-B[\\GENE] (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with [CHEMICAL]Met[\\CHEMICAL]-RANTES.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "mRNA levels of receptor activator of nuclear factor kappa-B ([GENE]RANK[\\GENE]), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with [CHEMICAL]Met[\\CHEMICAL]-RANTES.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand [GENE]RANKL[\\GENE], tumor necrosis factor alpha (TNF-\u03b1) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with [CHEMICAL]Met[\\CHEMICAL]-RANTES.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, [GENE]tumor necrosis factor alpha[\\GENE] (TNF-\u03b1) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with [CHEMICAL]Met[\\CHEMICAL]-RANTES.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha ([GENE]TNF-\u03b1[\\GENE]) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with [CHEMICAL]Met[\\CHEMICAL]-RANTES.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and [GENE]RANKL[\\GENE]/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with [CHEMICAL]Met[\\CHEMICAL]-RANTES.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL/[GENE]osteoprotegerin[\\GENE] (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with [CHEMICAL]Met[\\CHEMICAL]-RANTES.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL/osteoprotegerin ([GENE]OPG[\\GENE]) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with [CHEMICAL]Met[\\CHEMICAL]-RANTES.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "[CHEMICAL]Met[\\CHEMICAL]-RANTES treatment also reduced the levels of [GENE]cathepsin K[\\GENE] and metalloproteinase 13 (MMP13).",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Met[\\CHEMICAL]-RANTES treatment also reduced the levels of cathepsin K and [GENE]metalloproteinase 13[\\GENE] (MMP13).",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Met[\\CHEMICAL]-RANTES treatment also reduced the levels of cathepsin K and metalloproteinase 13 ([GENE]MMP13[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with [CHEMICAL]Met[\\CHEMICAL]-RANTES (an antagonist of [GENE]CCR5[\\GENE] and CCR1).",
        "label": 6,
        "major": 6,
        "len": 26
    },
    {
        "text": "Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with [CHEMICAL]Met[\\CHEMICAL]-RANTES (an antagonist of CCR5 and [GENE]CCR1[\\GENE]).",
        "label": 6,
        "major": 4,
        "len": 26
    },
    {
        "text": "The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and [CHEMICAL]matrine[\\CHEMICAL] carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and [GENE]hERG[\\GENE] blocking activity.",
        "label": 4,
        "major": 10,
        "len": 28
    },
    {
        "text": "The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of [CHEMICAL]O=C=N-C-C-C-N[\\CHEMICAL] that possessed positive ionotropic effect and [GENE]hERG[\\GENE] blocking activity.",
        "label": 4,
        "major": 10,
        "len": 28
    },
    {
        "text": "The [CHEMICAL]quinolizidine alkaloids[\\CHEMICAL] (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and [GENE]hERG[\\GENE] blocking activity.",
        "label": 4,
        "major": 9,
        "len": 28
    },
    {
        "text": "The quinolizidine alkaloids (natural products) such as [CHEMICAL]oxymatrine[\\CHEMICAL], sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and [GENE]hERG[\\GENE] blocking activity.",
        "label": 4,
        "major": 9,
        "len": 28
    },
    {
        "text": "The quinolizidine alkaloids (natural products) such as oxymatrine, [CHEMICAL]sophoridine[\\CHEMICAL], sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and [GENE]hERG[\\GENE] blocking activity.",
        "label": 4,
        "major": 9,
        "len": 28
    },
    {
        "text": "The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, [CHEMICAL]sophocarpine[\\CHEMICAL] and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and [GENE]hERG[\\GENE] blocking activity.",
        "label": 4,
        "major": 10,
        "len": 28
    },
    {
        "text": "Multifunctional targets of dietary [CHEMICAL]polyphenols[\\CHEMICAL] in disease: a case for the [GENE]chemokine[\\GENE] network and energy metabolism.",
        "label": 2,
        "major": -1,
        "len": 16
    },
    {
        "text": "Several effects of [CHEMICAL]polyphenols[\\CHEMICAL] are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, [GENE]AMPK[\\GENE] activators, calorie-restriction mimetics or epigenetic regulators.",
        "label": 3,
        "major": 4,
        "len": 33
    },
    {
        "text": "Several effects of [CHEMICAL]polyphenols[\\CHEMICAL] are useful in this scenario, including a reduction in the activities of [GENE]cytokines[\\GENE] and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Several effects of [CHEMICAL]polyphenols[\\CHEMICAL] are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through [GENE]histone deacetylase[\\GENE] inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]NFD[\\CHEMICAL] suppressed [GENE]EGF[\\GENE]-mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]NFD[\\CHEMICAL] abrogated [GENE]EGF[\\GENE]-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "Furthermore, the EGFR inhibitor [CHEMICAL]AG1478[\\CHEMICAL] inhibited EGF-induced [GENE]MMP-9[\\GENE] expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "These findings suggest that [CHEMICAL]NFD[\\CHEMICAL] inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent [GENE]PI3K[\\GENE]/Akt signaling, leading to the down-regulation of MMP-9 expression.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "These findings suggest that [CHEMICAL]NFD[\\CHEMICAL] inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K/[GENE]Akt[\\GENE] signaling, leading to the down-regulation of MMP-9 expression.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "These findings suggest that [CHEMICAL]NFD[\\CHEMICAL] inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K/Akt signaling, leading to the down-regulation of [GENE]MMP-9[\\GENE] expression.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "[CHEMICAL]NFD[\\CHEMICAL] suppressed EGF-mediated protein levels of [GENE]c-Jun[\\GENE] and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]NFD[\\CHEMICAL] suppressed EGF-mediated protein levels of c-Jun and [GENE]c-Fos[\\GENE], and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]NFD[\\CHEMICAL] suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced [GENE]MMP-9[\\GENE] expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Furthermore, the EGFR inhibitor [CHEMICAL]AG1478[\\CHEMICAL] inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that [GENE]PI3K[\\GENE]/Akt activation occur downstream of EGFR activation.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Furthermore, the EGFR inhibitor [CHEMICAL]AG1478[\\CHEMICAL] inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/[GENE]Akt[\\GENE] activation occur downstream of EGFR activation.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Furthermore, the EGFR inhibitor [CHEMICAL]AG1478[\\CHEMICAL] inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of [GENE]EGFR[\\GENE] activation.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Furthermore, the [GENE]EGFR[\\GENE] inhibitor [CHEMICAL]AG1478[\\CHEMICAL] inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Furthermore, the EGFR inhibitor [CHEMICAL]AG1478[\\CHEMICAL] inhibited [GENE]EGF[\\GENE]-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Furthermore, the EGFR inhibitor [CHEMICAL]AG1478[\\CHEMICAL] inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of [GENE]PI3K[\\GENE]/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Furthermore, the EGFR inhibitor [CHEMICAL]AG1478[\\CHEMICAL] inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/[GENE]Akt[\\GENE], suggesting that PI3K/Akt activation occur downstream of EGFR activation.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Inhibition of [GENE]EGF[\\GENE]/EGFR activation with [CHEMICAL]naphtho[1,2-b]furan-4,5-dione[\\CHEMICAL] blocks migration and invasion of MDA-MB-231 cells.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Inhibition of EGF/[GENE]EGFR[\\GENE] activation with [CHEMICAL]naphtho[1,2-b]furan-4,5-dione[\\CHEMICAL] blocks migration and invasion of MDA-MB-231 cells.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "These findings suggest that [CHEMICAL]NFD[\\CHEMICAL] inhibited the [GENE]EGF[\\GENE]-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K/Akt signaling, leading to the down-regulation of MMP-9 expression.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "These findings suggest that [CHEMICAL]NFD[\\CHEMICAL] inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via [GENE]EGFR[\\GENE]-dependent PI3K/Akt signaling, leading to the down-regulation of MMP-9 expression.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "[CHEMICAL]NFD[\\CHEMICAL] suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced [GENE]MMP-9[\\GENE] expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]NFD[\\CHEMICAL] abrogated EGF-induced phosphorylation of [GENE]EGF receptor[\\GENE] (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]NFD[\\CHEMICAL] abrogated EGF-induced phosphorylation of EGF receptor ([GENE]EGFR[\\GENE]) and phosphatidylinositol 3-kinase (PI3K)/Akt.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]NFD[\\CHEMICAL] abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and [GENE]phosphatidylinositol 3-kinase[\\GENE] (PI3K)/Akt.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]NFD[\\CHEMICAL] abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase ([GENE]PI3K[\\GENE])/Akt.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]NFD[\\CHEMICAL] abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/[GENE]Akt[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "The specific [GENE]PI3K[\\GENE] inhibitor, [CHEMICAL]wortmannin[\\CHEMICAL], blocked significantly EGF-induced cell migration and invasion.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "The specific PI3K inhibitor, [CHEMICAL]wortmannin[\\CHEMICAL], blocked significantly [GENE]EGF[\\GENE]-induced cell migration and invasion.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Herein, we report the identification and characterization of [CHEMICAL]3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile[\\CHEMICAL] (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated [GENE]insulin[\\GENE] secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ([CHEMICAL]ESI-09[\\CHEMICAL]), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated [GENE]insulin[\\GENE] secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic [CHEMICAL]nucleotide[\\CHEMICAL] EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated [GENE]insulin[\\GENE] secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of [CHEMICAL]3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile[\\CHEMICAL] (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular [GENE]EPAC[\\GENE]-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 6,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of [CHEMICAL]3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile[\\CHEMICAL] (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated [GENE]Rap1[\\GENE] activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of [CHEMICAL]3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile[\\CHEMICAL] (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and [GENE]Akt[\\GENE] phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of [CHEMICAL]3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile[\\CHEMICAL] (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as [GENE]EPAC[\\GENE]-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ([CHEMICAL]ESI-09[\\CHEMICAL]), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular [GENE]EPAC[\\GENE]-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 6,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ([CHEMICAL]ESI-09[\\CHEMICAL]), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated [GENE]Rap1[\\GENE] activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 6,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ([CHEMICAL]ESI-09[\\CHEMICAL]), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and [GENE]Akt[\\GENE] phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ([CHEMICAL]ESI-09[\\CHEMICAL]), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as [GENE]EPAC[\\GENE]-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 6,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic [CHEMICAL]nucleotide[\\CHEMICAL] EPAC antagonist that is capable of specifically blocking intracellular [GENE]EPAC[\\GENE]-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic [CHEMICAL]nucleotide[\\CHEMICAL] EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated [GENE]Rap1[\\GENE] activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic [CHEMICAL]nucleotide[\\CHEMICAL] EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and [GENE]Akt[\\GENE] phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 6,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic [CHEMICAL]nucleotide[\\CHEMICAL] EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as [GENE]EPAC[\\GENE]-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of [CHEMICAL]3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile[\\CHEMICAL] (ESI-09), a novel noncyclic nucleotide [GENE]EPAC[\\GENE] antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 6,
        "major": 3,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ([CHEMICAL]ESI-09[\\CHEMICAL]), a novel noncyclic nucleotide [GENE]EPAC[\\GENE] antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 6,
        "major": 3,
        "len": 39
    },
    {
        "text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic [CHEMICAL]nucleotide[\\CHEMICAL] [GENE]EPAC[\\GENE] antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells.",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "Our results show that [CHEMICAL]Metformin[\\CHEMICAL] directly inhibits stomach ghrelin production and secretion through [GENE]AMPK[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL] directly inhibits ghrelin secretion through [GENE]AMP-activated protein kinase[\\GENE] in rat primary gastric cells.",
        "label": 2,
        "major": 4,
        "len": 14
    },
    {
        "text": "Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the [GENE]AMPK[\\GENE] activator [CHEMICAL]5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide[\\CHEMICAL] (AICAR) significantly inhibited ghrelin secretion.",
        "label": 3,
        "major": 4,
        "len": 33
    },
    {
        "text": "Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the [GENE]AMPK[\\GENE] activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide ([CHEMICAL]AICAR[\\CHEMICAL]) significantly inhibited ghrelin secretion.",
        "label": 3,
        "major": 4,
        "len": 33
    },
    {
        "text": "Finally, [CHEMICAL]Metformin[\\CHEMICAL] treatment caused a significant increase in the level of [GENE]phosphorylated (active) AMPK[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "Metformin significantly reduced [GENE]ghrelin[\\GENE] secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor [CHEMICAL]compound C[\\CHEMICAL].",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "Metformin significantly reduced ghrelin secretion and [GENE]proghrelin[\\GENE] mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor [CHEMICAL]compound C[\\CHEMICAL].",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "Our results show that [CHEMICAL]Metformin[\\CHEMICAL] directly inhibits stomach [GENE]ghrelin[\\GENE] production and secretion through AMPK.",
        "label": 4,
        "major": 9,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL] treatment is also associated with lower circulating levels of the [GENE]orexigenic hormone[\\GENE] ghrelin.",
        "label": 4,
        "major": -1,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL] treatment is also associated with lower circulating levels of the orexigenic hormone [GENE]ghrelin[\\GENE].",
        "label": 4,
        "major": -1,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL] directly inhibits [GENE]ghrelin[\\GENE] secretion through AMP-activated protein kinase in rat primary gastric cells.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL] significantly reduced [GENE]ghrelin[\\GENE] secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL] significantly reduced ghrelin secretion and [GENE]proghrelin[\\GENE] mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide ([CHEMICAL]AICAR[\\CHEMICAL]) significantly inhibited [GENE]ghrelin[\\GENE] secretion.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the [GENE]AMPK[\\GENE] inhibitor [CHEMICAL]compound C[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Through identification of mammary [GENE]ABCG2[\\GENE] as a novel target gene of pesticide [CHEMICAL]prochloraz[\\CHEMICAL] and dioxin, our results may therefore help to improve the protection of breast-feeding infants and the consumer of dairy products.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "Through identification of mammary [GENE]ABCG2[\\GENE] as a novel target gene of pesticide prochloraz and [CHEMICAL]dioxin[\\CHEMICAL], our results may therefore help to improve the protection of breast-feeding infants and the consumer of dairy products.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "[CHEMICAL]TCDD[\\CHEMICAL] or prochloraz doubled [GENE]ABCG2[\\GENE]-mediated Hoechst H33342 secretion.",
        "label": 2,
        "major": -1,
        "len": 8
    },
    {
        "text": "TCDD or [CHEMICAL]prochloraz[\\CHEMICAL] doubled [GENE]ABCG2[\\GENE]-mediated Hoechst H33342 secretion.",
        "label": 2,
        "major": -1,
        "len": 8
    },
    {
        "text": "Fungicide [CHEMICAL]prochloraz[\\CHEMICAL] and environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial cells by the [GENE]arylhydrocarbon receptor[\\GENE] signaling pathway.",
        "label": 2,
        "major": 9,
        "len": 21
    },
    {
        "text": "Fungicide prochloraz and environmental pollutant [CHEMICAL]dioxin[\\CHEMICAL] induce the ABCG2 transporter in bovine mammary epithelial cells by the [GENE]arylhydrocarbon receptor[\\GENE] signaling pathway.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "Induction of AhR by [CHEMICAL]TCDD[\\CHEMICAL] and prochloraz resulted in a time- and dose-dependent increase of [GENE]ABCG2[\\GENE] gene expression and transporter protein levels.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Induction of AhR by TCDD and [CHEMICAL]prochloraz[\\CHEMICAL] resulted in a time- and dose-dependent increase of [GENE]ABCG2[\\GENE] gene expression and transporter protein levels.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Fungicide [CHEMICAL]prochloraz[\\CHEMICAL] and environmental pollutant dioxin induce the [GENE]ABCG2[\\GENE] transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Fungicide prochloraz and environmental pollutant [CHEMICAL]dioxin[\\CHEMICAL] induce the [GENE]ABCG2[\\GENE] transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.",
        "label": 3,
        "major": 9,
        "len": 21
    },
    {
        "text": "Induction of [GENE]AhR[\\GENE] by [CHEMICAL]TCDD[\\CHEMICAL] and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Induction of [GENE]AhR[\\GENE] by TCDD and [CHEMICAL]prochloraz[\\CHEMICAL] resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "This effect was almost completely reversed by specific [GENE]ABCG2[\\GENE] inhibitor [CHEMICAL]Ko143[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "As these regulatory motifs mediate regulation of target genes by [GENE]AhR[\\GENE] agonists including [CHEMICAL]TCDD[\\CHEMICAL] and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.",
        "label": 5,
        "major": 5,
        "len": 36
    },
    {
        "text": "As these regulatory motifs mediate regulation of target genes by [GENE]AhR[\\GENE] agonists including TCDD and [CHEMICAL]prochloraz[\\CHEMICAL], we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.",
        "label": 5,
        "major": 5,
        "len": 36
    },
    {
        "text": "Receptor binding was significantly reduced by specific [GENE]AhR[\\GENE] antagonist [CHEMICAL]salicyl amide[\\CHEMICAL].",
        "label": 6,
        "major": 2,
        "len": 11
    },
    {
        "text": "TCDD or prochloraz doubled [GENE]ABCG2[\\GENE]-mediated [CHEMICAL]Hoechst H33342[\\CHEMICAL] secretion.",
        "label": 9,
        "major": -1,
        "len": 8
    },
    {
        "text": "We found that [CHEMICAL]Ag[\\CHEMICAL] NPs were highly cytotoxic to hepatocytes (LC(50) [GENE]lactate dehydrogenase[\\GENE]: 2.5 \u03bcg/cm(2)) and affected hepatocyte homeostasis by reducing albumin release.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "We observed similar effects of [CHEMICAL]Ag[\\CHEMICAL] NPs on inflammatory mediator expression in vitro and in vivo with increase of [GENE]interleukin-8[\\GENE] (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "We observed similar effects of [CHEMICAL]Ag[\\CHEMICAL] NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 ([GENE]IL-8[\\GENE])/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "We observed similar effects of [CHEMICAL]Ag[\\CHEMICAL] NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/[GENE]macrophage inflammatory protein 2[\\GENE], IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "We observed similar effects of [CHEMICAL]Ag[\\CHEMICAL] NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, [GENE]IL-1RI[\\GENE], and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "We observed similar effects of [CHEMICAL]Ag[\\CHEMICAL] NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, IL-1RI, and [GENE]tumor necrosis factor-\u03b1[\\GENE] expression in both models and increased IL-8 protein release in vitro.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "We observed similar effects of [CHEMICAL]Ag[\\CHEMICAL] NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased [GENE]IL-8[\\GENE] protein release in vitro.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "We found that [CHEMICAL]Ag[\\CHEMICAL] NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 \u03bcg/cm(2)) and affected hepatocyte homeostasis by reducing [GENE]albumin[\\GENE] release.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Moreover, mutation of [GENE]ECII[\\GENE] can alter this coupled equilibrium from [CHEMICAL]GTP[\\CHEMICAL]-insensitive agonist binding to more conventional GTP-sensitive binding.",
        "label": 10,
        "major": 2,
        "len": 18
    },
    {
        "text": "Moreover, mutation of [GENE]ECII[\\GENE] can alter this coupled equilibrium from GTP-insensitive agonist binding to more conventional [CHEMICAL]GTP[\\CHEMICAL]-sensitive binding.",
        "label": 10,
        "major": 5,
        "len": 18
    },
    {
        "text": "Unlike the majority of G protein-coupled receptors, the [GENE]prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor[\\GENE] binds agonist with high affinity that is insensitive to the presence of [CHEMICAL]guanosine 5[prime]-O-(3-thio)triphosphate[\\CHEMICAL] (GTP\u03b3S).",
        "label": 10,
        "major": 2,
        "len": 30
    },
    {
        "text": "Unlike the majority of G protein-coupled receptors, the [GENE]prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor[\\GENE] binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate ([CHEMICAL]GTP\u03b3S[\\CHEMICAL]).",
        "label": 10,
        "major": 2,
        "len": 30
    },
    {
        "text": "Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the [GENE]W203A[\\GENE] receptor, conditions where high GTP levels are present; however, high affinity binding [CHEMICAL][(3)H]PGE(2)[\\CHEMICAL] was observed in broken cell preparations washed free of GTP.",
        "label": 2,
        "major": 2,
        "len": 39
    },
    {
        "text": "The [CHEMICAL][(3)H]PGE(2)[\\CHEMICAL] binding of [GENE]W203A[\\GENE] in broken cell membrane fractions was inhibited by addition of GTP\u03b3S (IC(50) 21 \u00b1 1.8 nM).",
        "label": 2,
        "major": 4,
        "len": 21
    },
    {
        "text": "The [(3)H]PGE(2) binding of [GENE]W203A[\\GENE] in broken cell membrane fractions was inhibited by addition of [CHEMICAL]GTP\u03b3S[\\CHEMICAL] (IC(50) 21 \u00b1 1.8 nM).",
        "label": 2,
        "major": 4,
        "len": 21
    },
    {
        "text": "This suggests that for the mutant receptors, ECII plays a critical role in linking the agonist bound receptor conformation to the [GENE]G protein[\\GENE] [CHEMICAL]nucleotide[\\CHEMICAL] bound state.",
        "label": 2,
        "major": 5,
        "len": 26
    },
    {
        "text": "[GENE]Extracellular loop II[\\GENE] modulates [CHEMICAL]GTP[\\CHEMICAL] sensitivity of the prostaglandin EP3 receptor.",
        "label": 2,
        "major": 7,
        "len": 11
    },
    {
        "text": "Extracellular loop II modulates [CHEMICAL]GTP[\\CHEMICAL] sensitivity of the [GENE]prostaglandin EP3 receptor[\\GENE].",
        "label": 2,
        "major": 7,
        "len": 11
    },
    {
        "text": "Seven point mutations were introduced into the conserved motif in the [GENE]second extracellular loop[\\GENE] (ECII) of EP3, resulting in acquisition of [CHEMICAL]GTP[\\CHEMICAL]-sensitive agonist binding.",
        "label": 2,
        "major": 1,
        "len": 24
    }
]